G1 Therapeutics CONFIDENTIAL  
  
 
 
 
Phase 1b/2a Safety and Pharmacokineti c Study of G 1T28 in Patients with 
Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin 
Chemotherapy  
 
Clinical Study Protocol G1T28-02  
EudraCT # 2016 -001583- 11 
  
Original Protocol Issue  Date: 27 April  2015 
Amendment 7 Issue Date: 15 September  2016 
Version: 8 .0 
 
Investigational Phase: 1b/2a 
 
Sponsored by:  
G1 Therapeutics  
79 T.W. Alexander Drive 
4501 Research Commons, Suite 100 
Research Triangle Park, NC 27709  
919-213-9835 
 
 
 
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET 
INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE 
LICENSING AND/OR REGISTRATION OF PRODUCTS FOR G1 THERAPEUTICS .  
THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN 
PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF 
G1 THERAPEUTICS . 
G 1 Therapeutics, Inc. 
Clinical Study Protocol G 1 T28-02 GlT28 
SPONSOR SIGNATURE PAGE 
SPONSOR:GlTHERAPEUTICS 
I have read and understand the contents of this clinical protocol for Study G 1 T28-02 dated 15 
September 2016 and I agree to meet all obligations of the sponsor as detailed in all applicable 
regulations and guidelines. In addition, I will inform the principal investigator and all other 
investigators of all relevant information that becomes available during the conduct of this 
study. 
Approved by: 
Rajesh~ f~~2o(C 
Date 
Chief Medical Officer, G 1 Therapeutics 
Version: 8.0, dated 15 September 2016 Page 2 of 105 
G 1 Therapeutics CONFIDENTIAL 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 3 of 105  
G1 Therapeutics CONFIDENTIAL  PROTOCOL SIGNATURE PAGE  
Clinical Study Protocol G1T28-02:  Phase 1b/2a Safety  and Pharmacokinetic Study of 
G1T28 in Patients with Extensive -Stage Small Cell Lung Cancer (SCLC) Receiving 
Etopos ide and Carboplatin Chemotherapy  
Original Protocol Issue Date: 27 April 2015 
Version: 8.0, dated 15 September  2016 
By signing below, the investigator agrees to adhere to the protocol as outlined.  
Principal Investigator:   
 
Principal Investigator Signature  Date  
Principal Investigator Name  Institution  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 4 of 105  
G1 Therapeutics CONFIDENTIAL  1. TABLE OF CONTENTS  
SPONSOR SIGNATURE PAGE  ........................................................................................................................... 2  
PROTOCOL SIGNATURE P AGE  ........................................................................................................................ 3  
1. TABLE OF CONTENTS  ............................................................................................................................... 4  
1.1. List of In -Text Tabl es ....................................................................................................................... 8  
1.2. List of In -Text Figures  ...................................................................................................................... 8  
2. LIST OF ABBREVIATIONS ........................................................................................................................ 9  
3. SYNOPSIS  .................................................................................................................................................. 13 
4. INTRODUCTION ....................................................................................................................................... 25 
4.1. Background  ..................................................................................................................................... 25 
4.2. Summary  of Clinical Data  ............................................................................................................... 26 
4.3. Summary of Nonclinical Data  ......................................................................................................... 27 
4.3.1.  Pharmacology Studies  ................................................................................................... 27 
4.3.2.  Pharmacokinetic Studies  ............................................................................................... 28 
4.3.3.  Toxicity and Safety Studies ........................................................................................... 29 
4.3.4.  Potential Risks  ............................................................................................................... 29 
4.4. Study and Dose Rationale  ............................................................................................................... 30 
4.5. Risk/Benefit Assessment  ................................................................................................................. 31 
5. STUDY OBJECTIVES  ................................................................................................................................ 32 
6. INVESTIGATIONAL PLAN  ...................................................................................................................... 33 
6.1. Overall Study Design and Plan  ....................................................................................................... 33 
6.1.1.  Part 1  ............................................................................................................................. 33 
6.1.1.1.  Definition of Dose -Limiting Toxicities (Applicable to 
Cycle 1 of the Phase 1b Dose- Finding Portion of Part 1)  ........................ 34 
6.1.1.2.  Criteria for Adjusting G1T28 Dose Based on 
Pharmacokinetic Parameters  .................................................................... 35 
6.1.1.3.  G1T28 Dose Evaluation ........................................................................... 35 
6.1.1.4.  Safety Monitoring Committee  ................................................................. 37 
6.1.2.  Part 2  ............................................................................................................................. 37 
6.1.3.  Criteria for Subsequent Cycles and Study Durat ion ...................................................... 38 
6.1.4.  Safety Assessments  ....................................................................................................... 39 
6.1.5.  Tumor Assessment  ........................................................................................................ 39 
7. STUDY POPULATION .............................................................................................................................. 41 
7.1. Selection of Patients  ........................................................................................................................ 41 
7.1.1.  Inclusion Criteria  ........................................................................................................... 41 
7.1.2.  Exclusion Criteria .......................................................................................................... 42 
8. TREATMENTS  ........................................................................................................................................... 44 
8.1. Treatments Administered  ................................................................................................................ 44 
8.2. Investigational Products  .................................................................................................................. 45 
8.2.1.  Identity  .......................................................................................................................... 45 
8.2.1.1.  G1T28  ...................................................................................................... 45 
8.2.1.2.  Placebo  ..................................................................................................... 45 
8.2.1.3.  Etoposide and Carboplatin  ....................................................................... 45 
8.2.2.  Packaging and Labeling  ................................................................................................ 45 
8.2.2.1.  G1T28  ...................................................................................................... 45 
8.2.2.2.  Placebo  ..................................................................................................... 45 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 5 of 105  
G1 Therapeutics CONFIDENTIAL  8.2.2.3.  Etoposide and Car boplatin  ....................................................................... 45 
8.2.3.  Storage  .......................................................................................................................... 46 
8.2.3.1.  G1T28  ...................................................................................................... 46 
8.2.3.2.  Placebo  ..................................................................................................... 46 
8.2.3.3.  Etoposide and Carboplatin  ....................................................................... 46 
8.2.4.  Procedure for Dispensing .............................................................................................. 46 
8.2.5.  Investigational Product Accountability  ......................................................................... 46 
8.3. Method of Assigning Patients to Treatment Groups  ....................................................................... 47 
8.4. Dose , Dosing Regimen, and Route  ................................................................................................. 47 
8.4.1.  G1T28  ........................................................................................................................... 47 
8.4.2.  Placebo  .......................................................................................................................... 48 
8.4.3.  Etoposide and Carboplatin  ............................................................................................ 48 
8.4.3.1.  Carboplatin ............................................................................................... 48 
8.4.3.2.  Etoposide  ................................................................................................. 49 
8.4.4.  Dose Modifications  ....................................................................................................... 49 
8.4.4.1.  G1T28  ...................................................................................................... 49 
8.4.4.2.  Modification of Etoposide  and Carboplatin  Dosing .................................. 49 
8.5. Randomization and Blinding ........................................................................................................... 55 
8.6. Prior and Concomitant Medications and Procedures  ...................................................................... 55 
8.7. Transfusions  .................................................................................................................................... 57 
8.8. Prophylactic Cranial Irradiation  ...................................................................................................... 57 
8.9. Treatment Compliance  .................................................................................................................... 57 
9. STUDY FLOWCHART  .............................................................................................................................. 58  
10. SCHEDULE OF STUDY PR OCEDURES  ................................................................................................. 62 
10.1.  Screening ......................................................................................................................................... 62 
10.2.  Enrollment ....................................................................................................................................... 62 
10.3.  Cycle 1  ............................................................................................................................................ 63 
10.4.  Cycle 2  ............................................................................................................................................ 64 
10.5.  Cycles 3, 4, and Subsequent Cycles  ................................................................................................ 65 
10.6.  Post-Treatment Visit  ....................................................................................................................... 66 
10.7.  Survival Follow -up Phase  ............................................................................................................... 66 
10.8.  Study Drug Discontinuation  ............................................................................................................ 67 
10.9.  Unscheduled Visits  ......................................................................................................................... 67 
11. STUDY ASSESSMENTS  ........................................................................................................................... 68 
11.1.  Efficacy Assessments  ...................................................................................................................... 68 
11.2.  Pharmacokinetic Assessments  ........................................................................................................ 68 
11.3.  Safety Assessments  ......................................................................................................................... 71 
11.3.1.  Adverse Events and Serious Adverse Events  ................................................................ 72 
11.3.1.1.  Definition of Adverse Event  .................................................................... 72 
11.3.1.2.  Definition of Serious Adverse Event  ....................................................... 73 
11.3.1.3.  Assessment  of the Severity of Adverse Events  ........................................ 74 
11.3.1.4.  Assessment of the Relationship of Adverse Events to 
Study Drug  ............................................................................................... 74 
11.3.1.5.  Asse ssment of the Outcome of Adverse Events ....................................... 74 
11.3.1.6.  Method, Frequency, and Time Period for Detecting Adverse Events and Serious Adverse Events  ........................................... 75
 
11.3.1.7.  Documentation of Adverse Events and Serious Adverse Events  ...................................................................................................... 75
 
11.3.1.8.  Adverse Event Coding  ............................................................................. 76 
11.3.1.9.  Reporting of Serious Adverse Events  ...................................................... 76 
11.3.1.10.  Follow -up of Adverse Events  .................................................................. 76 
11.3.1.11.  Regulatory Aspects of Adverse Event Reporting  .................................... 77 
11.3.1.12.  Handling of Overdoses and Toxicity  ....................................................... 78 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 6 of 105  
G1 Therapeutics CONFIDENTIAL  11.3.1.13.  Reporting of Pregnancies  ......................................................................... 78 
11.3.2.  Clinical Laboratory Assessments  .................................................................................. 78 
11.3.3.  Demographics and Vital Signs  ...................................................................................... 79 
11.3.4.  Physical Examination  .................................................................................................... 79 
11.3.5.  Electrocardiogram Assessments  .................................................................................... 79 
11.3.6.  Concomitant Medications  ............................................................................................. 79 
11.4.  Central Pathology Review to Confirm Diagnosis of SCLC  ............................................................ 80 
11.5.  Tumor Response  ............................................................................................................................. 80 
11.5.1.  Tumor Assessments ...................................................................................................... 80 
11.5.2.  Tumor Lesions: Identification and Follow -up ............................................................... 80 
11.5.2.1.  Measurable Lesions  ................................................................................. 80 
11.5.2.2.  Nonmeasurable Lesions  ........................................................................... 81 
11.5.2.3.  New Lesions  ............................................................................................ 81 
11.5.3.  Defini tions of Tumor Response and Disease Progression  ............................................. 82 
11.5.3.1.  Evaluation of Target Lesion Response  .................................................... 82 
11.5.3.2.  Evaluation of Nontarget Lesions  .............................................................. 82 
11.5.3.3.  Evaluation of Overall Response  ............................................................... 82 
11.6.  Patient Reported Outcomes  ............................................................................................................. 83 
11.7.  Immunologic Markers  ..................................................................................................................... 83 
11.8.  Appropriateness of Measurements  .................................................................................................. 84 
12. STUDY TERMINATION OR  STUDY DRUG DISCONTINUATION  ..................................................... 85 
12.1.  Study Termination ........................................................................................................................... 85 
12.2.  Site Termination  .............................................................................................................................. 85 
12.3.  Discontinuation of Study Drug  ....................................................................................................... 85 
12.4.  Withdrawal of Patients from the Study  ........................................................................................... 86 
13. STATISTICS  ............................................................................................................................................... 87 
13.1.  Sample Size and Power  ................................................................................................................... 87 
13.2.  General Considerations  ................................................................................................................... 87 
13.2.1.  Analysis Populations/Sets  ............................................................................................. 87 
13.2.2.  Timing of Analyses  ....................................................................................................... 87 
13.2.2.1.  Interim Safety Reviews  ............................................................................ 87 
13.2.2.2.  Final Analysis  .......................................................................................... 88 
13.2.2.3.  End of Study Analysis  ............................................................................. 88 
13.2.3.  General Considerations f or Data Analysis  .................................................................... 88 
13.3.  Baseline and Demographic Characteristics  ..................................................................................... 89 
13.4.  Efficacy Analysis  ............................................................................................................................ 89 
13.4.1.  Efficacy Endpoints  ........................................................................................................ 89 
13.4.2.  Methods of Analysis for Efficacy Endpoints  ................................................................ 90 
13.4.2.1.  Analysis of Hematologic Parameter Kinetic Endpoints  ........................... 90 
13.4.2.2.  Analysis of Hematologic Toxicity Endpoints  .......................................... 92 
13.4.2.3.  Analysis  of Chemotherapy Exposure and Compliance  ............................ 92 
13.4.2.4.  Other Efficacy Endpoints  ......................................................................... 93 
13.4.2.5.  Analysis of Exploratory Efficacy End points  ............................................ 93 
13.5.  Safety Analysis  ............................................................................................................................... 93 
13.5.1.  Safety Endpoints  ........................................................................................................... 93 
13.5.2.  Methods of Analysis for Safety Endpoints  .................................................................... 94 
13.6.  Exploratory Analyses  ...................................................................................................................... 95 
13.7.  Pharmacokinetic Analysis  ............................................................................................................... 95 
13.8.  Immunologic Markers  ..................................................................................................................... 95 
14. QUALITY CONTROL AND QUALITY ASSURANCE  ........................................................................... 96 
15. ETHICS AND PROTECTION OF HUMAN PATIENTS  .......................................................................... 97 
15.1.  Ethical Conduct Statement  .............................................................................................................. 97 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 7 of 105  
G1 Therapeutics CONFIDENTIAL  15.2.  Institutional Review Board/Independent Ethics Committee  ........................................................... 97 
15.3.  Informed Consent  ............................................................................................................................ 97 
15.4.  Patient Confidentiality  .................................................................................................................... 97 
15.5.  Adherence to the Protocol  ............................................................................................................... 98 
15.6.  Protocol Amendments  ..................................................................................................................... 98 
15.7.  Patient Compliance  ......................................................................................................................... 98 
15.8.  Study Discontinuation  ..................................................................................................................... 98 
16. DATA HANDLING AND RE CORD KEEPING ........................................................................................ 99 
16.1.  Data Collect ion and Retrieval  ......................................................................................................... 99 
16.2.  Data Monitoring Committee  ........................................................................................................... 99 
16.3.  Investigator Reporting Requirements .............................................................................................. 99 
16.4.  Records Retention  ........................................................................................................................... 99 
16.5.  Study Monitoring  .......................................................................................................................... 100 
16.6.  Audits and Inspections  .................................................................................................................. 100 
17. PUBLICATION POLICY ......................................................................................................................... 101 
18. REFERENCES  .......................................................................................................................................... 102 
19. APPENDICES  ........................................................................................................................................... 105 
 
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 8 of 105  
G1 Therapeutics CONFIDENTIAL  1.1. List of In -Text Tables  
Table 5 -1 G1T28- 02: Study Objectives  ......................................................................................... 32 
Table 8 -1 Etoposide and Carboplatin  Dose  Reductions  ................................................................ 50 
Table 8 -2 Etoposide and Carboplatin  Dose  Adjustments  Based on Lack of 
Recovery of Absolute Neutrophil or Platelet Counts on the First 
Day of Cycle 2 and Each Successive Cycle  .................................................................. 51 
Table 8 -3 Etoposide and Carboplatin  Dose  Adjustments  Based on Absolute 
Neutrophil Count  Nadir With or Without Fever  ........................................................... 52 
Table 8 -4 Etoposide and Carboplatin Dose Adjustment Based on Platelet Nadir  ............................................................................................................................. 53
 
Table  8-5 Etoposide and Carboplatin Reduction for Hepatic Toxicity .......................................... 54 
Table  9-1 Schedule of Assessments  .............................................................................................. 59 
Table 11 -1 Day 1 of Cycle 1 Blood Sampling Scheme Based on Predicted Administration Times of G1T28, Carboplatin, and Etoposide  ...................................... 69
 
Table 11 -2 Day 3 of Cycle 1 Blood Sampling Scheme Based on Predicted Administration Times of G1T28 and Etoposide  ........................................................... 70
 
Table 11 -3 Pharmacokineti c Parameters  ......................................................................................... 71 
Table 11 -4 Evaluation of Overall Response at Each Time Point  .................................................... 83 
 
 
1.2. List of In -Text Figures  
Figure  6-1 Study Schema: Phase 1b Dose -Finding Portion of Part 1  ............................................. 34 
Figure  6-2 G1T28 Dose Evaluation in the Phase 1b Dose -Finding Portion of 
Part 1  ............................................................................................................................. 36 
Figure 6 -3 Study Schema: Part 2  .................................................................................................... 38 
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 9 of 105  
G1 Therapeutics CONFIDENTIAL  2. LIST OF ABBREVIATIONS  
Abbreviation  Definition  
5-FU 5-fluorouracil  
ADR  adverse drug reaction  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine transamin ase 
ANC  absolute neutrophil count  
ANCOVA analysis of covariance  
ASCO  American Society of Clinical Oncology  
AST  aspartate aminotransferase  
AUC  area under the concentration -time curve  
AUC EDC area under the concentration -time curve from predose to end o f cycle  
AUC Nadir area under the concentration -time curve from predose to nadir  
AUC NEDC area under the concentration -time curve from nadir to end of cycle  
BCRP  breast cancer resistance protein  
BED  biologically effective dose  
β-hCG  beta human chorionic gonadotropin  
bpm beats per minute  
BSA  body surface area  
BSEP bile salt export pump   
BUN blood urea nitrogen 
CBC  complete blood count  
CDK2/4/6  cyclin -dependent kinase 2/4/6 
CFR  Code of Federal Regulations  
CI confidence i nterval  
CL clearance  
Cmax maximum concentration  
CR complete response  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  cytochrome P450 
D5W  dextrose 5% in water  
DDI drug-drug interaction  
DLT  dose-limiting toxicity  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 10 of 105  
G1 Therapeutics CONFIDENTIAL  Abbreviation  Definition  
DMC data monitoring committee  
DNA deoxyribonucleic acid  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EEG  electroencephalogram  
EOI end of infusion 
E/P etoposide and carboplatin  
E/P therapy  etoposide and carboplatin on Day 1 and etoposide on Days 2 and 3 of 21- day cycles  
ESA  erythropoietin stimulating agent  
FACT  Functional Assessment of Cancer Therapy quality of life instrument  
FACT -An Functional Assessment of Cancer Therapy –Anemia quality of life i nstrument  
FACT -L Functional Assessment of Cancer Therapy –Lung quality of life instrument  
FAS full analysis set  
FDA  Food and Drug Administration 
FDG -PET positron emission tomography with 2- deoxy -2-[fluorine -18]fluoro -D-glucose  
G1 gap 1 phase of the cell cycle  
G2 gap 2 phase of the cell cycle  
G1T28  formerly G1T28-1 
GCP  Good Clinical Practice  
G-CSF granulocyte colony -stimulating factor  
GFR  glomerular filtration rate  
GLP  Good Laboratory Practice  
GM-CSF granulocyte -macrophage colony -stimulating factor  
γH2AX  phosphorylated histone H2AX  
HBV hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
HSPC  hematopoietic stem and progenitor cell  
IB Investigator’s Brochure  
IC50 half maximal inhibitory concentration  
ICH International Confe rence on Harmonization  
IRB institutional review board  
IV intravenous  
IWRS  interactive web -response system  
LD longest diameter  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 11 of 105  
G1 Therapeutics CONFIDENTIAL  Abbreviation  Definition  
LDH  lactate dehydrogenase  
LS least square  
M mitosis phase of cell cycle  
MATE1 or 2 -K multidrug and toxin extrusion 1 or 2- K  
MDR1  p-glycoprotein  
MedDRA  
MHRA Medical Dictionary for Regulatory Activities  
Medicines and Healthcare Products Regulatory Agency  
MRI  magnetic resonance imaging  
MRP1 or 2  multidrug resistance protein 1 or 2  
NCI National Cancer Institute  
NCI-H69 human small cell lung cancer cell line  
NE not evaluable  
NYHA New York Heart Association  
OAT1 or 3  organic anion transporter 1 or 3  
OATP1B1 or 1B3  organic anion transporting polypeptide 1B1 or 1B3   
OCT1 or 2  organic cation transporter 1 or 2 
PCI prophylactic cranial irradiation  
PD progressive disease  
PET positron emission tomography 
PFS progression- free survival  
PK pharmacokinetic(s)  
PK/PD  pharmacokinetic/pharmacodynamic  
PP per protocol  
PR partial response  
PRO  patient -reported outcome  
QOL  quality of life  
Rb retinoblastoma protein  
RB-1 retinoblastoma gene  
RBC  red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
RH relative humidity  
RNA  ribonucleic acid  
RNASeq  RNA sequencing  
S synthesis phase of cell cycle in which DNA is  replicated  
SAE  serious adverse event  
SAP statistical analysis plan  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 12 of 105  
G1 Therapeutics CONFIDENTIAL  Abbreviation  Definition  
SCLC  small cell lung cancer  
SD stable disease  
SMC  safety monitoring committee  
SOP standard operating procedure  
t1/2 terminal half -life 
Tmax time to reach C max 
TP53  tumor protein 53 
UGT1A1  uridine disphosphate glucuronosyltransferase 1 family, polypeptide A1 
ULN  upper limit of normal  
Vz volume of distribution in the terminal elimination phase  
WBC  white blood cell  
WHO World Health Organization  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 13 of 105  
G1 Therapeutics CONFIDENTIAL  3. SYNOPSIS  
Title  Phase 1b/2a Safety  and Pharmacokinetic Study of G1T 28 in Patients 
with Extensive -Stage Small Cell Lung Cancer (SCLC) Receiving 
Etoposide and Carboplatin Chemotherapy  
Study Rationale Chemotherapy-induced myelosuppression is a significant issue in 
cancer treatment, including  treatment of SCLC. G1T28 (formerly 
G1T28-1) is a highly potent and selective cyclin -dependent kinase 4/6 
(CDK4/6 ) inhibitor that cause s a transient and reversible gap 1 phase 
(G1) cell cycle arrest of hematopoietic stem and progenitor cells 
(HSPCs) within  the bone marrow , thus protect ing their 
deoxyribonucleic acid (DNA) from damage by coadministered chemotherapy and preserving long-term function. In animal studies, 
administration of G1T28 just prior to dose(s) of 5 -fluorouracil (5- FU) 
resulted in  a more r apid recovery  of all hematopoietic lineages. This 
effect persisted following administration of m ultiple cycles of 
chemotherapy. Bone marrow obtained from mice that received 
4 cycles of G1T28 administered prior to every dose of 5- FU was 
more robust at hematopoietic reconstitution of lethally irradiated mice 
following bone marrow transplantation compared with bone marrow 
obtained from mice that received 4 cycles of 5 -FU alone , suggesting 
that G1T28 administered with chemotherapy can preserve stem cell function.  
The Phase 1 a, first-in-human Study G1T28 -1-01 demonstrated that 
G1T28 was well tolerated following administration of a single 
intravenous (IV) dose. The pharmacokinetics (PK) of G1T28 suggests 
that drug accumulation following repeated adm inistration is  unlikely 
to occur. Based on PK and pharmacodynamic parameters from the Phase 1a study and a preclinical PK/pharmacodynamic (PK/PD) model, a biologically effective dose (BED) of 192 mg/m
2 of G1T28 
was identified. Twenty -four hours following administration of the 
BED , a significant decrease was noted in the number of bone marrow 
HSPC s in the synthesis ( S)/gap 2 ( G2)/mitosis ( M) phase s of the cell 
cycle (ie , an increase in the proportion of cells in G1 arrest) , which 
persisted at 32 hours. Thus, dosing of G1T28 200 mg/m2 (rounded up 
from the BED of 192 mg/m2) prior to the administration of etoposide 
and carboplatin  on Day 1 and administration of etoposide on Days 2 
and 3 of  21-day cycles (hereafter referred to as E/P therapy) should 
maintain the bone marrow HSPCs in G1 arrest during and for several 
half- lives after chemotherapy administration , thus protecting their 
DNA from cytotoxic damage. The goals of this study are to assess the safety and tolerability of combining G1T28 with E/P therapy and to 
evaluate the effect of G1T28 on chemotherapy-induced 
myelosuppression. 
Clinical Phase  1b/2a 
Indication Reduction of chemotherapy-induced myelosuppression 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 14 of 105  
G1 Therapeutics CONFIDENTIAL  Objective s  Phase 1b 
Dose -
Finding 
Portion of 
Part 1  Phase 2a 
Expansion  
Portion of 
Part 1  Phase 2a 
Part 2  
Prima ry Objectives  
Assess the DLTs and define the 
Phase 2 dose of G1T28 administered with E/P  therapy  X   
Assess the safety and 
tolerability of G1T28 
administered with E/P therapy  X  X X 
Secondary Objectives  
Assess the PK profile of G1T28  X   
Assess the PK  profile of 
etoposide and carboplatin when administered with G1T28  X   
Assess the hematologic profile (kinetics and incidence/duration/frequency of 
toxicities) of G1T28 
administered with E/P therapy  X  
 X X 
Assess the incidence of febrile neutropenia  X X X 
Assess the incidence of infections  X X X 
Assess the utilization of RBC and platelet transfusions  X X X 
Assess the utilization of 
hematopoietic growth factors  X X X 
Assess the utilization of 
systemic antibiotics  X X X 
Assess the incidence of chemot herapy dose reductions 
and dose interruptions overall  X X X 
Assess the incidence of Grade 2 or greater nephrotoxicity  X X X 
Assess tumor response based on RECIST, Version 1.1  X X X 
Assess PFS and overall survival  X X X 
Exploratory Objectives  
Assess t he incidence of 
mucositis  X X X 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 15 of 105  
G1 Therapeutics CONFIDENTIAL   Phase 1b 
Dose -
Finding 
Portion of 
Part 1  Phase 2a 
Expansion  
Portion of 
Part 1  Phase 2a 
Part 2  
Assess the incidence of 
alopecia X X X 
Assess the incidence of fatigue X X X 
Assess patient -reported QOL  X X X 
Assess immunol ogic markers    X 
DLT = dose -limiting toxicity; E/P therapy = etoposide + carboplatin  on Day 1 and 
etoposide on Days 2 and 3 of 21- day cycles ; PFS = progression-free survival; 
PK = pharmacokinetic; QOL = quality of life; RBC = red blood cell; 
RECIST  = Resp onse Eva luation Criteria in Solid Tumors  
Study Design  This is a randomized, double -blind, placebo-controlled, multicenter 
Phase 1b/2a study of the safety and PK of G1T28 in combination with 
E/P therapy for patients with newly diagnosed extensive- stage SCL C. 
The study consists of 2 parts: Part 1 will be a limited P hase 1b, 
open-label, dose-finding portion followed by a P hase 2a, open- label , 
expansion portion in up to 18 patients at the selected dose to be used 
in Part 2 . Prior to initiating Part 2, up to a total of  24 patients will be 
enrolled at the chosen Part 2 dose (6 pati ents in the  Phase 1b 
dose-finding portion of Part 1 an d up to 18 patients in the Phase 2a 
expansion portion of Part 1 ). Part 2 will consist of a randomized, 
double-blind cohort (70 patients will be randomly assigned to G1T28 
administered IV with E/P therapy or placebo administered IV with E/P therapy). All  parts  of the study include 3 study phases: S creening 
Phase, Treatment Phas e, and Survival Follow-up Phase. The 
Treatment Phase begins on the day of first dose with study treatment and completes at  the Post -Treatment Visit.  
Part 1  
The goal of the Phase 1b dose -finding portion of Part 1 is to assess 
the safety , including dose- limiting toxicities ( DLTs ), and  PK of 
G1T28 administered at a starting dose of 200 mg/m
2 (derived from 
Study G1T28-1-01, a Phase 1 a, safety, PK, and pharmacodynamic 
study of G1T28 in healthy male and female patients ) on Days  1 to 3 
of E/P therapy.  
The goal of the Phase 2a expansion cohort of Part 1  is to obtain 
additional safety and efficacy data for  G1T28 in combination with 
E/P to inform further development in newly diagnosed 
extensive- stage SCLC.  
Six patients will initially be enrolled in the Phase 1b dose -finding 
portion of Part 1 . Depending on the evaluation of DLTs  and PK 
parameters from these initial patients in Cycle 1, additional cohorts of 
6 patients may be enrolled at higher or lower dose s. The PK profile of 
G1T28 is well established in healthy subjects, with good estimates of key parameters such as maximum concentration (C
max), area under the 
concentration -time curve ( AUC ), and Clearance (CL). In addition, the 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 16 of 105  
G1 Therapeutics CONFIDENTIAL  intersubject variability in these PK  parameters is low (see 
Section  4.2). Therefore, for  the initial coh ort of 6 patient s treated with 
200 mg/m2, the target AUC 0-24.5h  is 3100 h• ng/mL . If the mean 
AUC 0-24.5h  is not within 20% of th is target (AUC 2480 to 
3720 h•ng/mL ), the do se of G1T28 will be adjusted  in the next cohort  
of 6 patients to achieve a mean AUC 0-24.5h  of 3100 h• ng/mL . Any 
available PK data from additional cohort(s) of the Phase 1b dose 
finding portion of Part 1 may be utilized for modifying the G1T28 dose (if required). If the G1T28 dose level for a subsequent cohort 
requires escalation, the increase will not exceed 30%  from the 
previous dose level.   The magni tude of the dose modification is  based 
upon the fact that G1T28 displays linear PK over the dose range 
studied to date. The adjusted dose , if necessary,  will be tested in 
6 additional patients enrolled in the Phase 1b dose-finding portion of 
Part 1 , and up to 18 patients will be enrolled at the chosen Part 2 dose 
in the Phase 2a expansion portion of Part 1, prior to i nitiating the 
randomized part (Part 2) of the study.    
All dose escalation /de-escalation  decisions will be based on Cycle 1 
safety data from all patients enrolled into the cohort and available PK data, which will be  reviewed  by a safety monitoring committee 
(SMC) comprised of the sponsor, medical monitor, and the principal 
investigator(s) to determine the next dose level . If the G1T28 dose 
level for a subsequent cohort is adjusted by the SMC, the SMC may 
also recommend that all patients currently receiving G1T28 in 
combination with E/P therapy should have their G1T28 dose adjusted accordingly, starting with their next scheduled cycle. Additional 
cohorts for the Phase 1b dose-finding portion of Part 1 will be 
considered based on the review of safety and available PK data by the 
SMC . The dose for Part 2 will be obtained by utilizing all available 
safety and available PK  data  from patients enrolled in the Phase 1b 
dose-finding portion of Part 1. Once the dose for Part 2 has been 
established, additional patients will be enrolled at the selected Part 2 
dose in a Phase 2a expansion cohort i n Part 1 until up to 24 patients in 
total have been enrolled at that dose. The Phase 2a expansion cohort in Part 1 will complete enroll ment before enrollment to Part 2  of the 
study commences.  
Each patient will be evaluated for toxicity during each cycle. The 
toxicity of G1T28 administered IV with E/P therapy will be assessed 
by the investigators using National Cancer Institute (NCI) Common 
Terminology Criter ia for Adverse Events (CTCAE), V ersion  4.03. 
If there is ≤ 1 dose- limiting toxicity (as defined belo w) in  any of the 
first cohort of patients  (6 patients)  during Cycle 1 of the Phase 1b 
dose-finding portion of Part 1, and the target PK parameters are 
achieved , then the dose- finding portion of Part 1will end and 
subsequent patients will be enrolled into the Phase 2a expansion 
cohort, utilizing a dose of G1T28 200 mg/m2 in combination with 
E/P therapy. If an additional cohort(s) of 6 patients is enrolled in the 
Phase 1b dose-finding portion of Part 1, then the dose for Part 2 will 
be defined following evaluation of safety and available PK data from 
the additional cohort(s)  of patients  and enrollment into the Phase 2a  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 17 of 105  
G1 Therapeutics CONFIDENTIAL  expansion cohort will commence  at that dose .  
Dose -limiting toxicities (applicable to Cycle 1 of the Phase 1b 
dose-finding portion of Part 1) a re drug -related toxicities defined as 
follows: 
• Absolute neutrophil count (ANC) < 0.5 × 109/L lasting  for 
≥ 7 days  
• ≥ Grade 3 neutropenic infection/febrile neutropenia  
• Grade 4 thrombocytopenia or ≥ Grade 3 thrombocytopenia 
with bleeding 
• Unable to start next cycle of chemotherapy due to lack of 
recovery to a n ANC  ≥ 1.5 × 109/L and platelet count 
≥ 100 × 109/L 
• ≥ Grade 3 nonhematologic toxicity  (nausea, vomiting, and 
diarrhea failing maximal medical management ; fatigue 
lasting  for >  72 hours)  
Toxicities not clearly related to etoposide/carboplatin (E/P) therapy will also be considered for the purposes of determining DLTs. 
Part 2  
In Part 2, eligible patients will be randomized (1:1 fashion) to G1 T28 
or placebo admi nistered IV once daily on Days 1 to 3 of E/P therapy . 
Randomizat ion will be stratified by Eastern Cooperative Oncology 
Group ( ECOG) p erformance s tatus (0  to 1 versus 2 ). There will be no 
intrapatient dose modifications of G1T28 in Part 2 of the study. 
Criteria for Subsequent Cycles and Study Duration  
In both parts of the study, study drug administration will continue 
until disease progression per Response Ev aluation Criteria i n Solid 
Tumors (RECIST) , Version 1.1, unacceptable toxicity, withdrawal of 
consent, or discontinuation by investigator (eg, after completing 6 cycles), whichever occurs first. Treatment cycles will occur 
consecutively without interruption, except when necessary to manage 
toxicities  or for administrative reasons as described below . 
In order to start Cycle 2 and subsequent cycles as scheduled, patients must have an ANC  ≥ 1.5 × 10
9/L, platelet count ≥  100 × 109/L, and 
nonhematologic drug- related toxicities (except alopecia) must be 
≤ Grade 1 or have returned to baseline. A delay of up to 2 weeks is 
permitted to allow recovery from any toxicity in order to meet the 
continuation criteria for organ function. If  patients meet the criteria 
for sta rting the subsequent cycle as stated in Section  6.1.3 , a delay of 
up to 1 week is permitted for administrative reasons (eg, holiday, 
vacation, etc.). If the subsequent cycle is delayed, the patient should still complete the clinical laboratory assessments and the FACT -L and 
FACT -An questionnaires on the scheduled Day 1, as well as on the 
actual first dosing day of the next cycle.  A patient will be 
discontinued from the study if recovery from any toxicity, in orde r to 
meet the continuation criteria for organ function , and any delay for 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 18 of 105  
G1 Therapeutics CONFIDENTIAL  administrative reasons requires a total delay of >  2 weeks . 
After discontinuation of study drug, patients should be strongly 
encouraged to complete all scheduled assessments through the end of 
their current 21- day treatment cycle, including the patient -reported 
outcome (PRO) scales; CBC assessment on Day 22; the Post-Treatment Visit; and the Survival Follow -up Phase of the study , 
which is to continue until  at least  50% of the patients  randomized to 
Part 2 of the study have died. The G1T28 -02 study will be completed 
when the Survival Follow -up Phase has been completed , or upon 
sponsor termination of the study. 
Safety Assessments  
Safety assessments will include monitoring of adverse even ts (AEs), 
vital signs measurements, physical examinations,  electrocardiograms 
(ECGs), clinical laboratory studies , infusion -related reactions, tumor 
response based on RECIST, Version 1.1, progression- free survival 
(PFS), and overall survival . Safety survei llance reporting of AEs and 
concomitant medications  commences at the time that  informed 
consent  is obtained and continues through the Post -Treatment  Visit. 
An independent data monitoring committee (DMC) will monitor 
accumulating safety and disposition data approximatel y every 
4 months during the Treatment Phase of Part 2 of the study , 
depending upon the enrollment rate . Details of the DMC, including 
objectives, composition, scope, and frequency, will be described in a 
DMC charter.  
Tumor Assessment  
For tumor assessment, all sites of disease should be assessed radiologically by computed tomography (CT) or magnetic resonance 
imaging (MRI) at screening and after every even cycle, until the 
occurrence of disease progression. CT or MRI scans obtained as 
standard o f care prior to informed consent will not need to be 
repeated if performed within 14 days prior to dosing. Assessments should be performed within 7 days of starting the subsequent cycle.
  
Additional scans may be obtained at the discretion of the investigat or, 
if clinically indicated. If a patient shows a radiological response 
(complete response [CR] or partial response [PR]), a confirmatory radiological assessment will be performed at least 4 weeks after the 
response was first noted.  For patients who have a confirmed CR, it is 
strongly recommended that they receive pr ophylactic cranial 
irradiation  (PCI)  after completion of chemotherapy. Patients w ith a 
confirmed PR should also consider PCI after completion of 
chemotherapy based on the investigator’s judgment . For those 
patients who have not progressed at the time of study drug discontinuation, tumor assessments, including all sites of disease, will 
be assessed radiologically by CT or MRI, as performed at screening, 
every 2 months (approximately 60 ± 7 days) until the occurrence of 
progressive disease or study completion. The same method of 
assessment (CT or MRI) should be used to characterize tumors at screening and at all follow- up assessments.  If positron emission 
tomography ( PET) is used, it should also be accompanied by spiral 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 19 of 105  
G1 Therapeutics CONFIDENTIAL  CT or MRI.     
Treatment Duration  Study drug administration will continue for each patient until disease 
progression per RECIST , Version 1.1, unacceptable toxicity, 
withdrawal of consent, or discontinuation by investigator (eg, after completing 6 cycles), whichever occurs first . 
Study Duration The total study duration is at least 2 9 months.  
Part 1 is expected to be approximately 18 months, assuming 12 months of accrual, 2 weeks for screening, 4.5 months of treatment 
(assuming 6 cycles), a nd 1 month of safety follow -up. 
Part 2 will begin after the Part 2 dose is identified from the Phase 1b 
dose-finding portion of Part 1 and the Phase 2a expansion of Part 1  
has completed  enrollment , which is expected to occur approximately 
12 months after Part 1 begins. Part 2 is expected to be approximately 
17 months, assuming 11 months of accrual, 2 weeks of screening , 
4.5 months of treatment ( assuming 6 cycles), and 1  month of safety 
follow-up. 
The Survival Follow -up P hase will continue until at lea st 50% of the 
randomized patients in Part 2 have died. 
Approximate Number of 
Patient s Overall, up to  110 patients w ill be enrolled in the study. In Part 1, 
approximately 40 patients will be enrolled , assuming up to 3 cohorts.  
Cohorts will consist of 6 pa tients  each in the Phase 1b dose -finding 
portion of Part 1 and up to 18 patients in the Phase 2a expansion 
portion of Part 1 at the selected dose to be used in Part  2. Additional 
patients may be enrolled in the Phase 1b dose-finding portion of 
Part 1 if mo re than 1 cohort is enrolled.  In Part  2, 70 patients will be 
randomly assigned to 1 of 2 groups as follows: G1T28 administ ered 
IV with E/P therapy (Group  1) or placebo admini stered IV with 
E/P therapy (Group 2). 
Number of Study Centers Up to 80 centers in  North America and Europe 
Diagnosis and Main Criteria for Inclusion For a patient to be eligible for participation in this study, all of the 
following criteria must apply. 
1. Age ≥ 18 years  
2. Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of 
neuroendocrine features by immunohistochemistry 
3. Extensive- stage disease  
4. At least 1 target lesion that is unirradiated and measu rable by 
RECIST , Version 1.1 (Eisenhauer 2009) 
5. Hemoglobin ≥ 9.0 g/dL 
6. Absolute neutrophil count  ≥ 1.5 × 10
9/L 
7. Platelet count ≥  100 × 109/L 
8. Creatinine ≤  1.5 mg/dL OR  glomerular filtration rate (GFR) 
of ≥ 60  mL/min ute (by Cockcroft -Gault formula  [Cockcroft 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 20 of 105  
G1 Therapeutics CONFIDENTIAL  and Gault 1976] ); creatinine clearance calculated from a n 
isotopic method or 24-hour urine collection may be used 
instead of an estimated GFR  by the Cockcroft-Gault formula  
9. Total bilirubin ≤  1.5 × upper limit of normal (ULN) 
10. Aspartate aminotransferase (AST ) and ala nine 
aminotransferase (ALT ) ≤ 2.5 × ULN; ≤  5 × ULN in the 
presence of liver metastases  
11. Serum albumin ≥  3 g/dL 
12. Eastern Cooperative Oncology Group ( ECOG) performance 
status of 0 to 2 
13. Predicted life expectancy of ≥ 3 months  
14. Contraception: 
a. For females: A ll females of childbearing potential must 
have a negative serum beta human chorionic 
gonadotropin (β -hCG) test result  at screening and at 
baseline. Females must be either post menopausal, 
surgically sterile, or using an accep table method of 
contraception. Acceptable surgical sterilization techniques are hysterectomy, bilateral tubal ligation with 
surgery at least 6 months prior to dosing, and bilateral oophor ectomy, with surgery at least 2  months prior to 
dosing. Acceptable methods of contraception are an intraut erine device, contraceptive implant, oral 
contraceptive (stable dose of the same hormonal contraceptive product for at least 3 months prior to dosing), a vasectomized  partner, and a barrier method 
(condom or diaphragm) during the study and for 3 months after discontinuation of treatment 
b. For males: Patients with female partner of childbearing potential must agree to use a highly effective form of birth control, which entails the use of oral, injected, or 
implanted hormonal methods of contraception or an 
intrauterine device/system by the female partner, in 
combination with a barrier method (eg, condom, diaphragm, cervical cap) during the study and for 3 months after discontinuation of treatment, and will also 
refrain from sperm donation for 3 months following 
completion of the study  
15. Able to understand and sign an informed consent 
Criteria for Exclusion  A patient will not be eligible for participation in this study if any of 
the following criteria apply.  
1. Prior chemotherapy for limited or extensive- stage SCLC  
2. Presence of symptomatic brain metastases  requiring 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 21 of 105  
G1 Therapeutics CONFIDENTIAL  immediate  treatment with radiation therapy or steroids  
3. History of other malignancies, except for the following: 
(1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated  a) in situ carcinoma of the 
uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no 
evidence of disease for ≥ 3 years  
4. Uncontrolled ischemic heart disease or uncontrolled 
symptomatic congestive heart failure  (Class III or IV as 
defined by the New York Heart Association [NYHA]  
functional classification system)  
5. Known history of stroke or cerebrovascular accident within 6 months prior to enrollment 
6. Serious active infection  
7. Psychiatric illness/social situations that would limit study 
compliance 
8. Other uncontrolled serious chronic disease or conditions that in the investigator’s opinion could affect compliance or 
follow-up in the protocol 
9. Known human immunodeficiency virus (HIV), known 
hepatitis  B virus  (HBV), or known hepatitis C virus (HCV)  
positive that is symptomatic or requiring  active therapy  
10. Concurrent radiotherapy to any site or radiotherapy within 
2 weeks prior to enrollment or previous radiotherapy to the 
target lesion sites (the sites that are to be followed for 
determination of a response) 
11. Receipt of any investigational medication within 4  weeks 
prior to enrollment 
12. Hypersensitivity to any of the components of the formulation of etoposide or etoposide phosphate 
13. Hypersensitivity to 
cisplatin or other platinum -containing 
compounds, or mannitol  
14. Legal incapacity or limited leg al capacity   
15. Pregnant or lactating women 
Chemotherapy Treatment  Carboplatin dose calculated using the Calvert  formula with a target 
AUC = 5 (maximum dose of 750 mg) administe red IV over 
30 minutes on Day 1  and 100 mg/m2 etoposide administered IV over 
60 minutes daily on Days 1, 2, and 3 of each 21-day cycle 
Test Articles Dosage and Administration  A starting dose of G1T28 200 mg/m
2 in 250 mL of dextrose 5% in 
water (D5W)  or in  sodium chloride s olution 0.9% administered as an 
IV infusion over 30 minutes once daily on Days 1 to 3 of each 21-day 
cycle prior to the dose(s) of chemotherapy 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 22 of 105  
G1 Therapeutics CONFIDENTIAL  Comparator Dosage and 
Administration  Placebo  formulation of 250 mL of D5W or sodium chloride solution 
0.9% administered  as an  IV infusion over 30 minutes once daily on 
Days 1 to 3 of each 21- day cycle prior to the dose(s) of chemotherapy  
Efficacy Evaluation  Efficacy evaluation will be based  on the following: kinetics  of 
changes in complete blood counts (CBCs) ; hematologic toxicities , 
including febrile neu tropenia  and infections; red blood cell ( RBC) and 
platelet transfusions ; hematopoietic growth factor utilization ; 
systemic antibiotic use ; chemotherapy dose reductions and dose 
interruptions; alo pecia;  mucositis ; nephrotoxicity; fatigue; and PROs  
using the Functional Assessment of Cancer Therapy (FACT) quality 
of life (QOL) instruments for lung cancer (FACT -L) and anemia 
(FACT -An). 
Safety Evaluation  Safety will be assessed by evaluation of AEs, physical examinations, 
vital sign  measurements, clinical laboratory data , infusion- related  
reactions, ECGs, tumor response based on RECIST , Version  1.1, 
PFS, and overall survival .  
Pharmacokinetics Evaluation  In the Phase 1b dose-finding portion of Part 1 of the study, blood samples will be collected  for the measurement of G1T28, etoposide, 
and carboplatin concentrations in plasma as described below .  
Phase 1b dose-finding portion of Part 1: Cycle 1  Day 1  
Blood samples will be collected at the fo llowing tim e points relative 
to the start of G1T28 infusion on Cycle 1 Day 1 for all Cohort 1 
patients enrolled in the Phase 1b dose- finding portion of Part 1 of the 
study : predose (0  hour; prior to dosing of G1T28) and at 0.5 (end of 
infusion [EOI] of G1T28), 1 (EOI  of carboplatin), 1.5, 2 (EOI of 
etoposide), 2.5, 3, 4.5, 6.5, 8.5 (this time point  may be optional if 
approved by sponsor in advance) , and 24.5 ( prior to G1T28 dose on 
Day 2 ) hours. The EOI sample for G1T28 should be drawn 2 to 
5 minutes prior to the EOI . Collection of PK  blood samples from 
patients enrolled  in additional cohorts of the Phase 1b dose-finding 
portion of Part 1 is optional.  
Phase 1b dose-finding portion of Part 1: Cycle 1  Day 3  
Blood samples will be collected at the fo llowing time points re lative 
to the start of G1T28 infusion on Cycle 1 Day 3  for all Cohort 1 
patients enrolled in the Phase 1b dose- finding portion of Part 1 of the 
study : predose (0  hour; prior to dosing of G1T28) and at 0.5 (EOI of 
G1T28), 1, 1.5 (EOI of etoposide), 2, 2.5, 3.5, 4.5, 6.5, 8.5 (this time 
point may be optional if approved by sponsor in advance), and 24.5 
hours. The EOI sample for G1T28 should be drawn 2 to 5 minutes 
prior to the EOI.  Collection of PK blood samples from patients 
enrolled  in additional cohorts of the Phase 1b dose-finding portion of 
Part 1 is optional.  
Pharmacokinetic parameters (eg, C max, time to reach C max [T max], 
AUC 0-t, AUC 0-∞, terminal half -life [ t1/2], volume of distribution in the 
terminal elimination phase [ Vz], and CL) will be derived from 
G1T28, etoposide, and carboplatin plasma concentration- time data.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 23 of 105  
G1 Therapeutics CONFIDENTIAL  Pharmacokinetic  samples may also be obtained from additional 
patients in the Phase 2a expansion cohort of Part 1 and Part 2 
depending on the outcome of initial Phase 1b PK analysis.  
Patient -Reported Outcomes Functional Asse ssment of Cancer Therapy QOL  instruments for lung 
cancer (FACT -L) and anemia (FACT -An) 
Immunologic Marker  
Assessment  In Part 2 of the study, peripheral blood samples will be collected at 
predose on Day 1 of C ycles  1, 3, and 5; at the Post -Treatment V isit; 
and at 60 days after the Post- Treatment V isit. 
Statistical Analysis  Data will be summarized separ ately by study part (Part 1 and Part 2). 
Data from Part 1 will be summarized descriptively by dose level , if 
applicable, and overall. Data from Part 2 will be summarized 
descriptively by treatment group and overall. Treatment differences 
between treatment groups for Part 2 will be calculated as G1T28  + 
E/P therapy minus Placebo + E/P  therapy. Select safety summaries 
will include combined data from both Parts 1 and 2 of the study. The 
descriptive summary for the categorical variables will include counts 
and percentages. The descriptive summary for the continuous 
variables will include means, medians, standard deviations, and 
minimum and maximum values. The descriptive summaries of time to 
even t data will include median, twenty -fifth and seventy- fifth 
percenti les, and standard error. All data will be listed for all patients.  
This study is descriptive in nature, and no formal hypothesis testing 
will be perf ormed across treatment groups. All confidence intervals  
(CIs)  will be 95%, unless stated otherwise.  
A DMC will review accumulatin g safety and disposition data during 
the Treatment Phase for patient s randomized in Part 2. The final 
analysis will be performed after all patients have compl eted the 
Post-Treatment  Visit.  A supplemental analysis including the 
cumulat ive data collected during the Survival Follow -up Phase will 
be co mpleted at the end of study. 
The full analysis set (FAS) includes all patients who received at least 
1 dose of study drug and will be the primary population for efficacy 
and exploratory endpoints. Full analysis set  analyses will be 
conducted on the basis of the assigned treatment. The safety population includes all patients who received at least 1 dose of study 
drug and will be the population used for the analysis of safety endpoints. The safe ty population will be conducted on the basis of the 
actual treatment received. A per -protocol (PP) subset may also be 
used to analyze select endpoints and will be based on study drug 
exposure (compliance and/or time on study drug) and major protocol 
deviations. The PK analysis set will include all dosed  patients in the 
Phase 1b dose-finding portion of Part 1 with evaluable PK data.  
Summaries of efficacy will be performed using the FAS on hematologic kinetics, hematologic toxicity, infections, growth factor 
and antibiotic use, transfusions, chemotherapy exposure, and 
patie nt-reported QOL scores . Select summaries will also be repeated 
in the PP analysis set. Unless noted otherwise, hematologic endpoints 
will be summarized separately by each parameter type ( ie, ANC, 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 24 of 105  
G1 Therapeutics CONFIDENTIAL  lymphocytes, etc.). Analyses comparing treatment groups for Part 2 
will adjust for baseline ECOG and other relevant parameters. Event 
rates will be calculated based on cumulative E/P exposure to account for potential differences in E/P  exposure acros s treatment arms.  
Summaries of safety data will be performed using the safety population. Adverse event data will be coded to system organ class 
and preferred term using the Medical Dictionary for Regulatory 
Activities (MedDRA; Version  17.1 or later). The number and 
percentage of patients experiencing any treatment -emergent AE, 
overall, and by system organ class and preferred term will be tabulated. The incidence rates adjusted by cumulative exposure will 
also be presented overall and by cycle. Absolute values and changes 
from baseline in vital signs, ECG readings, and hematology and clinical chemistry parameters will be tabulated at each visit  during the 
Treatment Phase. Toxicities for clinical labs will be characterized according to the CTCAE, Version 4.03. Shifts in toxicity grades from 
baseline to each visit will be summarized. Overall disease responses 
as determined by RECIST, Version 1.1 will be summarized by 
response level at each visit and best overall response. 
Progression- free survival and overall survival will be summarized 
using Kaplan- Meier methods.  
Blood sample s will be collected in the Phase 1b dose-finding portion 
of Part 1  of the study for the determination of  G1T28, etoposide, and 
carboplatin plasma concentrations. P lasma PK parameters will b e 
calculated for each analyte, when possible , including C
max, Tmax, 
AUC 0-t, AUC 0-∞, t1/2, V z, and CL. Pharmacokinetic results will be 
analy zed and reported for the PK analysis set, separately for each 
analyte. Plasma concentration -time data will be tabulat ed 
descriptively and graph ed for  each blood sampling day. 
Pharmacokinetic parameters will be calculated using noncompartmental methods based on the plasma concentration- time 
data. Pharmacokinetic parameters will be summarized descriptively by visit and ana lyte. If applicable, G1T28 PK data will also be 
summarized by dose level.  
Rationale for Number of 
Patient s The sample size for this study is determined by clinical rather than statistical considerations. Up to  40 patients (open-label, dose-finding 
cohort[ s] and an open-label, expansion cohort) will be enrolled in 
Part 1 of the study  and 70 patients will be enrolled in Part  2 of the 
study (randomized). 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 25 of 105  
G1 Therapeutics CONFIDENTIAL  4. INTRODUCTION  
4.1. Background 
Chemotherapy -induced myelosuppression continues to represent the major dose -limiting 
toxicity (DLT) of cytotoxic chemotherapy , including the etoposide and platinum (cisplatin or 
carboplatin)  comb ination used to treat extensive -stage small cell lung cancer (SCLC)  
(Schmittel 2006; Socinski 2009 ). Whether using cisplatin or carboplatin, the combination of 
a platinum agent with etoposide results in significant myelosuppression (neutropenia 47% to 
92%, leukopenia 8% to 66%, thrombocytopenia 10% to 46%, and anemia 7% to 34%) (Eckardt 2006; Noda 2002; Hanna 2006; Socinski 2009; Hermes 2008; Schmittel 2011 ). 
Myelosuppression is the source of many of the important side effects of cancer treatment , 
such as infection, sepsis, bleeding, and fatigue , leading to the need for hospitalizat ions, 
hematopoietic growth factor support , and transfusions (red blood cells  [RBCs]  and/or 
platelets). Moreover, clinical concerns raised by myelosuppression commonly lead to chemotherapy dose reduct ions and limit therapeutic dose intensity.  
G1T28 (formerl y G1T28 -1) is a highly potent and selective, reversible, cyclin -dependent 
kinase 4/6 (CDK4/6 ) inhibitor  that transiently induces  gap 1 ( G1) phase  (resting phase in the 
cell cycle in which cel ls exist in a quiescent state ) cell cycle arrest of hematopoietic  stem and 
progenitor cells  (HSPCs)  in the bone marrow. These cells are dependent upon CDK4/6 for 
proliferation and enter the G1 phase of the cell cycle upon exposure to G1T28 . When the 
HSPCs  are transiently arrested in the G1  phase of the cell cycle, they are more resistant to the 
deoxyribonucleic acid ( DNA ) damaging effects of chemotherapy, thus potentially reducing 
subsequent myelosuppression. The initial indication for intravenous (IV) G1T28 is the 
reduction of chemotherapy -induced myelosuppression.  
The principal component of this therapeutic approach is to transiently arrest HSPCs  in the 
G1 phase of the cell cycle while  chemotherapy is administered. It is imperative that this 
therapeutic approach provides selective bone marrow protection without antagonizing the tumor efficacy of chemotherapy. To ensure this second feature, patients are required to have CDK4/6 -indpendent tumors.  The downstream target of CDK4/6 is the retinoblastoma  (Rb)  
protein, which is phosphorylated upon CDK4/6 activation, allowing the  cell to enter into the 
S phase  of the cell cycle (synthesis phase of cell cycle in which DNA is replicated) . In order 
to promote G1 cell cycle arrest by utilizing a CDK4/6 inhibi tor, a functional Rb  protein is 
required. For  SCLC, historical reports have consistently shown the most prevalent 
inactivated tumor suppressor genes are tumor protein 53 ( TP53 ) and retinoblastoma 1 ( RB-1) 
(D’Amico 1992; Heighway 2004 ; Yuan 1999; Cagle 1997; Gouy er 1994 ), and it has been 
accepted that almost all cases of SCLC are functionally Rb null. In addition , 2 recent reports 
provided a detailed characterization of the genomic landscape of SCLC using next generation sequencing approaches, including full exome sequencing, transcriptome profiling by RNA sequencing ( RNASeq ), copy number analyses, and limited whole genome sequencing to 
identify translocations  (Peifer  2012; Rudin 2012 ). These reports confirmed what had been 
previously proposed in studies that examined a smaller number of tumors, namely that concomitant inactivation of TP53 and RB -1 are driver mutations and occur nearly universal ly 
in SCLC. Consistent with these  data, preclinical in vitro and in vivo studies have 
demonstrated  that G1T28 exposure prior to chemotherapy does not diminish the effect of 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 26 of 105  
G1 Therapeutics CONFIDENTIAL  chemotherapy in tumors tha t are RB- 1 inactive , including SCLC. Therefore, as a result of 
near universal RB-1 inactivation, SCLC is inherently CDK4/6 -independent , which should 
allow selective protection of the HSPCs but not the tumor from the effects of chemotherapy.   
4.2. Summary of Clinical Data 
A brief summary of the clinical data is provided in the following sections. Detailed 
information is presented in the G1T28 Investigator’s Brochure (IB).  
Study G1T28 -1-01 was a Phase 1a, safety, PK, and pharmacodynamic study of G1T28.  
Forty -five healthy male and female subjects were enrolled into 7 dose cohorts where G1T28 
was administered IV as a 30 -minu te infusion (randomized, double- blind, plac ebo-controlled 
ascending doses of 6, 12, 24, 48, 96, or 192 mg/m2, and an open- label expanded 
pharmacodynamic cohort at 192 mg/m2). 
The most frequently  (> 10% of subjects) reported adverse events  (AEs)  were the following: 
headache (17 subjects, 38%), nausea (10 subjects, 22%), pain in extremity (8 subjects, 18%), and procedural pain (7 subjects, 16%). The treatment -emergent AEs of headache and nausea 
occurred more frequently in the combined 192 mg/m
2 dose group (14 events of headache 
reported by 13 subjects  [72%] and 10  events of nausea reported by 9  subjects [50%]) than in 
the lower dose groups . Most treatment- emergent AEs were mild in intensity; 13 subjects 
experienced a total of 19  treatment -emergent AEs of moderate intensity. Four AEs of 
moderate intensity occurred in the 96 mg/m2 dose group (2  events of headache [possibly 
related], 1  event of back pain [unlikely related], and 1  event of nausea [possibly related]). 
Fifteen  AEs of moderate intensity occurred in the combined 192 mg/m2 dose group (7 events 
of headache [all possibly related], 6  events of nausea [all possibly related], 1  event of 
procedural anxiety [not related] , and 1  event of loss of  appetite [possibly related]). No severe 
or life -threatening events were reported. There were no deaths, other serious adverse events 
(SAEs ), or treatment -emergent AEs resulting  in withdrawal from the study. All 
treatment -emergent AEs were transient and recovered/resolved by the end of the study.  No 
significant changes were noted in 12 -lead electrocardiograms  (ECGs ), vital signs, or 
laboratory values (including complete blood counts [ CBCs ]). 
Following a single 30- minute IV infusion of G1T28, the median time to reach the maximum 
concentration (T max) ranged between 0.25 and 0.47 hour after the start of infusion. The 
maximum concentration ( Cmax) increased in a dose -proportional manner following a single 
30-minute IV infusion of G1T28 over the dose range of 6 to 192 mg/m2. Total systemic ( area 
under the concentration -time curve [ AUC ]) exposure increased more than dose 
proportionally over the dose range of 6 to 192 mg/m2 of G1T28. The elimination kinetics of 
G1T28 appeared to follow a 3 -compartment model. The geometric mean  half-life ( t1/2) was 
12.9 to 14.7 h ours for the 48 to 192 mg/m2 dose levels. The interpatient variab ility (%CV) of 
the PK parameters at the 192 mg/m2 dose level was low (<15%). The PK of G1T28 suggests 
that drug accumulation following repeated admini stration is unlikely to occur. Urinary 
excretion appears to be a minor route of elimination for unchanged G1T28. 
G1T28 showed positive pharmacodynamic  effects in 2  assays. Dose -dependent inhibition of 
ex vivo whole blood stimulation occurred following a single IV infusion of G1T28 at 96 and 
192 mg/m2 (maximum mean inhibition of 37.2% and 60%, respectively, occurred  4 hours 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 27 of 105  
G1 Therapeutics CONFIDENTIAL  after the end of infusion) . Lymphocyte proliferation started to recover 8  hours after the end of 
infusion, but inhibition of proliferation persisted until the last sampling time point of 
24 hours . Assessment of bone marrow  24 hours after  admi nistration of G1T28 at the 
biologically effective dose (BED) of 192 mg/m2 revealed a significant decrease in the 
number of HSPCs in the synthesis ( S)/gap 2 ( G2)/mitosis  (M) phases of the cell cycle (ie, an 
increase in the proportion of cells in G1 arrest).  This G1 arrest persisted in the different 
progenitor lineages 32 hours after dosing.  However, no changes were noted in the peripheral 
blood counts, indicating that the bone marrow arrest is transient and reversible and is 
consistent with the effects seen in animals.   
4.3. Summary of Nonclinical Data 
A brief  summary of the nonclin ical data is provided in the following sections. Detailed 
information is presented in the G1T28 IB . 
4.3.1.  Pharmacology Studies 
Through a structure -based design approach to optimize potency, s electivity, and drug 
metabolism and PK properties, G1 Therapeutics , Inc.  identified G1T28 as a highly potent 
inhibitor of CDK4 and CDK6 (half maximal inhibitory concentration [IC 50] values of 0.8 and 
6 nM, respectively)  that is  highly se lective for CDK4 versus cyclin -dependent kinase 
2 (CDK2 ) (> 2000- fold selectivity).  
The G1T28 -induced G1 arrest of HSPCs has been shown to be transient and readily 
reversible in bot h in vitro and in vivo models. In vivo an alysis has demonstrated that 
coadm inistration of G1T2 8 with myelosuppressive chemotherapy  leads to  improved CBC  
recovery of all blood li neages and increased survival. In addition, administration of G1T28 
with every cycle of the highly myelosuppressive chemotherapy 5 -fluorouracil (5 -FU) for a 
total of 4 cycle s demonstrated that the reduction in chemotherapy -induced myelos uppression 
persisted following Cycle  4. While the extent and duration of nadir in CBCs worsened after 
each cycle of 5 -FU administered alone, co administration of G1T28 with 5- FU ameliorated 
this worsening effect and the animals that received G1T28 + 5 -FU demonstrated a faster rate 
of recovery of CBCs compared with  the 5 -FU alone group following Cycle 4. In accordance 
with the single -dose study, G1T28 administration with all cycles of 5 -FU mainta ined the 
protective effect against 5 -FU-induced DNA damage in HSPCs over multiple cycles, leading 
to an effect that persisted and was greater follo wing multiple cycles of G1T28  + 5- FU 
compared with 5- FU alone.  In addition, bone marrow obtain ed from mice th at received 
4 cycles of G1T28 administered prior to every dose of 5- FU was more robust at 
hematopoietic reconstitution of lethally irradiated mice following bone marrow transplantatio n compared with  bone marrow obtained from mice  that received 4  cycles of 
5-FU alone, suggesting that G1T28 administered with chemotherapy can preserve stem cell 
function. 
Retinoblastoma is the direct downstream target of CDK4/6 and its ex pression is required for 
CDK4/6 -dependent cells. Importantly, cancers that delete Rb do not  require CDK4/6 activity 
for cell cycle progression (Fry 2004) ; therefore , loss of Rb is a hallmark identifier of 
CDK4/6  independence.  Since inactivation of RB -1 is an obligate event in SCLC 
development  (D’Amico 1992; Heighwa y 2004; Yuan 1999; Cagle 1997; Gouyer 1994 , 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 28 of 105  
G1 Therapeutics CONFIDENTIAL  Peifer  2012; Rudin 2012 ), this tumor type is highly resistant to CDK4/6 inhibitors and 
coadministration of CDK4/6 inhibitors with DNA damaging chemotherapeutic agents such as 
those used in SCLC are not expected to antagonize the efficacy of such agents . In vitro  
analysis has shown that RB -1 inactive  cells are resistant to CDK4/6 inhibition and therefore 
are not protected from chemotherapy when co treated with G1T28. To expand these findings 
in vivo, G1T28 was tested alone and in combination with topot ecan or  an etoposide and 
carboplatin  (E/P)  combination regimen in a cell -based xenograft SCLC model (H69) in 
immune-deficient mice . G1T28 administered alone or 30  minu tes before E/P  or topotecan 
was well tolerated , with no add itive weight loss or toxicity. Single agent G1T28 was inactive 
towards NCI -H69 SCLC tumors and combina tion with a n E/P  regimen did not result in 
additive efficacy, nor did it antagonize the intended effects of E/P . Combination of G1T28 
and topotecan was superior to topotecan alone during dosing and the addition of G1T28 
extended the statistically significant (p  < 0.05)  antitumor  effect of topotecan after dosing.  
Thus , G1T28 was well tolerated and did not antagonize the effects of chemotherapy  in a 
CDK4 /6-independent (RB -1 inactive ) SCLC tumor  model . 
4.3.2.  Pharmacokinetic Studies  
Pharmacokinetic studies in rats and dogs showed that the relationship between dose level and 
plasma exposure to G1T28 was generally similar between males and females and did not change with repeated daily dosing. Exposure to G1T28 increased with dose level, but not always proportionally. Plasma half -life values for G1T28  after IV administration were 
approximately 4 hours in rats and dogs. 
In vitro ana lyses of direct and time -dependent inhibition suggest that drug interactions based 
on inhibition of cytochrome P40 ( CYP )1A2-, 2B6 -, 2C8- , 2C9 -, 2C19- , and 2D6- mediated 
metabolic pathways are unlikely at concentrations of G1T28 below 100 µM (44,600 ng/ml). 
Drug interactions based on G1T28 mechanism -based inhibition of CYP3A4- mediated 
metabolic pathways are possible. Additionally, in vitro induction studies of the 3 major inducible CYP enzymes (CYP1A2, CYP3A4, and CYP2B6) in human hepatocytes suggest that G1T 28-mediated  induction is unlikely.   
While etoposide is a CYP3A4 substrate, there are no specific label warnings regarding coadminist ration with CYP3A4 inhibitors. This may in part be due to the relatively equal 
contributions of renal and hepatic clearance to the  total clearance of etoposide. In addition, 
administration of oral ketoconazole, a potent CYP3A4 and uridine disphosphate 
glucuronosyltransferase 1 family, polypeptide A1 ( UGT1A1 ) inhibitor, with oral etoposide 
for 3 of every 5 -week cycles resulted in an increase of the median AUC of oral etoposide of 
only 20% and did not alter its toxicity profile ( Yong  2007 ). In the present Study G1T28-02, 
IV G1T28 will be administered prior to IV etoposide on Days 1 to 3 of 21- day c ycles  in 
patients with ade quate renal function. In the Phase 1b dose- finding portion of Part 1 of the 
study, PK of etoposide, carboplatin, and G1T28 will be assessed on D ays 1 and 3 of the first 
cycle. In addition , frequent CBCs will be assessed. Since myelotoxicity is the major toxicity 
of etoposide, this will be monitored closely in this study.  
In vitro inhibition studies with membrane transporter model systems also suggest G1T28 is unlikely to cause a drug -drug interaction (DDI) based on inhibition of b reast cancer 
resistance protein ( BCRP )-, bile salt export pump ( BSEP )-, organic anion transporter 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 29 of 105  
G1 Therapeutics CONFIDENTIAL  1 (OAT1 )-, organic anion transporter 3 ( OAT3 )-, organic anion transporting polypeptide 1B1 
(OATP1B1 )-, p- glycoprotein ( MDR1 )-, multidrug resistance protein 1 ( MRP1 )-, multidrug 
resistance protein 2 ( MRP2 )-, organic cation transporter 1 ( OCT1 )-, or organic anion 
transporting polypeptide 1B3 ( OATP1B3 )-mediated transport. G1T28 is a potent in hibitor of 
multidrug and toxin extrusion 1 ( MATE1 ), multidrug and toxin e xtrusion 2- K (MATE2 -K), 
and organic cation transporter 2 ( OCT2 ) (IC 50 values were 0.175, 0.071, and 0.152 µM, 
respectively) , and therefore, may be a cause of a DDI  if co administered with substrates of 
these transporters.      
Carboplatin has been reported (Yonezawa 2006 ) to not be a substrate for OCT2, MATE1, or 
MATE2. Etoposide has not been reported to be a substrate for any of these 3  transporters, 
and by structure is n ot expected to be a substrate. Based upon these data, a clinically 
significant alteration of carboplatin or etoposide PK  due to G1T28 inhibition of OCT2, 
MATE1 , or MATE2 -K is not expected.  
4.3.3.  Toxicity and Safety Studies 
The toxicity of IV and oral G1T28 was evaluated in single- and repeat -dose studies of up to 
14 days duration in rats and dogs and in a battery of in v itro genotoxicity studies. In addition, 
the compatibility of G1T28 clinical drug product with human blood was evaluated in vitro.  
For further information, please refer to the G1T28 IB.  
4.3.4.  Potential Risks  
When administered IV daily for 7 days, G1T28 was tolerated in rats at up to 50 mg/kg 
(approximately  300 mg/m2) and in dogs at up to 15 mg/kg (approximately  300 mg/m2), with 
toxicity characterized chiefly by reduced hematopoiesis that involved all cell lineages and was a reflection of the drug’s intended pharmacodynamic activity. The magnitude and/or 
duration of effect differed among cell lineages , but were dose related in all lineages. Effects 
on hematopoiesis were readily monitored by peripheral blood cel l counts and were r eversible 
when dosing stopped. Clinically significant leukopenia occurred in ra ts and dogs given  IV 
G1T28 for 7  days at ≥ 150 and 300 mg/m
2, respectively, and it led to morbidity and mortality 
in dogs given daily doses for 6 days at 900 mg/m2. 
In addition to the intended effects on hematopoiesis, animal studies with G1T28 suggest that 
potential side effects in human patient s might include  the following : 
• Pulmonary macrophage accumulation : In r ats, daily oral doses of G1T28 for 14 days at 
≥ 5 mg/kg (≥ 30 mg/m2) resulted in minimal to mild accumulation of foamy macrophages 
in alveoli. The magnitude of this finding increased with dose level, but it was not associated with any discernable change in the rate or character of respiration. Macrophage accumulation showed evidence of resolving withi n 3 weeks after dosing 
stopped. Pulmonary macrophage accumulation was also seen in dogs given daily IV 
doses of G1T28 by 30 -minute infusion at 45 mg/kg (900 mg/m
2) for 5 days, at which 
point dosing was stopped due to toxicity. The DLT in these dogs was considered to be severe immunocompromise secondary to inhibition of myelopoiesis and lymphopoiesis; ie, an extension of the primary pharmacodynamic activity of G1T28 . 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 30 of 105  
G1 Therapeutics CONFIDENTIAL  • Increased heart rate: In dogs, single IV doses  of G1T28 at ≥ 15 mg/kg (≥  300 mg/m2) 
produced  increases in heart rate that  were relatively mild (30 to 60 beats per minute 
[bpm]) and resolved within a few hours. 
• Effects on liver : Daily IV doses of G1T28 in rats at ≥ 10 mg/kg/day (≥  60 mg/m2/day) 
and in dogs at ≥  15 mg/kg/day (approximately  300 mg/m2/day)  resulted in  slightly 
increased alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) 
levels. Liver -related effects in both species were revers ible within 2  weeks after the last 
dose. There were no effects on liver in rats given daily oral doses for 14 days at up to 
30 mg/kg (180 mg/m2). 
• Local irritation at the infusion site : Dogs given daily doses of G1T28 for 7 days  had 
occasional episodes of  swelling/edema at the infusion site. This  was considered likely to 
be due to leakage or accidental injection of dosing solut ion into the perivenous tissue.  
Although G1T28 induced micronucleus formation in human lymphocytes exposed in vitro, 
G1T28 is not considered to pose a hazard to human patien ts, as G1T28 was negative for 
mutagenic potential in a Good Laboratory Practice ( GLP ) (and non -GLP) Ames assay, and 
did not induce  phosphorylated histone  H2AX  (γH2AX)  formation in primary human 
fibroblasts.  In the present study, G1T28 will be administered in conjunction with 
etoposide/carboplatin, which presents a genotoxic hazard to human subjects. In this context, any slight additional genotoxic hazard posed by G1T28 is negligible.  
In female rats, daily administration of G1T28 for 7 days resulted in lower  ovary and uterus 
weights and more rats in metestrus/diestrus, and these effects were reversible within 2 weeks after the last dose. These findings in rats raise the possibility that G1T28 may affect menstrual cycling in women; however, no studies have bee n done specifically to evaluate the 
effects of G1T28 on ferti lity in animals of either sex. For men, studies in rats and dogs do not 
suggest any potential for impairment of fertility; specifically, there were no pathologic findings in reproductive organs of male rats or dogs given d aily doses of G1T28 for 7 days.  
Nevertheless, patients who are pregnant or lactating should not receive G1 T28. Heterosexual 
coupl es in which  the female is of child bearing potential must use appropriate birth control 
methods. 
The nonclinical package as a whole indicates that rats and dogs were appropriate species for 
evalu ating the toxicity of G1T28. In both species, the toxicity profile was similar.  
4.4. Study and Dose Rationale 
Chemotherapy -induced myelosuppression is a significant is sue in cancer treatment, including 
treatment of SCLC. G1T28 is a highly potent and select ive CDK4/6 inhibitor that induces  a 
transient and reversible G1 cell cycle arrest of HSPCs within the bone marrow, thus protecting their DNA from damage by coadministe red chemotherapy and preserving 
long-term function. In animal studies, administration of G1T28 just prior to dose(s) of 5- FU 
resulted in a more rapid recovery of all hematopoietic lineages. This effect persisted following administration of multiple cycles of chemotherapy. Bone marrow obtained from mice that received 4 cycles of G1T28 administered prior to every dose of 5 -FU was more 
robust at hematopoietic reconstitution of lethally irradiated mice following bone ma rrow 
transplantation compared with  bone ma rrow obtained from m ice that received 4 cycles of 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 31 of 105  
G1 Therapeutics CONFIDENTIAL  5-FU alone, suggesting that G1T28 administered with chemotherapy ca n preserve stem cell 
function. 
Since inactivation of RB -1 is an obligate event in SCLC development ( D’Amico 1992 ; 
Heighway 2 004; Yuan 1999; Cagle 1997; Gouy er 1994, Peifer 2012; Rudin 2012 ), this tumor 
type is highly resistant to CDK4/6 inhibitors and coadministration of CDK4/6 inhibitors with 
DNA damaging chemotherapeutic agents , such as those used in SCLC , are not expected to 
antagonize the efficacy of such agents. In vitro analysis has shown that Rb -null cells are 
resistant to CDK4/6 inhibition. In vivo, G1T28 administered alone or 30 minutes before E/P or topotecan was well tolerated and did not antagonize the effects of chemotherapy in a cell-based xenograft model (H69) representing SCLC in immune -deficient mice (see details 
in Section 4.3.1 ).  
Study G1T28 -1-01 was a Phase 1a, safet y, PK, and pharmacodynamic study of G1T28.  
Forty -five healthy male and female subjects were enrolled into 7 dose cohorts where G1T28 
was administered IV as a 30 -minu te infusion (randomized, double- blind, placebo -controlled 
ascending doses of 6, 12, 24, 48, 96, or 192 mg/m
2, and an open- label expanded 
pharmacodynamic cohort at 192 mg/m2). G1T28 was well tolerated, with no DLTs  or SAEs  
reported. Additionally, over the dose range of 6 to 192 mg/m2, Cmax increased in a 
dose- proportional manner, total systemic (AUC) exposure increased more than dose 
proportionally, and  clearance (CL) was relatively constant.  The PK of G1T28 suggests that 
drug accumulation following repeated administration is unlikely to occur.  Based on PK/PD 
parameters from the Phase 1a study an d a preclinical PK/PD model,  a BED  of 192 mg/m2 of 
G1T28 was identified. Twenty -four hours following administration of the BED , a significant 
decrease was noted in the number of bone marrow HSPCs in the S/G2/M phases of the cell 
cycle (ie, an increase in t he proportion of cells in G1 arrest) , which persisted to  32 hours. 
Thus, dosing of G1T28 200 mg/m2 (rounded up from the BED of 192 mg/m2) prior to the 
administration of etoposide and carboplatin  on Day  1 and administration of etoposide  on 
Days 2 and 3 of 21-day cycles  (hereafter referred to as E/P therapy)  should maintain the bone 
marrow HSPCs in G1 arres t during and for several half -lives after chemotherapy 
administration , thus protecting their DNA from cytotoxic damage. The goals of this study are 
to assess the safety and tolerability of combining G1T28 with E/P  therapy  and to evaluate the 
effect of G1T28 on chemotherapy -induced myelosuppression.  
4.5. Risk/Benefit Assessment  
G1T28 is being developed to reduce chemotherapy -induced myelosuppression,  which is a 
significant issue. Bone marrow HSPCs require CDK4/6 for proliferation. SCLC tumors are 
almost universally CDK4/6 independent by virtue of various genetic m utations in the RB -1 
gene  that result in the loss of the Rb protein, which is the downstream target of CDK4/6. 
Therefore, the risk of producing a G1 cell cycle arrest of the tumor cells, and thereby 
protecting the tumor from chemotherapy, is small. As stated in Section  4.4, the BED of IV 
G1T28 is 192 mg/m2 and a dose of 200 mg/m2 will be used as the starting dose for 
administration on Days 1 to 3 of every 21- day cycle  of E/P therapy  in the present study. In 
conclusion , the potenti al benefits of combining G1T28 at a dose of 200 mg/m2 with 
E/P therapy  to protect the  bone marrow HSPCs outweigh the potential risks.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 32 of 105  
G1 Therapeutics CONFIDENTIAL  5. STUDY OBJECTIVE S  
The primary, secondary , and exploratory  objective s of this study are presented in  Table 5-1 . 
Table 5-1 G1T28- 02: Study Objectives  
 Phase 1b 
Dose -Finding 
Portion of 
Part 1  Phase 2a 
Expansion  
Portion of 
Part 1  Phase 2a 
Part 2  
Primary Objectives  
Assess the DLTs and define the Phase 2 dose of G1T28 
administered with E/P therapy  X   
Assess the saf ety and tolerability of G1T28 administered 
with E/P  therapy  X  X X 
Secondary Objectives  
Assess the PK profile of G1T28  X   
Assess the PK profile of etoposide and carboplatin when administered with G1T28  X   
Assess the hematologic profile (kinetics and incidence/duration/frequency of toxicities) of G1T28 
administered with E/P therapy  X  
 X X 
Assess the incidence of febrile neutropenia  X X X 
Assess the incidence of infections  X X X 
Assess the utilization of RBC and platelet transfusions  X X X 
Assess t he utilization of hematopoietic growth factors  X X X 
Assess the utilization of systemic antibiotics  X X X 
Assess the incidence of chemotherapy dose reductions and 
dose interruptions overall  X X X 
Assess the incidence of Grade 2 or greater nephrotoxicit y  X X X 
Assess tumor response based on RECIST, Version 1.1  X X X 
Assess PFS and overall survival  X X X 
Exploratory Objectives  
Assess the incidence of mucositis  X X X 
Assess the incidence of alopecia X X X 
Assess the incidence of fatigue X X X 
Asses s patient- reported QOL  X X X 
Assess immunologic markers    X 
DLT = dose -limiting toxicity; E/P  therapy  = etoposide + carboplatin on Day 1 and etoposide on Days 2 and 3 of 21- day 
cycles ; PFS = progression-free survival; PK = pharmacokinetic; QOL = quality of life; RBC = red blood cell; 
RECIST = Response Evaluation Criteria in Solid Tumors  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 33 of 105  
G1 Therapeutics CONFIDENTIAL  6. INVESTIGATIONAL PLAN 
6.1. Overall Study Design and Plan 
This is a randomized, double- blind, placebo -controlled , multic enter , Phase 1b/2a study  of the 
safety and PK  of G1T28 in  combination with E/P  therapy  for patients with newly diagnos ed 
extensive -stage SCLC . The study consists of 2 parts: Part 1 will be a limited Phase 1b, 
open -label, dose- finding portion followed by a Phase 2a, open- label, expansion portion in up 
to 18 patie nts at the selected dose to be used in Part 2. Prior to initiating Part 2, up to a total 
of 24 patients will be enrolled at the chosen Part 2 dose ( 6 patients in the dose -finding 
portion of Part 1 and up to 18 patients in the Phase 2a, open -label , expansio n portion of Part 
1). Part 2 will consist of a randomized, double -blind cohort (70 patients will be randomly 
assigned to G1T28 administered IV with E/P therapy or placebo administered IV with 
E/P therapy). All parts of the study  include 3  study phases: Screening Phase, 
Treatment  Phase , and Survival Follow- up Phase . The Treatment Phase begins on the day of 
first dose with study treatment and completes at  the Post- Treatment Visit.  
The initial diagnosis of SCLC should be made based on standard pathological examination , 
preferably including immunohistochemical staining for neuroendocrine features . Archived 
tumor samples should be available for sending to a central pathology laboratory to confirm the diagnosis of SCLC . If central pathology review does not confirm SCLC diagnosis, the 
patient may be withdrawn from the study a fter consultation between the principal 
investigator, medical monitor , and sponsor. Available tissue after confirming the diagnosis of 
SCLC will be banked for assessment of relevant DNA, ribonuc leic acid ( RNA ), and protein 
markers, such as those involved in the CDK4/6 pathway . 
6.1.1.  Part 1  
The goal of the Phase 1b dose -finding portion of Part 1  is to assess the safety, including 
DLTs (see Section  6.1.1.1 ), and PK  (see Section 6.1.1.2 ) of G1T28 administered at a starting 
dose of 200 mg/m
2 (derived f rom Study G1T28 -1-01 , a Phase 1a, safety, PK, and 
pharmacodynamic study of G1T28 in healthy male and female patients) once daily on Days 1 
to 3 of E/P therapy (Figure  6-1).  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 34 of 105  
G1 Therapeutics CONFIDENTIAL  Figure  6-1 Study Schema: Phase 1b  Dose -Finding Portion of Part 1  
 
E/P = etoposide + carboplatin  
a  Safety and available PK data from Cycle 1 will be considered in making dose escalation/de-escalation decisio ns (if 
required) and enrolling additional cohorts  
b  G1T28 + E/P will continue until disease progression, unacceptable toxicity, or discontinuation by th e patient or 
investigator  (eg, after completing 6 cycles) . The tumor should be assessed after every even cycle  using Response 
Evaluation Criteria in Solid Tumors ( RECIST), Version 1.1. Assessments should  be performed within 7 days of 
starting the subs equent cycle.  
c  G1T28 will be administered prior to the administration of etoposide and carboplatin on Day 1 and administration of 
etoposide on Days 2 and 3 of 21- day cycles  
d Patients will return to the study cen ter for a Post -Treatment Visit at 30  + 3 d ays after the last dose of study drug.  
e The Survival Follow -up Phase will continue until at least 50% of the patients randomized to Part 2 of the study have 
died.  
 
6.1.1.1.  Definition of Dose -Limiting Toxicities (Applicable to Cycle 1 of the Phase 1b 
Dose -Finding Portion of Part 1)  
Dose -limiting toxicities are drug -related toxicities defined as follows:  
• Absolute neutrophil count ( ANC ) < 0.5 × 109/L lasting  for ≥ 7 days  
• ≥ Grade 3 neutropenic infection/febrile neutropenia  
• Grade 4 thrombocytopenia or ≥ Grade 3 thrombocytopenia with bleeding  
• Unable to start next cycle of chemotherapy due to lac k of recovery to an 
ANC  ≥ 1.5 × 109/L and platelet count ≥  100 × 109/L 
• ≥ Grade 3 nonhematologic toxicity (nausea, vomiting, and diarrhea failing  maximal 
medical management ; fatigue lasting  for > 72 hours ) 
 
Toxicities not clearly related to etoposide/carboplatin (E/P) therapy will also be considered for the purposes of determin ing DLTs.  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 35 of 105  
G1 Therapeutics CONFIDENTIAL  6.1.1.2.  Criteria for Adjusting G1T28 Dose Based on Pharmacokinetic Parameters  
The PK profile of G1T28 is well established in healthy subjects , with good estimates of key 
parameters such as C max, AUC, and CL . In addition, the intersubject variability in these PK 
parameters is low (see Section 4.2). However, patients with SCLC enrolled in this study will 
likely be older and have more comorbidities compared with  subjects enrolled in the Phase  1a 
G1T28-1- 01 study , and  therefore, could  demonstrate differences in PK.   
Based on the observed PK profile of G1T28 in Study G1T28-1- 01, the extrapolated 
AUC 0-24.5h for a 200 mg/m2 dose is 3100 h•ng/mL . If the mean AUC 0-24.5h in the initial cohort 
of patients ( 6 patients ) in the Phase 1b, dose -finding portion of Part 1  is not within 20% of 
the target (eg, 2480 to 3720 h•ng/mL ), then the dose of G1T28 wi ll be adjusted in the next 
cohort of 6 patients to achieve a mean AUC 0-24.5h of 3100 h•ng/mL . The magnitude of the 
dose modifi cation is based upon the fact that G1T28 displays linear PK over the dose range 
studied to date .  Any  available PK data from  additional cohort(s) of the Phase 1b  
dose- finding portion of Part  1 may be utilized  for modifying the G1T28 dose (if required). If 
the G1T28 dose level for a subsequent cohort requires escalation, the increase will not 
exceed 30%  from the previous dose level .  A G1 cell cycle arrest of a minimum of 24 hours 
after G1T28 administration is desired to ensure that the bone marrow arrest is  maintained 
long enough to avoid releasing HSPCs into the S (DNA synthesis) phase of the cell cycle in the presence of high concentrations of chemotherapy and thereby potentially exacerbating myelosuppression.  
If the dose is adjusted due to DLTs and the P K was within the expected target range, then a 
new target AUC
0-24.5h will be calculated for the modified dose  as follows:  
Y = 2.11 + 1.1*X, where Y is the ln(AUC 0-24.5) h*ng/mL  and X is the ln(dose) mg/m2 
6.1.1.3.  G1T28 Dose E valuation  
Six patients will initially be enrolled into the Phase 1b, dose -finding portion of Part 1 and 
will receive G1T28 200 mg/m2 in combin ation with standard E/P therapy (see Section 8.1). 
Safety and available PK parameters  from this initial coh ort of 6 patients during  Cycle 1 will 
be considered in making dose escalation/de- escalation decisions (if required). If a patient is 
withdrawn prior to completing all assessments in  Cycle 1 for reasons other than toxicity in 
any cohort in the Phase 1b, dos e-finding portion of Part 1, the patient will be replaced.  
G1T28 dose evaluation criteria are listed below and are presented as a decision tree in 
Figure  6-2. While the dose evaluation criteria below will be used to guide all dose decisions, 
the SMC will be responsible for all dose and cohort recommendations.  
• If there is ≤  1 DLT in the first cohort of 6 pa tients during Cycle 1  of the Phase 1b, 
dose- finding portion of Part 1 and the available G1T28 PK parameters are as predicted  
(Section  6.1.1.2 ), the dose- finding portion of Part 1 will end and subsequent patients will 
be enrolled into the Phase 2a expansion  cohort of Part 1 , utilizing a dose of G1T28 of 
200 mg/m2 in combination with E/P  therapy . 
• If there is ≤  1 DLT in the first  cohort of 6 patients during Cycle 1  of the Phase 1b 
dose- finding portion of Part 1, and the available G1T28 PK parameters suggest that the 
G1T28 dose needs to be escalated or de- escalated  (see Section 6.1.1.2 ), a second cohort 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 36 of 105  
G1 Therapeutics CONFIDENTIAL  of 6 patients will be enrolled at the higher or lower predicted G1T28 dose in combination 
with E/P  therapy . For assessment of data from the second cohort enrolled in the Phase 1b 
dose- finding portion of Part  1, please see the decision tree in  Figure  6-2. 
• If there is  > 1 DLT in t he first cohort of 6 patients during Cycle 1 of the Phase 1b 
dose- finding portion of Part 1 and the available G1T28 PK parameters su ggest that the 
G1T28 dose needs to be escalated  or de -escalated (ie , in order to increase or decrease the 
magnitude and duration of G1 cell cycle arrest of HSPCs  predicted by the PK/PD model 
and data from the Phase  1a Study G1T28 -1-01; see Section 6.1.1.2 ), a second cohort of 6 
patients will be enrolled at the modified  G1T28 dose in combination with E/P  therapy. 
For assessment of data from the second cohort enrolled in the Phase 1b dose -finding 
portion of Part 1,  please see the decision tree in Figure  6-2. 
• If there is  > 1 DLT in the first cohort of 6 patients  enrolled in the Phase 1b dose- finding 
portion of Part 1  and the available G1T28 PK parameters from these 6 patients are as 
predicted (Section  6.1.1.2 ), the dose of G1T28 should be d ecreased to 16 0 mg/m2 and an 
additional 6 patients should be enrolled at the modified G1T28 dose in combination with 
E/P therapy . For a ssessment of data from the second cohort enrolled in the Phase 1b 
dose- finding portion of Part 1, please see the decision tree in Figure  6-2.  
• If there is >  1 DLT following a G1T28 dose of 160 mg/m2 in co mbination with 
E/P therapy in the second cohort of patients  and if  available,  PK parameters  are as 
predicted (Section  6.1.1.2 ), an additional cohort of 6 patients will be enrolled at a further 
decreased G1T28 do se of 130 mg/m2 in combination with E/P  therapy. For assessment of 
data from the third cohort enrolled in the Phase 1b dose- finding portion of Part 1, please 
see the decision tree in Figure  6-2.  
• If there  is > 1 DLT following the second dose reduction of G1T28 and if available,  PK 
parameters from  the third cohort are as predicted (Section 6.1.1.2 ), no further dose 
modifications will be made and the study will be  terminated.  
• At any time, if ≥  2 DLTs are observed in any given cohort , further enrollment into that 
cohort will be stopped  until the SMC can review the available data and make dose and 
cohort recommendations . 
Figure  6-2 G1T28 Dose Evaluation in the Phase 1b Dose -Finding Portion of Part 1 
 
a      Assess the adjusted G1T28 dose in the next cohort of 6 patients based on DLTs and PK  (if available)  per the decision     
        tree  
b Maximum of 2 G1T28 dose reduc tions are allowed  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 37 of 105  
G1 Therapeutics CONFIDENTIAL  All dose- escalation/de- escalation decisions will be based on Cycle 1 safety  data from all 
patients enrolled into the cohort  and available PK data and will be reviewed by a safety 
monitoring committee  (SMC)  comprised of the sponsor, medic al monitor , and the principal 
investigator(s) to determine the next dose level. If the G1T28 dose level for a subsequent 
cohort is adjusted by the SMC, the SMC may also recommend that all patients currently receiving G1T28 in combination with E/P therapy should have their G1T28 dose adjusted accordingly, starting with their next scheduled cycle. Additional cohorts for the Phase 1b dose- finding portion of Part 1 will be considered based on review of the safety  data from all 
patient s enrolled into the cohort  and available PK data by the SMC . The dose for Part  2 will 
be obtained by utilizing all available safety and available PK data from patients enrolled in 
Part 1. Once the dose for Part 2 has been established, additional patients will be enrolled at 
the selected Part 2 dose in a Phase 2a expansion cohort in Part 1 until up to a total of 
24 patients  (6 from the Phase 1b dose -finding portion of Part 1 and up to 18 from the 
Phase  2a expansion cohort) have been enrolled at that dose.  The Phase 2a expansion cohort 
in Part 1 will complete enroll ment before enrollment in to Part 2  commences .    
There will be no intrapatient dose modifications of G1T28 in the Phase 2a expansion cohort 
of Part 1  and Part  2 of the study.  
Each patient will be evaluated for toxicity during  each cycle. The toxicity of IV G1T28 
administered with E/P therapy will be assessed by the investigators using National Cancer Institute (NCI) Common Terminology Criter ia for Adverse Events (CTCAE), V ersion  4.03.  
6.1.1.4.  Safety  Monitoring Committee  
The SMC will b e set up to review safety of G1T28 for all patients enrolled in the Phase 1b 
dose- finding portion of Part 1 of the study. The SMC will consist of the clinical 
investigator(s), the medical monitor, and G1 Therapeutics representatives and/or designees.  Durin g the Phase 1b dose- finding portion of Part 1, the SMC will review any 
DLTs, SAEs, PK , and all other available data. The committee will make recommendations 
for dose escalation /de-escalation  based on the criteria listed in S ections 6.1.1.1  to 6.1.1.3 . 
While the dose evaluation criteria will be used to guide all dose decisions, the SMC will be responsible for all dose and cohort recommendations , including any adjustment s to the PK 
collection schedule. If the G1T28 dose level for a subsequent cohort is adjusted by the SMC, the SMC may also recommend that all patients currently receiving G1T28 in combination with E/P therapy should have their G1T28 dose adjusted accordingl y, starting with their next 
scheduled cycle.   
In the Phase 2a expansion cohort of Part 1, the SMC will review any SAEs, efficacy , and all 
other available data.  The SMC may make recommendations for continuing with the Phase 2a 
expansion cohort in Part 1 with enrollment of up to 18 patients, or moving to Part 2 based on 
safety  and efficacy.  
6.1.2.  Part 2  
In Part 2, eligible patients will be randomized (1:1 fashion) to  G1T28 or placebo 
administered IV once daily  on Days 1 to 3 of E/P therapy ( Figure 6-3 ). Randomization will 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 38 of 105  
G1 Therapeutics CONFIDENTIAL  be stratified b y Eastern Cooperative Oncology Group ( ECOG ) performance status (0 to  1 
versus 2). There will be no intrapatient dose modifications of G1T28 in Part 2 of the study.  
Figure 6-3 Study Schema: Part 2  
 
E/P = etoposide + carboplatin  
a  G1T28 + E/P will continue until disease progression, unacceptable toxicity, or discontinuation by the patient or 
investigator  (eg, after completing 6 cycles) . The tumor should be assessed after every even cycle using Response 
Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. Assessments should  be performed within 7 days of 
starting the subsequent cycle.  
b G1T28 will  be administered prior to the administration of etoposide and carboplatin on Day 1 and administration of 
etoposide on Days 2 and 3 of 21- day cycles  
c Patients will return to the study cen ter for a Post -Treatment Visit at 30 + 3 days after the last dose of study drug.  
d The Survival Follow -up Phase will continue until at least 50% of the patients randomized to Part 2 of the study have 
died.  
 
An independent data monitoring committee (DMC) will monitor accumulating safety and 
disposition data approximately every 4 months during the Treatment Phas e of Part 2 of the 
study, depending upon the enrollment rate. Details of the DMC, including objectives, composition, scope, and frequency , will be described in a DMC charter.  
6.1.3.  Criteria for Subsequent Cycles  and Study Duration 
In all parts of the study, s tudy drug administration will continue until disease progression per 
Response Evaluation Criteria in Solid Tumors  (RECIST), V ersion 1.1,  unacceptable toxicity, 
withdrawal of consent, or discontinuation by investigator  (eg, after completing 6  cycles) , 
whicheve r occurs first. Treatment cycles will occur consecutively without interruption, 
except when necessary to manage toxicities  or for administrative reasons as described below .   
In order to start Cycle 2 and subsequent cycles as scheduled, patients should meet all of the 
following criteria:  
• ANC  ≥ 1.5 × 10
9/L  
• Platelet count ≥  100 × 109/L 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 39 of 105  
G1 Therapeutics CONFIDENTIAL  • Nonhematologic drug -related toxicities (except alopecia) must be ≤ Grade 1 or have 
returned to baseline  
A delay of up to 2 weeks is permitted to allow recovery from any toxicity in order to meet 
the continuation criteria for organ function . If patients meet the criteria for starting the 
subsequent cycle as described above, a delay of up to 1 week is permitted for administrative reasons (eg, holiday, vacation, etc.). If the subs equent cycle is delayed, the patient should still 
complete the clinical laboratory assessments and the FACT -L and FACT -An questionnaires 
on the scheduled Day 1, as well as on the actual first dosing day of the next cycle. A patient will be discontinued fro m the study if recovery from any toxicity, in order to meet the 
continuation criteria for organ function, and any delay for administrative reasons requires a total delay of >  2 weeks  (see Section 8.4.4.2.1  and Table 8-2 ).  
After discontinuation of study drug, patients should be strongly encouraged to complete all 
scheduled assessments thro ugh the end of their current 21- day treatment cycle, including the 
patient- reported outcome ( PRO ) scales;  CBC assessment on Day 22;  the Post- Treatment  
Visit ; and the Survival Follow -up Phase of the study .  
The G1T28 -02 study will be completed when the Survival Follow -up Phase has been 
completed, or upon sponsor termination of the  study.  
The total study duration is at least  29 months.   
Part 1 is expected to be approximately 18 months, assuming 12 months of accrual, 2 weeks for screening, 4.5 months of treatment ( assuming 6 cycles), and 1 month of safety follow -up. 
Part 2 will begin  after the Part 2 dose is identified from the Phase 1b dose- finding portion of 
Part 1  and the Phase 2a expansion portion of Part 1 has completed enrollment, which is 
expected to occur ap proximately 12  months after Part  1 begins . Part 2 is expected to be 
approximately 17 months, assuming 11 months of accrual, 2 weeks of screening, 4.5 months 
of treatment ( assuming 6 cyc les), and 1 month of safety follow -up. 
The Survival Follow -up Phase of the study will continue until at least 50% of the randomized 
patients in Part 2 have died . 
6.1.4.  Safety Assessment s 
Safety assessments will include monitoring of AEs, vital signs measurements, physical examinations, ECGs, and clinical laboratory studies  as described in Section 11.3. Safety 
surveillance reporting of AEs commences at the time  that informed consent is obtained and 
continues through the Post- Treatment  Visit .  
6.1.5.  Tumor Assessment  
For tumor assessment, all sites of disease should be assessed radiologically according to RECIST , Version 1.1 using  computed tomography (CT) or magnetic resonance imaging 
(MRI) at screening; after every even cycle, until the occurrenc e of disease progression . CT or 
MRI scans obtained as standard of care prior to informed consent will not need to be repea ted 
if performed within 14 days prior to dosing.  Assessments should be performed within 7 days 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 40 of 105  
G1 Therapeutics CONFIDENTIAL  of starting the subsequent cycle.  Additional scans may be obtained at the discretion of the 
investigator, if clinically indicated. If a patient shows a radiological response (complete 
response [CR] or partial response [PR]), a confirmatory radiological assessment will be performed at least 4 weeks after the response was first noted.  For patients who have a 
confirmed CR, it is strongly recommended that they receive  prophylactic cranial irradiation 
(PCI) after completion of chemotherapy . Patients w ith a confirmed PR  should also consider 
PCI after completion of chemotherapy based on the investigator’s judgment (see Section  8.8). For those patients who have not progressed at the time of study drug 
discontinuation, tumor assessments, including all sites of disease, will be assessed radiologically by CT or MRI, as performed at screening, every 2 months (approximately 60 ± 7 day s) until the occurrence of progressive disease or study completion. The same 
method of assessment (CT or MRI) should be used to characterize tumors at screening and at all follow -up assessments. If positron emission tomography ( PET) is used, it should also  be 
accompanied by spiral CT or MRI. Tumor assessment is further described in Section 11.5. 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 41 of 105  
G1 Therapeutics CONFIDENTIAL  7. STUDY POPULATION  
7.1. Selection of Patient s 
Overall, up to 110 patients  will be enrolled in the study.   
In Part 1, approxim ately  40 patients will be enrolled, assuming up to 3 cohorts . Cohorts will 
consist of 6 patients each  in the Phase  1b dose -finding portion of Part 1 and up to 18 patients 
in the Phase 2a expansion portion of Part  1 at the selected dose to be used in Part 2 . 
Additional patients may be enrolled in the Phase 1b dose -finding portion of Part 1 if more 
than 1 cohort is enrolled.   
In Part 2, 70 patients will be randomly assigned (1:1 ratio) t o 1 of 2 groups : G1T28 
admini stered IV with E/P  therapy  (Group  1) or pla cebo admini stered IV wit h E/P  therapy  
(Group  2). 
The study will be conducted at up to 80 centers in North America and Europe . 
7.1.1.  Inclusion Criteria  
For a patient  to be eligible for participation in this study, all  of the following criteria must 
apply.  
1. Age ≥ 18 years  
2. Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably 
including the presence of neuroendocrine features by immunohistochemistry  
3. Extensive -stage disease  
4. At least 1 target lesion that is unirradiated and measurable by  RECIST , Version 1.1 
(Eisenhauer 2009 ) 
5. Hemoglobin ≥ 9.0 g/dL  
6. Absolute neutrophil count ≥ 1.5 × 109/L 
7. Platelet count ≥  100 × 109/L 
8. Creatinine ≤  1.5 mg/dL OR  glomerular filtration rate ( GFR ) of ≥  60 mL/min  (by 
Cockcroft -Gault formula [ Cockcroft and Gault  1976 ]); creatinine clearance calculated 
from an isotopic method or a 24 -hour urine collection may be used instead of an 
estimated GFR by the Cockcroft -Gault formula  
9. Total bilirubin ≤  1.5 × upper limit of normal ( ULN ) 
10. AST and ALT ≤ 2.5 × ULN ; ≤ 5 × ULN in the presence of liver metastases  
11. Serum albumin ≥  3 g/dL  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 42 of 105  
G1 Therapeutics CONFIDENTIAL  12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 
13. Predicted life expectancy of ≥ 3 months  
14. Contraception: 
a. For females: A ll females of childbearing potential must have a negative serum beta 
human chorionic gonadotropin (β -hCG) test result at screening and at baseline. 
Females must be either post menopausal, surgically sterile , or using an accep table 
method of contraception. Acceptable surgical sterilization techniques 
are hysterectomy, bilateral tubal ligation with surgery at least 6  months prior to 
dosing, and bilateral oophorectomy, with surgery at l east 2 months prior to dosing. 
Acceptable methods of contraception are an intrauterine device, contraceptive 
implant, oral contraceptive (stable dose of the same hormonal contraceptive product for at least 3 months prior to dosing), a vasectomized  partner, and a barrier method 
(condom or diaphragm) during the study and for 3 mont hs after discontinuation of 
treatment  
b. For males: Patient s with female partner of childbearing potential must agree to use a 
highly effective form of birth control, which entails the use of oral, injected, or implanted hormonal metho ds of contraception or an intra uterine device/system by the 
female partner, in combination with a barrier method (eg , condom, diaphragm, 
cervical cap) during the study and for 3 months after discontinuation of treatment, and will also refrain from sperm donation for 3 months foll owing completion of the study  
 
15. Able to understand and sign an informed consent  
 
7.1.2.  Exclusion Criteria  
A patient  will not be eligible for participation in this study if any  of the following criteria 
apply.  
1. Prior chemo therapy for 
limited or extensive -stage SCLC  
2. Presence of symptomatic brain metastases requiring immediate treatment with radiation 
therapy or steroids  
3. History of other malignanci es, except for the following: (1 ) adequately treated basal or 
squamous cell carcinoma of the skin; (2) curatively treated  a) in situ carcinoma of the 
uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3 ) other curatively 
treated solid tumor with no evidence of disease for ≥ 3 years  
4. Unco ntrolled ischemic heart disease or uncontrolled symptomatic congesti ve heart failure 
(Class III or IV as defined by the New York Heart Association [NYHA]  functional 
classification system)  
5. Known history of stroke or cerebrovascular accident within 6 months prior to enrollment  
6. Serious active infection  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 43 of 105  
G1 Therapeutics CONFIDENTIAL  7. Psychiatric illness/social situations that would limit study compliance  
8. Other uncontrolled serious chronic disease or conditions that in the investigator’s opinion 
could affect compliance or follow -up in the protocol  
9. Known human immunodeficiency virus ( HIV), know n hepatitis B vi rus (HBV), or known 
hepatitis C virus (HCV)  positive that is symptomatic or requiring  active therapy  
10. Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or 
previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)  
11. Receipt of any investigational medication within 4  weeks prior to enrollment  
12. Hypersensitivity to any of the components of the formulation of etoposide or etoposide phosphate 
13. Hypersensitivity to cisplatin or other platinum -containing compounds, or mannitol  
14. Legal incapacity or limited legal capacity  
15. Pregnant or lactating women  
Patients may withdraw from study drug or from the  study at their own discretion (or at the 
discretion of the investigator) for any reason at any  time (see Section  12.3 and 12.4).  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 44 of 105  
G1 Therapeutics CONFIDENTIAL  8. TREATMENTS 
8.1. Treatments Administered  
The initial group  of patients in Part 1 of the study will receive G1T28  200 mg/m2 
administered IV once daily on Days 1 to 3 of each 21 -day E/P chemotherapy cycle. All dose 
escalation /de-escalation  decisions  and additional cohort s of patients  to be enrolled in the 
Phase 1b  dose- finding portion of Part 1 , if any,  will be based on Cycle 1 safety and available 
PK data (see Section 6.1.1 ). If the G1T28 dose level for a subsequent cohort is adjusted by 
the SMC, the SMC may also recommend that all patients currently receiving G1T28 in 
combination with E/P therapy should have their G1T28 dose adjusted accordingly, starting with their next scheduled cycle.  
Patients enrolled to the Phase 2a expansion portion of Part  1 and Part 2 will receive the dose 
of G1T28 derived from the Phase 1b  dose- finding portio n of Part 1  or placebo administered 
IV once daily on Days 1 to 3 of each 21 -day E/P chemotherapy cycle. There will be no 
intrapatient dose modifications of G1T28 in the Phase 2a expansion portion of Part  1 and 
Part 2 of the study. 
Patients will receive standard E/P chemotherapy in 21- day cycles. The carboplatin dose will 
be calculated using the Calvert  formula with a target AUC  = 5 (maximum 750 mg) IV on 
Day 1, and 100 mg/m
2 etoposide will be administered IV daily on Days 1, 2, and 3 of each 
21-day cycle.  
The interval between doses of G1T28 or placebo on successive days should not be 
greater than 28 hours. The interval between the dose of G1T28 or placebo and the first dose o f chemotherapy on a given day (etoposide or carboplatin ) should not be greater 
than  4 hours.  
G1T28 or placebo will only be administered with E/P  therapy . If administration of 
E/P therapy is discontinued, G1T28 or placebo will also be discontinued.  
Chemotherapy cannot be administered until after completion of the G1T28 or placebo  
infusi on. If the second or third dose of G1T28 or placebo in any given cycle is not 
administered for any reason, do not administer the dose of etoposide  chemotherapy on 
that day, since this could potentially exacerbate myelosuppression (see Section 8.4.4.1).  
Study drug administration will continue until disease progression, unacceptable toxicity, withdrawal of consent, or discontinuation by investigator (eg, after completing 6 cycles) , 
whichever occurs first. Treatment  cycles will occur consecutively without interruption, 
except when necessary to manage toxicities  or for up to a 1 week delay  for administrative 
reasons , for a maximum total delay of up to 2 weeks . If the subsequent cycle is delayed, the 
patient should sti ll complete the clinical laboratory assessments and the FACT -L and 
FACT -An questionnaires  on the scheduled Day 1, as well as  on the actual first dosing day of 
the next cycle.  
Patients should meet the laboratory parameter requirements outlined in Section 10.4 before 
initiation of Cycle 2 and each subsequent cycle of E/P  therapy . All nonhematologic 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 45 of 105  
G1 Therapeutics CONFIDENTIAL  drug-related toxicities (except alopecia) should have resolved to Grade 1 or baseline before 
initiation of the next c ycle of E/P  therapy .  
8.2. Investigational Products 
8.2.1.  Identity  
8.2.1.1.  G1T28 
G1T28 is supplied as a single- use, sterile powder with 40 or 100 mg G1T28 in each 10 -mL 
flint glass vial. D -mannitol, USP is added as a cake forming agent and citrate buffer is added 
to maintain  the reconstituted pH at 4.0 to 5.0. The process for reconstitution of study drug is 
detailed in the Pharmacy Manual.  
8.2.1.2.  Placebo  
The placebo formulation of 250 mL of dextrose 5% in water ( D5W ) or sodium chloride 
solution 0.9% will be prepared by the pharmacis t/designee  on site.   
8.2.1.3.  Etoposide and Carboplatin 
Descriptions of the formulations of commercially -available  etoposide and c arboplatin  can be 
found in the respective current prescribing information (see Appendix 2 ).  
8.2.2.  Packaging and Labeling  
8.2.2.1.  G1T28 
G1T28 s terile powder is manufactured and packaged by  University of Iowa Pharmaceuticals , 
Iowa City, Iowa, United States of America . 
Individual vials of G1T28 will be labeled and supplied to the unblinded pharmacist /designee  
who will inve ntory the contents and document them according to the drug accountability 
requirements (Section 8.2.5 ). 
8.2.2.2.  Placebo  
The placebo formulation of 250 mL of D5W or sodium chloride solution 0.9% will be 
prepared by the pharmacist/designee on site, and labeled with the randomization number . 
8.2.2.3.  Etoposide and Carboplatin 
Descriptions of the packaging and labeling of commercially -available carboplatin and 
etoposide can be found in the respective current prescribing information  (see Appendix 2).  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 46 of 105  
G1 Therapeutics CONFIDENTIAL  8.2.3.  Storage 
8.2.3.1.  G1T28 
The G1T28 sterile powder  40-mg/10 mL or 100- mg/10 mL vial should be stored refrigerated 
at 2°C to 8°C.  
Stability data for the current formulation of G1T28 sterile powder 40 -mg/10 mL vial 
demon strates satisfactory stability for up to 6 months  at 5°C and 25°C/60% relative humidity 
(RH). Based on these data, stability is expected to exceed 18 months at refrigerated storage 
conditions.  
Stability data for the current formulation of G1T28 sterile po wder  100- mg/10 mL vial 
demonstrates satisfactory stability for up to 1 month at 40°C/75% RH . Based on these data, 
stability is expected to exceed 12 months at refrigerated storage conditions.  
Study drugs will be stored in a locked refrigerator under applic able storage conditions at the 
site and only the pharmacist /designee  and designated personnel will have access to the study 
drugs.  
8.2.3.2.  Placebo  
The placebo formulation of 250 mL of D5W or sodium chloride solution 0.9% will be stored 
identically to G1T28 to prot ect the integrity of the blind.  
8.2.3.3.  Etoposide and Carboplatin 
Information regarding the storage of commercially -available carboplatin and etoposide can 
be found in the respective current prescribing information  (see Appendix 2) . 
8.2.4.  Procedure for Dispensing  
Dispensing  instructions , including instructions for masking the G1T28 or placebo infusion 
bags,  will be provided in the Pharmacy Manual and will be maint ained in the pharmacy 
records.   
8.2.5.  Investigational Product Accountability 
The p harmacist/designee will verify the integrity of the clinical trial supplies (storage 
conditions, correct amount received, condition of shipment, kit numbers, etc.) according to 
the investigative site’s standard operating procedures (SOPs) . 
At a minimum, th e following data will be tracked on the drug accountability log at the site 
pharmacy:  
• Date received  
• Lot number  
• Vial number  
• Date dispensed  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 47 of 105  
G1 Therapeutics CONFIDENTIAL  • Patient number  
• Identification of the person dispensing the drug  
Records of study medication (used, lost, destroyed, and returned containers, individual vials) 
should be made at each visit in the drug accountability and dispensing forms. Drug accountability and reconciliation will be checked and verified by the pharmacy team during the study and by the site monitor  during and  at the completion of the study. 
Once the site monitor has verified drug accountability at the site, any used drug remaining at 
the completion of the study will be destroyed. Unused and unopened study medication will be retur ned by the site monitor to t he sponsor or may be destroyed on site according to the 
investigative site’s SOPs.  
8.3. Method of Assigning Patients to Treatment Groups  
A unique patient identification number (screen number) will be assigned to each patient who signs an informed consent form. Once a patient  is determined eligible, ie, meets all 
inclusion/exclusion criteria, an enrollment number will be assigned by an interactive 
web-response system  (IWRS ).  
Part 1 of the study  (dose -finding and expansion cohorts) is open -label and there will  be no 
randomization.  
Part 2 is randomized and blinded. Patients meeting all inclusion and exclusion criteria in Part 2 will be randomized 1:1 to receive G1T28 or placebo as described in Section  8.5. Each 
patient w ill be assigned a unique randomization number, which will not be reused.   
8.4. Dose, Dosing Regimen, and Route 
8.4.1.  G1T28  
The starting dose level for the Phase 1b  dose- finding portion of Part 1 will be 200 mg/m
2, 
which is derived from the G1T28-1- 01 study, a Phase  1a safety, PK, and pharmacodynamic 
study of G1T28 in healthy male and  female subjects . See Section 6.1 for possible dose 
escalation/de- escalation decisions based on safety and available PK data.   
G1T28 diluted in 250 mL of D5W  or sodium chloride solution 0.9% is to be administered b y 
IV infusion over 30 minutes. If there is any study drug remaining in the infusion bag at the end of the 30 minutes, the infusion should be continued at the same rate until the enti re 
contents of the bag have been administered to ensure patients receive the full  dose. Details 
regarding the reconstitution and dilution of G1T28 vials are detailed in the Pharmacy Manual.  
The interval between doses of G1T28 on successive day s should not be greater than 
28 hours . G1T28 will only  be administered with E/P  therapy . If administration of 
E/P therapy  is discontinued, G1T28  will also be discontinued.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 48 of 105  
G1 Therapeutics CONFIDENTIAL  8.4.2.  Placebo  
The placebo formulation of 250 mL of D5W or sodium chloride solution 0.9% will be 
adminis tered over 30  minutes.  If there is any volume  remaining in the infusion bag at the end 
of the 30 minutes, the infusion should be continued at the same rate until the entire contents 
of the bag have been administered to ensure patients receive the full  dose. 
The interval between doses of placebo on successive days should not be greater than 28 hours. Placebo will only be administered with E/P  therapy . If administration of 
E/P therapy is discontinued, placebo will also be discontinued.  
8.4.3.  Etoposide and Carboplat in 
Etoposide and carboplatin will be administered IV in accordance with the prescribing information  (see Appendix 2 ) and according to the study site’s standard practice.  
Needles or IV  administration sets containing aluminum  parts that may come in contact with 
carboplatin should not be used for the preparation or administration of the drug. Aluminum 
can react with  carboplatin causing precipitate formation and loss of potency.  
The interval between the dose of G1T28 or placebo and the first dose o f chemotherapy 
on a given day (etoposide or carboplatin ) should not be greater than 4 hours.  
Chemotherapy cannot be administered until after completion of the G1T28 or placebo  
infusion. If the second or third dose of G1T28 in any given cycle is not administered for any reason, do not administer the dose of etoposide  chemotherapy on that day , since 
this could potentially exacerbate myelosuppression (see Section 8.4.4.1) .    
8.4.3.1.  Carboplatin  
The carboplatin dose will be calculated using the Calver t formula with a target AUC  = 5 on 
Day 1  of each 21 -day cycle and administered as an IV infusion over 30 minutes . The Calvert 
formula is as follows: 
Total carboplatin dose (mg) = (target AUC) × (GFR + 25)  
Because each patient’s estimated GFR will be based on serum creatinine measurements 
obtained using standardized isotope dilution mass spectrometry, the dose of carboplatin 
should be capped at 750 mg  to avoid potential toxicity due to overdosing. The cap dose  of 
750 mg for carboplatin is based on a GFR estimate that is capped at 150 mL/min for patients with normal renal function (ie, maximum carboplatin dose = target AUC  of 
5 mg•min/mL  × 150 mL/min = 750 mg).  
Refer to the carboplatin prescribing information  (see Appendix 2) for details regarding 
preparation, administration,  instructions and precautions. Pre medications may be provided 
per local standard of care.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 49 of 105  
G1 Therapeutics CONFIDENTIAL  8.4.3.2.  Etoposide 
Etoposide 100  mg/m2 will be administered  as an  IV infusion over 60 minutes  on Days  1, 2, 
and 3 of each 21 -day cycle.  
Refer to the etoposide prescribing information  (see Appendix 2)  for details regarding 
preparation, administration, instructions, and precautions. 
8.4.4.  Dose Modifications 
8.4.4.1.  G1T28 
To ensure the greatest level of safety when G1T28  is co administered with chemotherapeutic 
agents, the magnitude and duration of G1T28- induced HSPC arrest was simulated using a 
PK/PD model and verified by performing bone marrow cell cycle analysis befo re or after 
administration of G1T28 IV at 192 mg/m2 to different groups of human subjects  in the 
Phase  1a Study G1T28 -1-01. G1T28 at a dose of 192 mg/m2 (rounded to 200 mg/m2 for this 
study) demonstrated robust bone marrow HSPC arrest for >  24 hours and wa s determined to 
be the BED  (Section 4.2). It is unknown if lower doses will produce the same magnitude and 
duration of HSPC cell cycle arrest. Insufficient HSPC arrest ( ie, for too short a duration) 
could result  in the release of HSPCs into the S (DNA synthesis) phase of the cell cycle while 
chemotherapy is present , thereby potentially exacerbating myelosuppression . To minimize 
this risk, the dose of G1T28 will not be modified and will remain at 200 mg/m2 (or the  
adjusted dose from the Phase 1b dose -finding portion of Part 1 as described in 
Section  6.1.1) throughout the study . 
8.4.4.2.  Modificati on of Etoposide and Carboplatin  Dosing  
Patients should meet the laboratory parameter  requirements outlined in Section 10.4 before 
initiation of Cycle 2 and each subsequent cycle of E/P  therapy . All nonhematologic 
drug-related toxicities (except alopecia) should have resolved to Grade 1 or baseline before 
initiation of the next cycle of E/P  therapy . 
Dose adjustments are to be made according to the organ system showing the greatest degree 
of drug-related  toxicity. Toxicities will be graded using NCI  CTCAE , Version 4.0 3. Initiation 
of the next cycl e of E/P therapy may be delayed by no more than 2 weeks to allow recovery 
from toxicity due to the chemotherapy agents. A treatment delay of > 2 weeks due to toxicity will lead to discontinuation of E/P  therapy . 
No more than 2 dose reductions in total are allowed for any patient. Simultaneous reduction in the doses of etoposide and carboplatin will count as 1 dose reduction. Toxicity that requires dose reduction more than twice will lead to discontinuation of E/P  therapy . Under 
this circumstance, administra tion of G1T28 should also be discontinued. All dose reductions 
are permanent and no dose increases are allowed.  
Since fatigue can be a symptom of cancer progression, dose reduction will only be performed if it is deemed to be drug -related in the opinion of  the investigator.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 50 of 105  
G1 Therapeutics CONFIDENTIAL  The dose reductions in  Table 8-1  will be utilized for the purpose of dose mo difications for 
toxicity.  
Table 8-1 Etoposide and Carboplatin Dose Reductions  
Dose level  Etoposide (mg/m2) Carboplatin (AUC)  
Dose  level  -1 (first dose reduction)  Reduce  to 75  mg/m2 Reduce  to AUC  = 4 
Dose  level  -2 (second dose reduction)  Reduce  to 50 mg/m2 Reduce  to AUC  = 3 
AUC = area under the concentration -time cu rve 
 
Dose Modifications for Hematologic Toxicity  
First Day of Cycle 2 and Beyond  
In order to start Cycle 2 and subsequent cycles as scheduled, on Day 1 of the cycle, patients 
must h ave an ANC  ≥ 1.5 × 109/L, platelet count ≥  100 × 109/L, and nonhematologic 
drug-related toxicities (except alopecia) must be ≤ Grade 1 or have returned to baseline . The 
dose adjustments in Table 8-2  are based on the ANC  and platelet counts on the first day of 
treatment for Cycle 2 and each subsequent cycle.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 51 of 105  
G1 Therapeutics CONFIDENTIAL  Table 8-2 Etoposide and Carboplatin Dose  Adjustments  Based  on Lack of Recovery 
of Absolute Neutrophil  or Platelet Co unts on the First Day of Cycle 2 and 
Each Successive Cycle  
Absolute Neutrophil 
Count < 1.5  × 109/L  
Etoposide   
Carboplatin  
First episode  No change. Use G-CSF with subsequent 
cycles . Refer to the American Society of 
Clinical Oncology (ASCO) guidelines  
(Smith 2006 ). No change. Use G -CSF with 
subsequent cycles . Refer to ASCO 
guidelines  (Smith 2006). 
 
Second episode   
First dose reduction   
First dose reduction  
 
Third episode   
Second dose reductio n  
Second dose reduction  
 
Fourth episode   
Discontinue drug   
Discontinue drug  
Platelet Count < 100 x 109/L  
Etoposide   
Carboplatin  
First episode  First dose reduction   
First dose reduction  
 
Second episode   
Second dose reduction   
Second dose reduction  
 
Third episode   
Discontinue drug   
Discontinue drug  
G-CSF = granulocyte colony -stimulating factor  
 
Neutrophils  
The dose adjustments in Table 8-3  are based  on the ANC  nadir  with or without fever during  
the preceding  treatment cycle . 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 52 of 105  
G1 Therapeutics CONFIDENTIAL  Table 8-3 Etoposide and Carboplatin Dose  Adjustments  Based  on Absolute 
Neutrophil Count  Nadir  With or Without Fever  
Absolute  Neutrophil  
Coun t Nadir  
Etoposide   
Carboplatin  
Grade  3 (without  fever)  No Change  No change  
Grade  4 for ≥ 7 days  
(without  fever)   
 
  
 
 
First episode  No change. Use G-CSF with subsequent 
cycles . Refer to the A SCO  guidelines  
(Smith 2006) . No change. Use G -CSF with 
subsequent cycles .  Refer to ASCO 
guidelines  (Smith 2006). 
 
Second episode   
First dose reduction   
First dose reduction  
 
Third episode   
Second dose reduction   
Second dose reduction  
 
Fourth episode   
Discontinue drug   
Discontinue drug  
Grade  3/4 with fever   
First episode  No change. Use G-CSF with subseq uent 
cycles . Refer to the ASCO  guidelines  
(Smith 2006 ). No change. Use G -CSF with 
subsequent cycles . Refer to ASCO 
guidelines  (Smith 2006 ). 
Second episode  First dose reduction  First dose reduction  
 
Third episode   
Second dose reduction   
Second dose reduction  
Fourth episode  Discontinue drug  Discontinue drug  
G-CSF = granulocyte colony -stimulating factor  
 
Platelets  
The dose adjust ments in Table 8-4  are based on the platelet nadir during the preceding 
treatment cycle . 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 53 of 105  
G1 Therapeutics CONFIDENTIAL  Table 8-4 Etoposide and Carboplatin Dose Adjustment Based on Platelet  Nadir  
Platelet  Count Nadir  Etoposide  Carboplatin  
Grade  4 or ≥ Grade 3 with bleeding    
First episode  First dose reduction  First dose reduction  
 
Second episode   
Second dose reduction   
Second dose reduction  
 
Third episode   
Discontinue  drug  
Discontinue  drug 
 
Colony Stimulating Factors  
Patients will  not receive colony stimulating factors (eg, granulocyte colony- stimulating 
factor [G -CSF]; granulocyte -macrophage colony-stimulating factor [GM- CSF]) or 
erythropoiesis stimulating agents (ESAs) during Cycle 1  (ie, prior to the actual Cycle 2 
Day 1 dosing visit). Subsequent use will be based on toxicities as outlined above. Please also 
refer to the ASCO guidelines  (Smith  2006 ) for neutropenia . For a hemoglobin level 
< 9.0 g/dL or symptomatic anemia, ESAs may be used per the current prescribing 
information .  
When indicated, as outlined above in Table 8-2  and Table 8-3 , either filgra stim or 
pegfilgrastim may be used per the prescribing information detailed in the package insert s (see 
Appendix 3 ). In the event a patient has a neutropenic event requiring G -CSF in the 
subsequent cycle, then f ilgrastim or pegfilgrastim should not be initiated until at least 
24 hours after dosing of the next subsequent cycle is complete (ie , no earlier than D ay 4 of 
the next subsequent cycle). Filgrastim or pegfilgrastim should not be used to increase low neutrophil counts mid- cycle or prior to the start of  the subsequent  cycle.   
When indicated, epoetin alfa or darb epoetin alfa may be used to treat patients with anemia  
per the prescribing information detailed in the package inserts (see Appendix 4 ).     
8.4.4.2.1.  Dose Modifications for Nonhematologic Toxicity  
Hepatic Toxicity  
The following dose adjustments for E/P are based on serum AST /ALT  and bilirubin levels 
(Table 8-5 ) during the preceding treatment cycle. 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 54 of 105  
G1 Therapeutics CONFIDENTIAL  Table 8-5 Etoposide and Carboplatin Reduction for Hepatic Toxicity 
AST/ALT   Bilirubin  Etoposide  Carboplatin  
 Grade 1  
> Grade 2a 
 
First episode  
 
Second episode  
 
Third episode  and/ or  
and/or  < Grade 2  
>Grade 3  
 
First episode  
 
Second episode  
 
Third episode  No change  
 
 
First dose reduction  
 
Second dose reduction  
 
Discontinue drug  No change  
  
First dose reduction  
 
Second dose reduction  
 
Discontinue drug  
a  If baseline is Grade 2 in the presence of liver metastases,  an increase of 1  Grade will result in the first dose lev el 
reduction  
 
Gastrointestinal toxicity  
Nausea and vomiting should be managed with the use of adequate antiemetic therapy. 
Prophylactic anti- emetic therapy can be used at the discretion of the treating physician. 
Patients are encouraged to take plenty of o ral fluids.  
Diarrhea should be managed with appropriate antidiarrheal therapy. Patients should be encouraged to take plenty of oral fluids.  
Hypersensitivity Reactions  
For patients who had a mild to moderate hypersensitivity reaction and have been successfu lly 
re-challenged, careful attention to prophylaxis and bedside monitoring of vital signs is 
recommended for all subsequent doses.  
Mild symptoms (eg, mild flushing, rash, pruritus): c omplete infusion. Supervise at bedside. 
No treatment required.  
Moderate symptoms (eg, moderate rash, flushing, mild dyspnea, chest discomfort):  stop 
infusion. Give IV diphenhydramine 25 mg and IV dexamethasone 10 mg. Resume infusion 
after recovery of symptoms at a low rate, 20 mg/hour. If no further symptoms occur after 
15 minu tes, the rate may be increased to the full rate until the infusion is complete. If 
symptoms recur, the infusion must be stopped. The patient should receive no additional 
etoposide or carboplatin  for that cycle, but may receive additional doses at the discr etion of 
the investigator.  
Severe life -threatening symptoms (eg, hypotension requiring vasopressor therapy, 
angioedema, respiratory distress requiring bronchodilation therapy, generalized u rticarial ): 
stop infusi on immediately. Give IV diphenhydramine and dexamethasone as above. Add 
epinephrine or bronchodilators if indicated. If wheezing is present, that is not responsive to bronchodilators, epinephrine is recommended. Patient should not receive any further doses of etoposide or carboplatin . Report this oc currence as an AE.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 55 of 105  
G1 Therapeutics CONFIDENTIAL  Other Toxicities  
For the first occurrence of any nonhematologic Grade 2 chemotherapy -related toxicity  
(except alopecia) , all study treatments should be withheld until the toxicity recovers to Grade 
1 or baseline. Treatment may then be resumed at the same dose level. For the second 
occurrence of any nonhematologic  Grade 2 chemotherapy -related toxicity  (except alopecia) , 
following recovery of the toxicity to Grade 1 or baseline, treatment should be resumed at dose level -1; for the third oc currence, the dose s hould be reduced to dose level  -2. A fourth 
occurrence will result in discontinuation of E/P  therapy . No dose reduction should be made 
for Grade 1 toxicities.  
For any Grade 3 or 4 chemotherapy -related toxicities not mentioned above, all  study 
treatments  should be withheld until the toxicity recovers to Grade 1 or baseline. Treatment 
should then be resumed at dose level -1 for the first occurrence and dose level - 2 for the 
second occurrence. A third occurrence will result in discontinuation of E/P  therapy . 
8.5. Randomization and Blinding  
Part 1  is open -label and  no randomization or blinding will be required.  
Part 2 is randomized and blinded.  Patients meeting all inclusion a nd exclusion criteria in 
Part 2 will be randomized 1:1 to receive G1T28  or placebo by an IWRS according to a 
randomization schedule generated  by an unblinded statistician. Randomization of patients 
will be performed centrally and will be stratified by ECOG performance status (0 to  1 ver sus 
2). Each patient will be assigned a u nique randomization number , which will not be reused.   
Each site will have an unblinded pharmacist /designee , who will have access to the treatment 
assignment to label and distribute the blinded stud y drug. The patients, investigators, other 
site staff invo lved in the clinical care of the patients, and the sponsor or designees involved in 
the conduct of the study will not be aware of the treatment group to which a particular patient has been randomized . If an investigator determines that a patient’s assignme nt should be 
unblinded for reasons of safety, this should be discussed with the medical monitor prior to unblinding, unless an urgent and immediate intervention is required that precludes this discussion. If unblinding of the treatment assignment is necess ary, the investigator will 
obtain the  treatment assignment details from the  IWRS . Any unplanned unblinding must be 
communicated to the project manager and study statistician for  documentation in the study 
files and the clinical study report .   
8.6. Prior and Co ncomitant Medications and Procedures  
All concomitant medications including prescription medications, over -the-counter 
preparations, growth factors, blood products, and parenteral nutrition taken during the 14 days before the date of enrollment , during the study tre atment, and through 30 days after  
the last dose of study drug will be documented. Documentation will include information regarding start and stop dates, dose(s), and reasons for the medication use.   
Administration of other concomitant nonprotocol  anticancer therapies prior to progression is 
not permitted while on this study.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 56 of 105  
G1 Therapeutics CONFIDENTIAL  Administration of other concomitant investigational agents for any indication  is not permitted 
while on this study.  
Concomitant radiation therapy treatment for SCLC will be re garded as disease progression , 
and is not permitted while on this study.  
Caution should be exercised when administering etoposide phosphate with drugs that are 
known to in hibit phosphatase activities (eg, levamisole hydrochloride). Although carboplatin 
has limited nephrotoxic potential, caution should be exercised when administering carboplatin with aminoglycosides, which has resulted in increased renal and/or audiologic toxicit y. Any medication that is contraindicated when  using etoposide or carboplatin i s not 
permitted, and special warnings and precautions for use of carboplatin and etoposide should be observed.   
Necessary supportive care such as antiemetics, antidiarrheals, etc., per the standard of care at the study center will be permitted. A dministrat ion of hematopoietic growth factors in 
Cycle 1 will not be permitted  (ie, no growth factors should be used prior to the actual 
Cycle 2 Day 1 dosing visit). However, hematopoietic growth factors may be utilized in 
subsequent cycles at the investigator’s dis cretion as stated in Section  8.4.4.2 . To reduce 
potential immune system interactions, the use of dexamethasone as an antiemetic should be minimized where possible.  
G1T28 is a time -dependent inhibitor of CYP3A4 and is a substrate for CYP3A4.  G1T28 
exposure may be altered by concomitant use of drugs that are strong CYP3A inhibitors or 
inducers. The exposure of drugs that are CYP3A substrates may be altered by concomitant use of G1T28  (Section 4.3.2 ).  
• Caution should be exercised with concomitant use of drugs that are  strong CYP3A 
inhibitors (eg , aprepitant, clarithromycin, itraconazole, ketoconazole, nefazodone, 
posaconazole, telithromycin, verapamil, and voriconazole).  
• Caution should be exercised with concomitant use of drugs that are strong or 
moderate CYP3A inducers (eg , phenytoin, rifampin, carbamazepine, St John’s Wort, 
bosentan, modafinil, and nafcillin).   
• Caution should be exercised with concomitant use of drugs that are extensively 
metabolized by CYP3A.  
 
G1T28 is a potent inhibitor of MATE1, MATE2- K, OCT2 membrane transporters and 
therefore caution should be exercised with concomitant use of drugs that are substrates for 
these transporters  (Section 4.3.2 ). 
Any diagnostic, therapeutic, or surgical procedures performed during the study period will be documented. Documentation will include information regarding the date(s), indication(s), description of the procedure(s), and any clinical or pathological findings.  
Medications will be coded using the most recent World Health Organization (WHO) Drug 
Dictionary version. 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 57 of 105  
G1 Therapeutics CONFIDENTIAL  8.7. Transfusions 
Platelets should be transfused at a threshold of ≤ 10,000/ µL. Platelets should also be 
transfused in any patient who is bleeding with a platelet count < 50,000/ µL (100,000/ µL for 
central nerv ous system or ocular bleeding) . Please also refer to the American Society of 
Clinical Oncology (ASCO)  guidelines  (Smith  2006 ). 
Patients with hemoglobin <  8.0 g/dL  or with symptomatic anemia can be treated with RBC 
transfusions at the investigators discretion.  
8.8. Prophylactic Cranial Irradiation  
Prophylactic cranial irradiation for patients without detectable brain metastases has been 
shown to decrease the frequency of subsequent intracranial relapse and improve survival for patients with SCLC  (Aupérin A 1999 ; Slotman 2007 ). Therefore, patients wi th a confirmed 
CR are strongly encouraged to receive PCI  after completion of chemotherapy . Patients w ith a 
confirmed PR  should also consider PCI after completion of chemotherapy based on the 
investigator’s judgment.  
8.9. Treatment Compliance  
The investigator or designee will dispense the study medicatio n, via an unblinded 
pharmacist/designee, only for use by patients enrolled in the study as described in this 
protocol. The study drug is not to be used for reasons other than those described in this protocol. The investigator or other study staff will supe rvise each dose of the study drug 
administered in the clinic. The clinical study site will maintain records of study drug receipt, preparation, and dispensing, including the applicable lot numbers; patient’s height, body weight, and BSA; date and time of t he start and end of each G1T28 or placebo, etoposide, 
and carboplatin  infusion; and total drug administered in milligrams. Any discrepancy 
between the calculated dose and dose administered and the reason for the discrepancy will be recorded on the electronic case report form ( eCRF ) and in the source documents.  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 58 of 105  
G1 Therapeutics CONFIDENTIAL  9. STUDY FLOWCHART  
The procedures and assessments to be performed during the study are outlined in Table 9-1 .
G1 Therapeutics  
Clinic al Study Protocol G1T28 -02 G1T28  
 
Version: 7.0, dated 11  May 2016  Page 59 of 105  
G1 Therapeutics CONFIDENTIAL  Table 9-1 Schedule of Assessments  
  Screen -
ing  Enroll  Cycle 1 and Every Odd Cyclea 
(21 days)  Cycle 2 and Every Even Cyclea 
(21 days)  Last Cycle  Post-
Treatment 
Visitb Survival 
Follow -upc 
Cycle Day  -14  -3 to 1  1 2 3 8 10 15 1 2 3 8 10 15 22   
Informed Consentd X                 
Demographics  X                 
Medical Historye X                 
Eligibility Eval.  X X                
Performance Status  X  X      X       X  
Physical Exam  X  X      X       X  
Height, Weight & 
Vital Signsf X  X      X       X  
Clinical Chemistry  X  Xg   X  X Xg   X  X  X  
Hematology  X  Xh  X X X X Xh  X X X X X X Xi 
Urinalysis  X  Xg      Xg       X  
ECG  X  Xj  Xj           X  
Pregnancy testk X   X         X             
Randomizationl 
 X                       
Tumor 
Assessmentm Xm2 
            X  Xm1,m2  Xm1 
Tumor Testingn 
  X                       
PKo 
   X   X                 
G1T28 or Placebop 
   X X X    X X X        
Carboplatin    X      X         
Etoposide  
   X X X    X X X       
FACT -L and 
FACT -Anq 
   X    X  X    X   X  
Immunologic 
Markerr   X             X X 
AEss X X  
Con. Medications  X X  
Survival 
Follow -upc   X 
AE = adverse event; ECG = electrocardiogram ; FACT -AN = Functional Assessment of Cancer Therapy – Anemia quality of life instrument; FACT -L = Functional Assessment of Cancer Therapy –
Lung quality of life instrument; PRO = patient reported outcome; Eval. = evaluation; PK = pharmacokinetics 
G1 Therapeutics  
Clinic al Study Protocol G1T28 -02 G1T28  
 
Version: 7.0, dated 11  May 2016  Page 60 of 105  
G1 Therapeutics CONFIDENTIAL  a G1T28 or placebo + E /P therapy  will continue until disease progression, unacceptable toxicity , or discontinuation b y the patient or investigator  (eg, after completing 6 cycles) . The tumor should 
be assessed after every even cycle . Assessments should  be performed within 7 days of starting the subsequent cycle.   
b Patients will return to the study center for a Post-Treatment  Visit at 30 days  (+ 3 days)  after the last dose of study drug .  
c Monthly phone calls will be made to each patient that is in the long -term Survival Follow -up Phase. Patients will be followed for survival until  at least  50% of the patients  in Part 2  have died.  
Any anticancer therapies used will be collected.  In addition, blood sample s for hematology and immunologic marker assessment will be collected at 60 ± 7 days after the Post -Treatment Visit  for 
patients in Part 2 only .    
d Informed co nsent may be obtained up to 28 days prior to the first study treatment administration . 
e Including medical , surgical , radiation  history, smoking history, family history, documentation of tumor diagnosis, baseline signs and symptoms within 4 weeks prior to randomization, weight 
loss in the  6 months prior to randomization (≤  5% or >  5%), and medications taken within 14 days  of enrollment.  
f H eight will only be measured at the screening visit. Body surface area calculation  (based on actual body weight)  will be completed on Day 1 of each cycle and vital signs obtained immediately 
before and after G1T28 or placebo and  E/P infusions.  Vitals only need to be taken once between infusions.   
g Clinica l chemistry will be obtained  (albumin, alkaline phosphatase, total bilirubin, calcium, chloride, creat inine, glucose, inorganic phosphorus, potassium, total protein, ALT, AST, lactate 
dehydrogenase [ LDH ], sodium, and blood urea nitrogen [ BUN ]); see S ection 11.3.2 . Clinical chemistry  and urine analysis may be obt ained up  to 72 hours  prior to  the first dose of each cycle of 
G1T28 or placebo + E /P therapy .  
h Hematology will be obtained  (hemoglobin, hematocrit, WBCs with differential, and platelet counts) ; see Section 11.3.2. Hematology may be obtained up to 24 hours prior to first dose of each 
cycle of G1T28/placebo + EP therapy.  
i In Part 2 only, hematology will be collected at 60 days after the Post-Treatment Visit.  
j Patients participating in the Phase 1b dose-finding portion of Part 1 of the study , who have PK samples obtained,  will have ECGs completed at the following time points on Days 1 and 3 of 
Cycle  1: predose, end of infusion (EOI) of G1T28, 2 hours (±  10 minutes) after the start of G1T28, and 6.5 hours (±  15 minutes) after the start of G1T28. The 2-hour ECG will be completed once 
the etoposide infusion is complete.  
k For female patients of childbearing pote ntial, serum ß -hCG at screening;  serum or urine ß -hCG  obtained up to 72 hours prior to Day 1 dose  of G1T28 or placebo +  E/P chemotherapy in each 
cycle .   
l For patients enrolled in Part 2, r andomization is to be done within 3 days  prior to first dose of G1T28 or placebo +  E/P chemotherapy , following confirmation that the patient is eligible for the 
study . 
m For tumor assessment, all sites of disease should be assessed radiologically by CT or MRI  at screening  and after every even cycle, until the occurrence of disease progression. Additional scans 
may be obtained at the discretion of the investigator, if clinically indicated. If a patient shows a radiologic al response (CR or PR), a confirmatory radiological assessment will be performed at 
least 4 weeks after the response was first noted.  Assessments should be performed within 7 days of starting the subsequent cyc le. The same method of assessment (CT or MRI) should be used to 
characterize tumors at screening and at all follow -up assessments.  If positron emission tomography is used, it should also be accompanied by spiral CT or MRI.   
 m 1: At the Post-Treatment Visit , obtain tumor assessment  for patients who have not progressed at the time of study drug discontinuation (may be performed within 4 weeks).  For those patients  in 
the survival follow -up who have not progressed at the time of study drug discontinuation, tumor assessments, including all sites of disease, will be assessed radiologically by CT or MRI, as 
performed at screening, every 2 months (approximately 60 ± 7 days) until the occurrence of progressive disease or study completion.  
 m 2: Brain scans with contra s t (by CT or MRI) to be obtained with tumor assessment at screening  (within 28 days of dosing)  and at the P ost-Treatment Visit 
n Send archived tumor samples to a central pathology laboratory to confirm the diagnosis of SCLC . Available tissue after confirmi ng the diagnosis of SCLC will be banked for assessment of 
relevant DNA, RNA , and protein markers, such as those involved in the CDK4/6 pathway . If central pathology review does not confirm SCLC diagnosis, the patient may be withdrawn from the 
study after c onsultation between the principal investigator, medical monitor, and s ponsor.  This should be done as soon as possible after a patient has enrolled i n the study.  
o Patients enrolled in  Cohort 1 of the Phase 1b dose-finding portion of  Part 1 will have G1T28 , etoposide, and carboplatin  PK samples collected on Days 1 and 3  (as applicable)  of Cycle 1 at the  
time points  specified in Section  11.2. Collection of PK blood samples from patients enrolled in additional cohorts of the Phase 1b dose -finding portion of Part 1 is optional.  
G1 Therapeutics  
Clinic al Study Protocol G1T28 -02 G1T28  
 
Version: 7.0, dated 11  May 2016  Page 61 of 105  
G1 Therapeutics CONFIDENTIAL  p G1T28 or placebo will be administered as an IV  infusion in 250 mL of D5W or sodium chloride solution 0.9% over 30 minutes pri or to E /P chemotherapy on Days 1 to 3 of every cycle (see 
Section  8.1). If there is any volume  remaining in the  G1T28 or placebo infusion bag at the end of the 30 minutes, the infusion should be continued at the same rate until the entire contents of the  
bag have been administered to ensure patients receive the full dose.  The interval between doses of G1T28 or placebo on successive days should not be greater than 28 hours. The interval 
between the dose of G1T28 or placebo and the first dose of chemotherapy on a given day (eto poside or carboplatin) should not be greater than 4 hours. G1T28 or placebo will only  be 
administered with E/P  therapy . If administration of E/P  therapy  is discontinued, G1T28 or  placebo should also be discontinued . Chemotherapy cannot be administered unti l after completion of 
the G1T28 or placebo infusion. If the second or third dose of G1T28 in any given cycle is not administered for any reason, do not administer the  dose of etoposide or carboplatin chemotherapy 
on that day  (see Section 8.1 ). After discontinuation of study drug, patients should be strongly encouraged to complete all scheduled assessments through the end of their current 21- day treatment 
cycle, including the patient -reported outcome (PRO) scales;  CBC assessment on Day 22; the Post -Treatment Visit; and the Survival Follow -up Phase of the study.  
q Patient-reported outcomes should be comple ted at Days 1  and 10 of each cycle and at the Post -Treatment Visit . If a cycle is delayed, the patient should st ill complete the PRO on the scheduled 
Day 1  of the next cycle, a s well as the actual first dosing day of the next cycle of G1 T28 or placebo + E/P therapy. Patient -reported outcomes may be obtained up to 24 hours prior to the first 
dose of each cycle of G1T 28 or placebo + E/P therapy.  
r In Part 2 only, peripheral blood samples for immunologic marker assessment will be collected at predose on Day 1 of Cycles 1, 3, and 5; at the Post -Treatment Vis it, and at 60 days after the 
Post-Treatment Visit . 
s Adverse ev ents will be recorded from the time of informed consent . All A Es should be reported within 30 days of the last dose of study drug, and followed until they are resolved, have returned 
to baseline, or it is deemed that further recovery is unlikely . 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 62 of 105  
G1 Therapeutics CONFIDENTIAL  10. SCHEDULE  OF STUDY PROCEDURES  
Study procedures are summarized across all study visits within the schedule of assessments 
(Table 9-1 ). Both Parts 1 and 2 of the study will follow the same st udy schedule, except 
wher e noted below.  
10.1. Screening  
Patients should be screened no more than 14 days before the first dose of study treatment  is 
administered.  Written informed consent must be obtained from each patient before the 
initiation of any screening procedures . Informed cons ent and brain scans  may be obtained up 
to 28 days prior to the first  study treatment administ ration . After a patient has given informed 
consent, eligibility will b e determined by a review of the inclusion/exclusion criteria and 
completion of all screening procedures outlined in Table  9-1 and listed below .  
• Collection of demographics  
• Collection of medical history  
• ECOG performance status evaluation  
• Physical examination  
• Height, weight, and vital signs measurements  
• Clinical chemistry, hematology, and urinalysis  tests  
• Electrocardiogram  
• Pregnancy test  
• Tumor assessment (by CT scan or MRI; see details in Section 11.5.1 ); CT or MRI scans 
obtained prior to informed consent will not need to be repeated if performed within 14 days prior to dosing.  
• Brain scan with contrast (by MRI or CT); b rain MRI or CT scans obtained prior to 
informed consent will not need to be repeated if performed within 28 days prior to 
dosing.  
Advers e events and concomitant medications will be monitored continuously from the time 
of informed consent through the Post- Treatment  Visit .  
10.2. Enrollment  
Eligibility will be determined prior to enrollment, randomization (Part 2), and the start of study treatment. Eligible patients will be instructed on all protocol requirements, including any restrictions on concomitant medication usage.  
For Part 2 of the study, randomization will be performed within 3 days  of the first dose of 
G1T28 or placebo + E/P chemotherap y, following confirmation that the patient is eligible for 
the study . 
Archived tumor samples must be sent to a central pathology laboratory to confirm the diagnosis of SCLC . Available tissue after confirming  the diagnosis of SCLC will be banked 
for assessm ent of relevant DNA, RNA, and protein markers, such as those involved in the 
CDK4/6 pathway  (see Section 11.4). This should be done as soon as possible after a patient 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 63 of 105  
G1 Therapeutics CONFIDENTIAL  has enrolled in the study. If central patho logy review does not confirm SCLC diagnosis, the 
patient may be withdrawn from the study a fter consultation between the principal 
investigator, medical monitor , and s ponsor. For additional guidance regarding the shipment 
of samples to the central pathology  laboratory, please refer to the Laboratory  Manual.  
10.3. Cycle 1 
Adverse events an d concomitant medications will be monitored  throughout the study. Safety 
surveillance reporting of AEs commences at the time informed consent  and continues 
through the Post- Treatment  Visit .  
Cycle 1  Day 1  
Enrolled  patients will return to the study center on study Day 1. The following procedures 
will be performed and results reviewed before study drug administration: 
• ECOG performance status evaluation  
• Physical examination  
• Weight  and vital signs measurements  
• Clinical chemistry, hematology, and urinalysis  tests (note: clinical chemistry and 
urinalysis tests may be obtained up to 72 hours prior to the first dose of each cycle of 
study treatments, and hematology tests may be obtained up to 24  hours prior to the first 
dose of each cycle of study treatments ). For the Phase 1b dose -finding portion of 
Part  1, Cycle 1 only, the clinical chemistry and hematology results may be reviewed 
prior to or after dosing, depending on the availability of the lab report. For Day 1 of all 
subsequent cycles, the clinical chemistry and hematology results should be reviewed before dosing.  
• Electrocardiogram  (as applicable and optional after Cohort 1 , predose, Cycle 1 in the 
Phase 1b dose- finding portion of Part 1 only) 
• Plasma PK sample ( as applicable  and optional after Cohort 1 , predose, Cycle 1 in the 
Phase 1b dose-finding portion of Part 1 only) 
• Pregnancy test  (note: may be obtained up to 72 hours prior to the first dose of each cycle)  
• Functional Assessment of Cancer Therapy – Lung quality of life (QOL) instrument 
(FACT -L) and Functional Assessment of Cancer Therapy – Anemia QOL instrument 
(FACT -An) Questionnaires  
• Immunologic marker  blood sample collection (predo se, Part 2 only) 
The t iming for cri tical assessment s/procedures is  outlined in Table  9-1.  
Patients that still meet all of the eligibility criteria will begin treatment Cycle 1. The first dose of study treatments  (G1T28 or placebo +  E/P chemotherapy)  will be administered ( as 
described in Section 8.1) and all Day 1 postdose procedures outlined in Table  9-1 will be 
completed. Postdose  assessments on Day 1 are as fo llows:  
• Vital signs (obtained immediately before and after G1T28 or placebo  infusion, and  
etoposide and carboplatin  infusions ; only needed once between infusions ) 
• Electrocardiogram (as applicable, end of infusion [EOI] of G1T28, 2 hours 
(± 10 minutes) after  the start of G1T28, and 6 .5 hours (± 15 minutes) after  the start of 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 64 of 105  
G1 Therapeutics CONFIDENTIAL  G1T28, Cycle 1 in the Phase  1b dose-finding portion of Part 1 only). The 2- hour ECG 
will be completed once the etoposide infusion is complete.  
• Plasma PK sample s (as applicable  and optiona l after Cohort 1 , postdose samples as 
described in Section 11.2, Cycle 1 in the Phase  1b dose -finding portion of Part 1 only) 
 
Cycle 1  Days 2, 3, 8, 10, and 15 
All pr ocedures  and assessments to be conducted duri ng Cycle 1 Days 2, 3, 8, 10 , and 15 are 
outlined in Table  9-1. The DMC may recommend decreasing the frequency of hematological 
evaluations based on accumulating data. The investigators and institutional re view boards 
(IRBs ) will be notified if the frequency is reduced.  
At Day 2 and Day 3 , study treatments (G1T28 or placebo + etoposide)  will be administered 
(as described in Section  8.1). 
At Day 3 in Cycle 1 of the  Phase 1b dose -finding portion of Part 1 only , the following 
additional assessments will be performed:  
• Electrocardiogram (as applicable, predose, EOI, and 2 hours (± 10 minutes) and 6.5  hours 
(± 15 minutes) after  the start of G1T28) 
• Plasma PK sample ( as ap plicable  and optional after Cohort 1 , predose and postdose 
samples as described in Section  11.2) 
10.4. Cycle 2 
Adverse events and concomitant medications will be monitored throughout the study. Safety 
surveillance rep orting of AEs commences at the time  of informed consent  and continues 
through the Post- Treatment  Visit . 
Cycle 2  Day 1  
Patients will return to the study center on Cycle 2 Day 1 . The following procedures will be 
performed and results reviewed before study dr ug administration:  
• ECOG performance status evaluation  
• Physical examination  
• Weight and vital signs measurements  (calculate BSA)   
• Clinical chemistry, hematology, and urinalysis tests (note: clinical chemistry and 
urinalysis tests may be obtained up to 72 hours prior to the first dose of each cycle of 
study treatments, and hematology tests may be obtained up to 24 hours prior to the first 
dose of each cycle of study treatments)  
• Pregnancy test  (note: may be obtained up to 72 hours prior to the first dose of eac h cycle)  
• FACT -L and FACT -An Questionnaires  
Vital signs should be obtained immediately  before and  after G1T28 or placebo, etoposide, 
and carboplatin  infusions ; only once between infusions . 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 65 of 105  
G1 Therapeutics CONFIDENTIAL  In order to start Cycle 2 and subsequent cycles as scheduled, on Day  1 of the cycle, patients 
must h ave an ANC  ≥ 1.5 × 109/L, platelet count ≥  100 × 109/L, and nonhematologic 
drug-related toxicities (except alopecia) must be ≤ Grade 1 or have returned to baseline . Dose 
modifications based on lack of recovery to these absolute neutrophil  and platelet counts on 
the first day of treatment for Cycle 2 are outlined in Table 8-2 . A delay of up to 2 weeks is 
permitted to allow recovery from any toxicity in order to meet the continuatio n criteria for 
organ function. If the patient meets the criteria for starting the subsequent cycle as stated in 
protocol S ection 6.1.3 , a delay of up to 1 week is permitted for administrative reasons (eg , 
holiday, vacation, etc .). If a cycle is dela yed, the patient should still complete  the clinical 
laboratory assessments  and the FACT -L and FACT -An questionnaires on the scheduled Day 
1 of the next cycle, as well as the actual first dosing day of the next cycle of G1T28 or placebo + E/P therapy.  
A pat ient will be discontinued from the study if recovery from any toxicity, in order to meet 
the continuation criteria for organ function, and any delay for administrative reasons requires a total delay of >  2 weeks.    
Study treatments (G1T28 or placebo + E/P chem otherapy) will be administered as described 
in Section 8.1 .  
Cycle 2  Days 2, 3, 8, 10, and 15 
All procedures and assessments  to be conducted during Cycle 2 Days 2, 3, 8, 10 , and 15  are 
outlined in Table  9-1. The DMC may recommend decreasing the frequency of hematological 
evaluations based on accumulating data. The investigators and IRBs will be notified if the frequency is reduced.  
For Cycle 2 Day 2  and Da y 3, study treatments (G1T28 or placebo + etoposide ) will be 
administered as described in Section 8.1 . 
For tumor assessment, all sites of disease should be assessed radiologically by CT or MRI  at 
screening and after every even cycle, until the occurrence of disease progression. CT or MRI 
scans obtained as standard of care prior to informed consent will not need to be repeated if performed within 14 days prior to dosing. Additional scans may be obtained at the discretion 
of the investigator, if clinically indicated. If a patient shows a radiologic al response (CR or 
PR), a confirmatory radiological assessment will be performed at least 4  weeks after the 
response was first noted. The same method of assessment (CT or MRI ) should be used to 
characterize tumors at screening and at all follow -up assessments.  
10.5. Cycles 3, 4, and Subsequent Cycles 
Procedures and assessments to be performed during Cycle 3 and all subsequent odd 
numbered cycles  are similar to Cycle 1 (see Section 10.3 and Table  9-1).  
Procedures and assessments to be performed during Cycle 4 and all subsequent even numbered cycles  are similar to Cycle 2 (see Section 10.4 and Table  9-1).  
In order to start each subsequent cycle as scheduled
 on the first day of the cycle , patients 
must h ave an ANC  ≥ 1.5 × 109/L, platelet count ≥  100 × 109/L, and nonhematologic 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 66 of 105  
G1 Therapeutics CONFIDENTIAL  drug-related toxicities (except alopecia) must be ≤ Grade 1 or have returned to baseline . Dose 
modifications based on lack of recovery to these absolute neutrophil  and platelet counts on 
the first day of treatment for each subsequent cycle  are outlined in Table 8-2. A delay of up to 
2 weeks is permitted to allow recovery from any toxicity in order to meet the continuatio n 
criteria for organ fun ction. If the patient meets the criteria for starting the subsequent cycle  as 
stated in protocol Section  6.1.3 , a delay of up to 1 week is permitted for administrative 
reasons (eg , holiday, vacation, etc.). A pa tient will be discontinued from the study if recovery 
from any toxicity, in order to meet the continuation criteria for organ function, and any delay 
for administrative reasons requires a total delay of >  2 weeks . 
After discontinuation of study drug, patie nts should be strongly encouraged to complete all 
scheduled assessments through the end of their current 21- day treatment cycle, including the 
patient- reported outcome (PRO) scales; CBC assessment on Day 22; the Post -Treatment 
Visit; and the Survival Follo w-up Phase of the study , which is to continue until at least 50% 
of randomized patients in Part 2 have died . 
10.6. Post-Treatment  Visit  
Patients will return to the study center for a Post- Treatment  Visit  within 30 days from the last 
dose (+ 3 days) . The following procedures will be performed at this v isit: 
• ECOG performance status evaluation  
• Physical examination  
• Weight and vital signs measurements  
• Clinical chemistry, hematology, and urinalysis tests  
• Electrocardiogram  
• Tumor assessment ( obtain tumor assessment by C T scan or MRI  for patients who have 
not progressed at the time of study drug discontinuation [ may be performed within 
4 weeks]); see details in Section 11.5.1 ) 
• Brain scan with contrast ( obtain brain scans by MRI  or CT  for patients who have not 
progressed at the time of study drug discontinuation [may be performed within 4 weeks] ) 
• FACT -L and FACT -An Questionnaires  
• Immunologic marker s blood sample  collection ( Part 2 only) 
 For patients who have a confirmed CR, it i s strongly recommended that they receive PCI  
after completion of chemotherapy . Patients with a confirmed partial response should also 
consider PCI after completion of chemotherapy based on the investigator’s judgment.  
After completing  the Post- Treatment  Visit, patients will enter the long -term Survival 
Follow -up Phase. 
10.7. Survival Follow- up Phase  
Monthly phone calls will be made to each patient that is in the long -term Survival Follow -up 
Phase. Patients will be followed for survival at a minimum until 50% of t he patients  
randomized to Part 2  of the study  have died. In addition, for patients who have not had 
disease progression  at the time of study drug discontinuation, tumor assessments , including 
all sites of disease, will be assessed radiologically by CT or M RI, as performed at screening, 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 67 of 105  
G1 Therapeutics CONFIDENTIAL  every 2 months (approxim ately 60 ± 7 days) until the occurrence of progressive disease  or 
study completion .   
The following information will be collected  monthly for all patients : 
• Survival status  
• Details  of any anticancer treatment  
The following additional information will  be collected at 60 ± 7 days after the 
Post- Treatment Visit ( Part 2 only) :  
• Immunologic marker s blood sample  collection  
• Hematology sample collection  
10.8. Study Drug  Discontinuation 
After discontinuation of stud y drug, patients should be strongly encouraged to complete all 
scheduled assessments through the end of their current 21- day treatment cycle, including the 
patient- reported outcome (PRO) scales; CBC assessment on Day 22; the Post -Treatment 
Visit; and the S urvival Follow -up Phase of the study , which is to continue until at least 50% 
of randomized patients in Part 2 have died . Any abnormal results that are believed to be 
related to the study drug treatment should be repeated as often as deemed appropriate by the 
investigator until the abnormality resolves, returns to predose levels, or is otherwise explained.  
10.9. Unscheduled Visits  
Additional visits can be performed as appropriate and at the discretion of the i nvestigator.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 68 of 105  
G1 Therapeutics CONFIDENTIAL  11. STUDY ASSESSMENTS  
11.1. Efficacy Assessments  
Efficacy evaluation will be based on the following: kinetics of  changes in CBC s; 
hematologic toxicities, including febrile neutropenia and infections; RBC and platelet 
transfusions; hematopoietic growth factor utilization; systemic antibiotic use; chemother apy 
dose reductions and dose interruptions; alopecia; mucositis; nephrotoxicity; fatigue; and 
FACT -L and FACT -An. All of these variables, except for the PROs, will be assessed as 
described in the safety assessmen ts (monitoring of AEs , clinical laboratory assessments, 
study treatment exposure, and concomitant medications) (see Section 11.3 and Table 9-1 ). 
PROs are described in Section  11.6. 
The toxicity of G1T28 administered IV with E/P therapy will be assessed using the NCI 
CTCAE, V ersion  4.03. 
11.2. Pharmacokinetic Assessments   
In the Phase 1b  dose- finding portion of Part 1 of the study, s erial b lood samples  (5-mL 
samples)  will be collected for measurement of G1T28, etoposide, and carboplatin  
concentrations in plasma at the time points  outlined below and  in Table  9-1. Comprehensive 
information on blood sample acquisition, the  specific type of collection tube with 
anticoagulant , and handling and storage are to be found in the Laboratory M anual. The 
analytical laboratory will measure plasma concentrations of G1T28, etoposide, and carboplatin using a validated method. Any remaini ng sample may be stored long term for the 
future analysis of G1T28 drug metabolites.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 69 of 105  
G1 Therapeutics CONFIDENTIAL  Phase 1b Dose -Finding  Portion of Part 1 : Cycle 1  Day 1 
Blood samples will be collected at the f ollowing time points on Cycle 1  Day 1  for all patients 
enrolled in Cohort 1 of the Phase 1b  dose- finding portion of Part 1 of the study:  predose 
(0 hour; prior to dosing of G1T28) and at 0.5 (end of infusion [EOI] of G1T28), 1 (EOI of 
carboplatin), 1.5, 2 (EOI of etoposide), 2.5, 3, 4.5, 6.5, 8.5 (optional time  point, if approved 
by the sponsor in advance ), and 24.5 hours postdose  (relative to the start of G1T28 infusion ).  
Collection of PK b lood samples in additional cohorts of the Phase 1b dose -finding portion of 
Part 1  is optional . The EOI sample for G1T28 should be drawn 2 to 5  minutes prior to the 
EOI. The EOI samples for G1T28, carboplatin , and etoposide must be drawn after 
completing infusion of the drugs and the actual times at which the samples were drawn 
should be documented. A ±  5-minute time window will be allowed  for sa mples collected 
between the f ollowing time points: predose to 2.5 hours after the end of G1T28 infusion . 
A ± 10-minute time window will be allowed for samples collected between the following 
time points: 3 to 8.5 hours af ter the end of G1T28 infusion. A ±  1-hour time window will be 
allowed for the 24.5 hours a fter the end of G1T28 infusion time point . The actual time of 
blood sample collection sh ould be documented in the eCRF.  The Cycle 1  Day  1 sampling 
scheme is summarized in  Table 11-1 .   
Table 11-1 Day 1 of Cycle 1 Blood Sampling Scheme Based on Predicted 
Administration Times of G1T28, Carboplatin, and Etoposide 
Sample  1 2 3 4 5 6 7 8 9 10 11 
Sample  
Time (h) 0 
(Predosea) 0.5b 
(G1T28 
EOI) 1 
(Carbo 
EOI) 1.5 2 
(Etop 
EOI) 2.5 3 4.5 6.5 8.5 
(optionalc) 24.5 
Carbo = carboplatin; EOI = end of infusion; Etop = etoposide; h = hour  
Times are approximate. For simplicity, assumptions wer e based on 0.5 hour increments.  Actual times will be recorded and 
may vary from those listed here.  
a Predose is defined as prior to dosing of G1T28.  
b The EOI sample for G1T28 should be drawn 2 to 5 minutes prior to the EOI.  
c 8.5 hour sample (optional time  point, if approved by the s ponsor in advance)  
 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 70 of 105  
G1 Therapeutics CONFIDENTIAL  Phase 1b Dose -Finding Portion of Part 1 : Cycle 1  Day 3 
Blood samples will be collected at the f ollowing time points on Cycle 1  Day 3  for all 
Cohort 1 patients enrolled in  the Phase 1b  dose- finding portion of  Part 1 of the study: predose 
(0 hour; prior to dosing of G1T28) and at 0.5  (EOI  of G1T28), 1, 1.5 (EOI of etoposide), 2, 
2.5, 3.5, 4.5, 6.5, 8.5 (optional time  point, if approved by the sponsor in advance), and 
24.5 hours postdose  (relative to the start of G1T28 infusion). Collection o f PK b lood samples 
in additional cohorts of the Phase 1b dose -finding portion of Part 1 is optional . The EOI 
sample for G1T28 should be drawn 2 to 5 minutes prior to the EOI. The EOI samples for 
G1T28 and etoposide must be drawn after completing infusion of the drugs and the actual times at which the samples we re drawn should be documented. Time window parameters 
noted above for Cycle 1 Day 1  also appl y to Cycle 1  Day 3 . The Cycle 1  Day 3  sampling 
scheme is summarized in  Table 11-2 . 
Table 11-2 Day 3 of Cycle 1 Blood Sampling Scheme Based on Predicted 
Administration Times of G1T28 and Etoposide 
Sample  1 2 3 4 5 6 7 8 9 10 11 
Sample  
Time (h) 0 
(Predosea) 0.5b 
(G1T28 
EOI) 1 1.5 
(Etop 
EOI) 2 2.5 3.5 4.5 6.5 8.5 
(optionalc) 24.5 
EOI = end of infusion; Etop = etoposide; h = hour  
Times are approximate. For simplicity, assumptions were based on 0.5 hour increments. Actual times will be recorded and 
may vary from thos e listed here.  
a Predose is defined as prior to dosing of G1T28.  
b The EOI sample for G1T28 should be drawn 2 to 5 minutes prior to the EOI.  
c 8.5 hour sample  (optional time  point, if approved by the s ponsor in advance)  
 
Pharmacokinetic Parameters  
Pharmacokinetic parameters to be derived from G1T28, etoposide, and carboplatin plasma concentration -time data are presented in Table 11-3. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 71 of 105  
G1 Therapeutics CONFIDENTIAL  Table 11-3 Pharmacokineti c Parameters  
Cmax The observed peak plasma concentration determined from the plasma concentration vs. time data 
Tmax The time to reach the observed peak plasma concentration from the plasma concentration vs. time 
data 
AUC 0-t Area under the plasma concent ration -time curve from 0 to t hours after dosing, calculated by 
linear/log trapezoidal method  
λz Terminal phase rate constant, determined by linear regression of at least 3 points on the terminal 
phase of the log -linear plasma concentration -time curve. The correlation coefficient (r2) for the 
goodness of the fit of the regression line through the data points has to be 0.80 or higher, for the 
value to be considered reliable.   
t1/2 Terminal half -life, defined as 0.693 divided by λ z 
AUC 0-∞ Area under the c oncentration -time curve from time -zero extrapolated to infinity, calculated as:  
zClastAUClast AUCl+ =inf
 
where C last is the last quantifiable concentration in the terminal elimination phase.  
CL Clearance after intravenous administration, calculated as:  
inf AUCDoseCL= 
Vz Volume of distribut ion in the terminal elimination phase, calculated as:  
zlCLVz=  
 
Pharmacokinetic samples may also be obtained from additional patients depending on the 
outcome of initial PK analysis.  
11.3. Safety Assessments 
Safety evaluations will be conducted at baseline and  through out the study. Safety  evaluations 
will include monitoring of AEs, vital signs measurements, physical examinations, ECGs , 
clinical laboratory studies , infusion -related  reactions, tumor response based on RECIST , 
Version 1.1 (see Section 11.5), PFS, and overall survival.  
The toxicity of G1T28 administered IV with chemotherapy will be assessed by the investigators using the NCI CTCAE, V ersion 4.0 3. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 72 of 105  
G1 Therapeutics CONFIDENTIAL  11.3.1.  Adverse Events and Serious Adverse Events  
11.3.1.1.  Definition of Adverse Event  
An AE  is defined as any untoward medical occurrence in a patient  administered a medicinal 
product that does not necessarily have a causal rel ationship with this treatment. An AE can, 
therefore, be any unfavorable and unintended sign (including an abnormal  laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the study (investigational) product.  
An abnormal laboratory value is not an AE unless it is considered to be cl inically significant.  
Adverse events  include the following:  
• All suspected adverse drug reactions (ADRs)  
• All reactions from medication overdose, abuse, withdrawal, sensitivity, or toxicity  
• Apparently unrelated illnesses, including the worsening  of a pre -existing illness (see 
pre-existing c onditions below)  
• Injur y or accidents ( Note that if a medical condition is known to have  caused the injury or 
accident [eg, a fall secondary to dizziness], the medical condition [dizziness] and the accident [fall] should be reported as 2 separate AEs ). The outcome of the ac cident (eg , 
hip fracture secondary to the fall) should be recorded under comments.  
• Abnormalities in physiological testing or physical examination (findings that require 
clinical intervention or further inve stigation beyond ordering a repeat [confirmatory] test)  
• Laboratory abnormalities that are clinically significant and require clinical intervention or further investigation (beyond ordering a repeat [confirmatory] test) unless they are 
associated with an already reported clinical event. Laboratory abnormalities associated with a clinical event (eg, elevated liver enzymes in a patient with jaund ice) should be 
described under c omments on the report of the clinical event rather than listed as a 
separate AE.  
An AE does not include:  
• Medical or surgical procedures (eg , surgery, endoscopy, tooth extraction, transfusion); 
the condition that leads to the procedure will be an AE  
• Pre-existing diseases or conditions present or detected at the start of the study that do n ot 
worsen  
• Situations where an untoward medical  occurrence has not occurred (eg , hospitalization 
for elective surgery, social, and/or convenience admissions)  
• Overdose of either study drug or concomitant medicatio n without any signs or symptoms  
• Disease progr ession  
An unexpected AE  is any AE that is not identified in nature, severity, or frequency in the 
current Investigator Brochure or product information.  
• An unexpected ADR  is an adverse reaction, the nature or severity of which is not 
consistent with the app licable product information ( eg, IB for an unapproved 
inves tigational medicinal product). All noxious and unintended responses to a medicinal 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 73 of 105  
G1 Therapeutics CONFIDENTIAL  product related to any d ose should be considered ADRs. The phrase “responses to a 
medicinal product” means that a causal relationship between a medicinal product and an 
AE is at least a reasonable possibility,  ie, the rel ationship cannot be ruled out. All serious 
and unexpected  ADR s will have expedited reporting to the regulatory agencies following 
the International Conference on Harmonisation ( ICH) requirements  
It is the responsibility of the i nvestigator to document all AEs that occur during the study and 
every effort should be made to  remain alert to possible AEs. Patient s should be encouraged to 
report AEs spontane ously or in response to genera l, nondirected questioning. Adverse events  
should be reported on the appropriate page of the eCRF.  
In the event of an AE, the primary concern  is the safety of the patient. If necessary, 
appropriate medical intervention should be provided, and the investigational drug 
discontinued.  
11.3.1.2.  Definition of Serious Adverse Event  
The ICH topic E2A on Clinical Safety Data Management, Definitions and Standards for Expedited Reporting defines  an SAE  as any untoward medical occurrence that at an y dose:  
• Resu lts in death  
• Is life threatening  
NOTE: The term "life threatening" in the definition of "serious" refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might h ave caused death if it were more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or signif icant disability/incapacity  
• Is a congenital anomaly/birth defect  
Medical and scientific judgment should be exercised in deciding whether expedited reporting (see Section  11.3.1.9 ) is appropriate in other situations, such as important medical events that 
may not be immediately life threatening or result in death or  hospitalization but may 
jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious.  Examples of such 
events are intensive treatment in an emergenc y room or at home for allergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospitaliz ation; or development of drug 
dependency or drug abuse.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 74 of 105  
G1 Therapeutics CONFIDENTIAL  To ensure there is no confusion or misunderstanding of the difference between the terms 
“serious” and “severe”, the following note of clarification is provided:  
The term “severe” is often used to describe the intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (su ch as severe headache). This is not the same as 
“serious ,” which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a patient’s life or functioning. Seriousness (not severity) serves as 
a guide for defining regulatory reporting obligations.  
11.3.1.3.  Assessment of the Severity of Adverse Events  
The severity (toxicity grade) of AEs will be graded according to the NCI CTCAE, Version  4.03 (see Appe ndix 1 ). 
11.3.1.4.  Assessment of the Relationship of Adverse Events to Study Drug  
The investigator will determine the assessment of the causal relationship of the AE to the study drug . The following terms for assessment of the causality to study drug or study 
proce dures are to be used:  
• Unrelated : There is not a temporal relationship to study drug administration (eg, too 
early, too late, or study drug not taken), or there is a reasonable causal relationship between another drug, concurrent disease, or circumstance an d the AE. 
• Unlikely Related : There is a temporal relationship to study drug administration, but there 
is not a reasonable causal relationship between the study drug and the AE (ie , the AE is 
doubtfully related to study drug). 
• Possibly Related : There is a reasonable causal relationship betw een the study drug and 
the AE. Information related to withdrawal of study drug is lacking or unclear.  
• Probably Related : There is a reasonable causal relationship betw een the study drug and 
the AE. The event respond s to with drawal of study drug. Re -challenge is not required.  
• Definitely Related : There is a reasonable causal relationship betw een the study drug and 
the AE. The event responds to withdrawal of study drug, and recurs with re -challenge, 
when clinically feasible.  
11.3.1.5.  Assessment of the Outcome of Adverse Events  
The action taken for study drugs (eg , dose i ncreased, dose not changed, dose reduced, dose 
interrupted, drug withdrawn, not applicable, u nknown)  will be recorded on the eCRF.  
Other actions (eg , none, concomitant me dication given, new or prolonged hospitalization, 
procedural surgery)  will also be recorded on the eCRF.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 75 of 105  
G1 Therapeutics CONFIDENTIAL  The outcome will be assessed accord ing to the following : 
• Fatal  
• Not recovered/not resolved  
• Recovered/resolved with sequelae 
• Recovering/resolving  
• Recovered/resolved  
• Unknown  
11.3.1.6.  Method, Frequency, and Time Period for Detecting Adverse Events and 
Serious Adverse Events  
Safety surveillance reporting of AEs commen ces at the time of informed consent  and 
continues through 30 days after last dose of study drug  (eg, t he Post- Treatment  Visit ). 
11.3.1.7.  Documentation of Adverse Events and Serious Adverse Events  
All AEs will be documented in the ap propriate section of the eCRF. The CTCAE , Version  
4.03 grading scale referenced in  Appendix 1  is provided to assist in categorizing and grading 
AEs. A ll SAEs (see Section 11.3.1.2 ) will be additionally documen ted on the SAE report 
form . For AEs occurring while the patient  is in the clinic setting, ie , before, dur ing, or after 
study drug administration, the start time and stop time of the AE should be recorded in the source document.  
The following  will be recorded for each AE  in the eCRF:  
• A description of the AE in medical terms, not as reported by the patient. Whenever possible, a diagnosis should be given when signs and symptom s are due to common 
etiology (eg , cough, runny nose, sneezing, sore throat, and head congestion should be 
reported as “upper respiratory infection”).  
• Date of onset (start date)  
• Date of recov ery (stop date)  
• Grade as assessed by the i nvestigator according to the de finitions in the AE Grading 
Scale. If the AE is not specifically listed in Appendix 1 , use the following grades:  
Grade 1  mild 
Grade 2  moderate 
Grade 3  severe  
Grade 4  life-threatening or disabling  
Grade 5  death  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 76 of 105  
G1 Therapeutics CONFIDENTIAL  11.3.1.8.  Adverse Event Coding  
Adverse event verbatim terms provided by the investigator will be coded by G1 Therapeutics  
or its designee  using the latest version of the Medical Dictionary for Regulator y Ac tivities 
(MedDRA) as specified in the statistical analysis plan (SAP).  
11.3.1.9.  Reporting of Serious Adverse Events  
The reporting period for SAEs begins from the time of informed consent  through and 
including 30 calendar days af ter the last administration of G1T28  or placebo + E/P  therapy . 
Any SAE that is thought to be related to the study drug and that occurs  after the reporting 
period must be reported within 24 hours  of discovery of the SAE.  
All SAEs must be entered into the eCRF and the initial SAE form should be  completed and 
sent to the  safety t eam within 24 hours of first knowledge of the event by the study 
personnel.  The contact information for the safety team will be provided in the Site Reference 
Manual.  
In addition, any known untoward event that occurs subs equent to th e AE -reporting period 
that the investigator assesses as related to the investigational medication should also be 
reported as an AE.  
11.3.1.10.  Follow -up of Adverse Events  
All AEs (both serious and nonserious) will be followed up in accordance with good me dical 
practice until resolution, return to baseline, or it is deemed that  further recovery is unlikely. 
All measures required for AE management and the ultimate outcome of the AE will be recorded in the sourc e document and reported to the s ponsor. 
All unre solved AEs should be followed by the i nvestigator until the events are resolved, the 
patient is lost to follow -up, or the AE is otherwise explained , or further recovery is not 
deemed to be feasible. At  the last scheduled visit, the i nvestigator should inst ruct each patient  
to report any subsequent event(s) that the patient , or the patient ’s personal physician, believes 
might reasonably be related t o participation in this study.  
Prior to the conclusion of the study at the site , the investigator should notif y the medical 
monitor of any death or AE occurring at any time after a patient  has discontinued or 
terminated study participation that may reasonably  be related to the study drug.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 77 of 105  
G1 Therapeutics CONFIDENTIAL  After study conclusion , the investigato r should notify G1 Therapeutics  of any death or AE 
they are aware of occurring at any time after a patient  has discontinued or terminated study 
participation that may reasonably  be related to the study drug. G1 Therapeutics should also 
be notified if the investigator should become aware of the development of cancer or of a 
congenital anomaly in a subsequently conceived offspring of a patient that has participated in this study.  
11.3.1.11.  Regulatory Aspects of Adverse Event Reporting  
Unexpected serious adverse reactions are subject  to expedited reporting to the Food and Drug 
Administration ( FDA) , the Medicines and Healthcare Products Regulatory Agency (MHRA), 
and European National Competent Authorities in other Member States, if applicable, in an expedited time frame in compliance with current legislatio n. All SAEs must be entered into 
the eCRF and the initial SAE form shoul d be completed and sent to the medical  monitor 
/drug safety t eam within 24  hours of first knowledge of the event by the study personnel.  
The i nvestigator is encouraged to discuss with the medical monitor any adverse experiences 
for which the issue of reportability is unclear or questioned.  
It is important that the i nvestigator provide his/her assessment of relationship to study drug at 
the time of the initial report. The following infor mation must be reported on the eCRF SAE 
report form:  
• Protocol number  
• Site and/or i nvestigator number  
• Patient number  
• Demographic data 
• Brief description of the event  
• Onset date and time  
• Resolution date and time, if the event has resolved  
• Current status, if e vent has not yet resolved  
• Any concomitant treatment and medication  
• Investigator’s assessment of whether the SAE was related to i nvestigative product or not  
• Outcome of the event if available  
 The medical monitor or member of the safety t eam will contact the  site for clarification of 
data entered in the eCRF, or to obtain missing information. In the event of questions regarding SAE repor ting, the site may contact the medical monitor or a member of the safety 
team.  The contact information for the medical monitor and safety t eam will be provided in 
the Site Reference Manual.  
G1 Therapeutics, or their designee, is responsible for submitting reports of AEs associated with the use of the drug that are both serious and unexpected to FDA , MHRA, and European 
National Competent Authorities  in other Member States, if applicable, in an expedited time 
frame in compliance with current legislation . Unexpected serious adverse that are already 
reported to the European Medicines Agency Eudravigilance database do not have to be reported again to the relevant authorities.  All i nvestigators participating in ongoing clinical 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 78 of 105  
G1 Therapeutics CONFIDENTIAL  studies with the study medication will receive copies of these reports for prompt  submission 
to their IRB  or independent ethics committee . 
11.3.1.12.  Handling of Overdose s and Toxicity  
No information on treatment of overdose of G1T28 is currently available.  General supportive 
measures should be used as appropriate.  
11.3.1.13.  Reporting of Pregnancies  
Pregnancy per se is not considered an AE unless there is cause to believe that the 
investigational drug may have interfered with the effectiveness of a contraceptive medication. Hospitalization for normal delivery of a healthy newborn should not be considered a SAE.  
Each pregnancy in a study patient  or partner of a study patient  must be reported to the 
sponsor within 24 hours of learning of its occurrence. If a patient  becomes pregnant, study 
drug administration must be discontinued immediately. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary t ermination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and /or 
newborn complications. Follow -up and documentation must occur even if the patient  
withdraws from the study or the study is completed.  
The avoidance of pregnancy or fathering a child (including spe rm donation) is suggested for 
3 months following the di scontinuation of study drug. No information is currently available 
regarding the effects of G1T28 on fertility, gestation, or subseq uent child development.  
11.3.2.  Clinical Laboratory Assessments 
Blood samples will be collected for clinical laboratory assessments as outlined in  Table 9-1 . 
The following clinical laboratory tests will be perform ed: 
• Hem atology ( hemoglobin,  hematocrit, white blood cells [ WBCs]  with differential and 
platelet count s) 
• Chemistry (albumin, alkaline phosphatase [ALP] , total bilirubin, calcium, chloride, 
creatinine, glucose, inorganic phosphorus, potassium, total pro tein, ALT, AST , LDH , 
sodium, and BUN)  
• Urinalysis (semiquantitative dipstick: specific gravity, pH , evaluation of glucose, protein, 
bilirubin, ketones, leukocytes, and hemoglobin; and a microscopic examination, including RBC, WBC, and casts will be performed, if  necessary ) 
If the subsequent cycle is delayed, the patient should still complete the clinical laboratory assessments on the scheduled Day 1, as well as on the actual first dosing day of the next 
cycle.  
Laboratory parameters will be analyzed by a local certified laboratory and a report of the laboratory values will be sent to the study center. The i nvestigator will review the laboratory 
report within 24 hours (except during clinic holidays, when review will be performed within 72 hours) after receipt of th e results and indicate the clinical significance of all abnormal 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 79 of 105  
G1 Therapeutics CONFIDENTIAL  values, and subsequently sign and file the laboratory report with the patient ’s source 
records/charts. Laboratory parameters for which clinically significant values are noted will be 
re-measured on the appropriate clin ical follow -up arranged by the investigator. Values will 
be documented on the laboratory report until stabilized, or the laboratory value returns to a clinically acceptable range (regardless of relationship to study medication). Any laboratory value that remains abnormal at the end of the study  and that is considered clinically 
significant will be followed according to accepted medical standards for up to 30 days or until resolution of the abnormality , or it is deemed that recover y is not feasible . 
Laboratory toxicities  will be assessed using the NCI CTCAE , Version  4.03 (see Appendix 1 ). 
The DMC may recommend decreasing the frequency of hematological evaluations based on accumulating data. The investigators and IRBs will be notified if the frequency is reduced.  
11.3.3.  Demographics and Vital Signs  
The following will be collected:  
• Height in centimeters (cm)  
• Body weight in kilogram (kg)  
• Body temperature (Celsius)  
• Systolic and diastolic blood pressure , pulse rat e, and respiration rate will be measured 
with the patient. Blood pressure should be assessed after 5 minutes of rest.  
11.3.4.  Physical Examination 
Full physi cal examination evaluations at s creening should include general appearance, skin, 
neck, eyes, ears, nose, t hroat, lungs, heart, abdomen, back, lymph nodes, extremities, and 
neurological examinations. Subsequent physical exams should include body systems as appropriate.  
Information about the physical examination must be present in the source documentation at the study site. The result of the physical examination prior to the start of study drug must be 
included in the relevant eCRF. Clinically relevant findings made after the start of study drug, which meet the definition of an AE, must be recorded on the AE eCRF . 
11.3.5.  Electrocardiogram  Assessments  
Standard 12 -lead ECGs will be performed as outlined in Table  9-1. Obtain ECGs in the 
Phase 1b dose -finding  portion of  Part 1 only if PK samples are also obtained.  Patients s hould 
rest for 5  minutes prior to each ECG assessment.  
The investigator or designee should review the ECGs for any abnormalities  as compared with  
predose ECGs.  
11.3.6.  Concomitant Medications  
Review of concomitant medications will occur at the times outlined in Table 9-1 . See 
Section  8.6 for more information on concomitant medications.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 80 of 105  
G1 Therapeutics CONFIDENTIAL  11.4. Central Path ology Review to Confirm Diagnosis of SCLC  
Archived tumor samples should be sent to the central pathology laboratory as soon as 
possible after enrollment to confirm the diagnosis of SCLC . Available tissue after confirming 
the diagnosis of SCLC will be banked for assessment of relevant DNA, RNA , and protein 
markers, such as tho se involved in the CDK4/6 pathway  (as described in the Laboratory 
Manual).  If central pathology review does not confirm SCLC diagnosis, the patient may be 
withdrawn from the study a fter consultation between the principal investigator , medical 
monitor , and sponsor. Archived tumor samples may also be used for future genomic testing 
related to the mechanism of drug action.  
11.5. Tumor Response  
11.5.1.  Tumor Assessments  
For tumor assessment, all sites of disease should be assessed radiologically by CT or MRI  at 
screening and  after every even cycle, until the occurrence of disease progression  (see 
Table  9-1). CT or MRI scans  obtained prior to informed consent will not need to be repeated 
if performed  within 14 days prior to do sing.  Assessments should be performed within 7 days 
of starting the subsequent cycle. Additional scans may be obtained at the discretion of the 
investigator, if clinically indicated. If a patient shows a radiologic al response (CR or PR), a 
confirmatory rad iological assessme nt will be performed at least 4  weeks after the response 
was first noted. For patients who have a confirmed CR, it is strongly recommended that they 
receive PCI  after completion of chemotherapy . Patients with a confirmed partial response 
should also consider PCI after completion of chemotherapy based on the investigator’s 
judgment (see Section 8.8). For those patients who have not progressed at the time of study 
drug discontinuation, tumor asses sments, including all sites of disease, will be assessed 
radiologically by CT or MRI, as performed at screening, every 2 months (approximately 60 ± 7 days) until the occurrence of progressive disease or study completion.  
The same method of assessment (CT or MRI) should be used to characterize tumors at screening and at all follow -up assessments.  If PET is used, it should also be accompanied by 
spiral CT or MRI.  
Investigators should follow the RECIST, V ersion 1.1 guidelines ( Eisenhauer 2009 ) for tumor 
assessments.  
11.5.2.  Tumor Lesions: Identification and Follow- up 
11.5.2.1.  Measurable Lesions  
Measurable tumor lesions are defined as tumor lesions  with a longest diameter (measured in 
at least 1 dimension) with a minimum size as follows ( Eisenhauer 2009 ):  
• 10 mm by CT  or MRI (with a scan slice thickness of no greater than 5 mm)  
Measurable lymph nodes must be ≥ 15  mm on the short axis by CT or MRI (with a scan slice 
thickness of no greater than 5 mm); only the short axis is to be measured at baseline and 
follow -up. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 81 of 105  
G1 Therapeutics CONFIDENTIAL  Lytic bone lesions or mixed lytic -blastic lesions with a soft tiss ue component meeting the 
definition of measurability above can be considered measurable lesions. Cystic lesions 
representing cystic metastases that meet the definition of measurability described above can be considered measurable lesions. If present, noncystic lesions should be selected as target lesions for this study.  
A tumor lesion that has been previously irradiated may be considered measurable if unequivocal growth of the lesion has been demonstrated.  
Target lesions:  At baseline, up to 5 measurable tu mor lesions/lymph nodes (with a 
maximum of 2  lesions per organ) should be identified as target lesions that will be followed 
to quantitate the statu s of disease during the study. Lesions with the longest diameter, that are 
representative of all involved organs, and for which reproducible repeated measurements can be obtained should be selected as the target lesions.  
At baseline and each follow -up time point (see Table  9-1), each target lesion should be 
measured and the overall tumor burden will be calculated as the sum of the diameters of the 
target lesions (longest diameter  [LD]  for tumor lesions and short axis for lymph nodes)  and 
documented in the eCRF . If a target lesion fragments into multiple smaller lesions, the LDs 
of all fragmented portions are added to the sum of the diameters. If multiple lesions coalesce, 
the LD of the coalesced lesion will be included in the sum of the diameters.  
11.5.2.2.  Nonmeasurable Lesions 
Nonmeasurable lesions include tumor lesions with a longest diameter < 10 mm, lymph nodes with ≥ 10 to < 15 mm short axis, or nonmeasurable lesions such as leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, or abdom inal masses/abdominal organomegaly identified by 
physical exam that is not measurable by CT scan or MRI ( Eisenhauer 2009 ).  
Nontarget lesions:  All other lesions (or sites of disease)  identified at baseline should be 
identified as nontarget lesions and recorded in  the eCRF.  Measurements of these lesions are 
not required, but the presence, absence, or unequivocal progression of each nontarget lesion should be recorded in the eCRF at each follow -up time point . Multiple nontarget  lesions in 
the same organ may be noted as a single item on the eCRF.  
11.5.2.3.  New Lesions  
Any new lesions should be identified and recorded at each follow -up assessment , as these are 
markers of disease progression . As defined in the RECIST, Version 1.1 guidelines  
(Eisenhauer 2009 ), new lesions include the following:  
• A lesion in an anatomical location that was not scanned at baseline  
• Equivocal new lesion of small size that with continued therapy and follow -up is found to 
progress and represent new disease (progression should be considered as of the date of the initial scan)  
• Negative positron emission tomography with 2- deoxy -2-[fluorine -18]fluoro -D-glucose 
(FDG -PET) at baseline, but has a positive FDG -PET at follow -up 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 82 of 105  
G1 Therapeutics CONFIDENTIAL  • No FDG- PET at bas eline and a positive FDG -PET at follow -up that corresponds to a new 
site of disease as confirmed by CT (date of disease progression should be the date of the 
initial abnormal FDG -PET scan)  
Note: Findings attributable to differences in scanning technique or  a change in type of 
imaging (CT versus MRI) and findings representing something other than tumor (eg, healing or flare of exiting bone lesions, necrosis of a liver lesion) should not be considered new lesions. 
11.5.3.  Definitions of Tumor Response and Disease Pro gression  
The determination of  SCLC tumor response and progression will be based on the 
RECIST , Version 1.1 criteria ( Eisenhauer 2009 ). The definitions for tumor response per the 
RECIST , Version 1.1 criteria are as follows:  
11.5.3.1.  Evaluation of Target Lesion Response  
• Complete response (CR) : Disappearance of all target lesions. Any pathological lymph 
nodes (whether target or nontarget) must have reduction in short axis to < 10 mm.  
• Partial response (PR) : At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum of diameters.  
• Progressive disease (PD) : At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline s um if 
that is the smallest on study). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression. 
• Stable disease (SD) : Neither suf ficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum of diameters while on study.  
A response category of not evaluable (NE) is to be used when there is inadequate information to otherwise categ orize the response status.  
11.5.3.2.   Evaluation of Nontarget Lesions  
• Complete response (CR) : Disappearance of all nontarget lesions and normalization of 
tumor marker level. All lymph nodes must be < 10 mm short axis.  
• Non-CR/Non -PD: Persistence of 1 or more nontarget lesions and/or maintenance of 
tumor marker level  above the normal limits.  
• Progressive Disease (PD) : Unequivocal progression of existing nontarget lesions  or the 
appearance of at least 1 new lesion.  
11.5.3.3.  Evaluation of Overall Response  
Patients who have at least 1 postdose tumor assessment (CT scan or MRI) will be considered evaluable for tumor response.  
Table 11-4  describes the evaluation of overall response at each  time  point based on target and 
nontarget l esion response s at each time point, as well as the appearance of n ew lesions. The 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 83 of 105  
G1 Therapeutics CONFIDENTIAL  best overall response is the best response recorded from the start of the treatment until 
disease progression . Confirmation of CR and PR is required as described in Sections 11.5.3.1  
and 11.5.3.2 .  
Table 11-4 Evaluation of Overall Response at Each Time Point 
Target Lesions  Nont arget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD/not evaluated  No PR 
SD Non-PD/not evaluated  No SD 
NE Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response, PR= partial response, SD = stable disease, PD = progressive disease, NE = not evaluable  
Source: ( Eisenhauer 2009) 
11.6. Patient Reported Outcomes  
The FACT -L and FACT -An instrument s will be administered to the patients by a designated 
trained study site staff member. The instruments will be administered in the clinic for the 
baseline assessment ( on or within 1 day prior to initiation of study treatment), at Day 1 of 
each cycle, Day 10 of each cycle (may be administered by phone if the patient is unable to 
return to clinic) , and at the Post -Treatment visit. If the subsequent cycle is delayed, the 
patient should still complete the PRO on the scheduled Day 1, as well as on the actual first  
dosing day of the next cycle. Where possible, the same staff member will administer the instrument at each site.  
Both the FACT -L and FACT -An contain  a core general questionnaire that  measures physical, 
social/family, emotio nal, and functional well -being. The FACT -L has an additional lung 
cancer subscale (FA CT-L) (Cella 1995 ). The FACT -An has a n additional  subscale that 
measures the imp act of fatigue and other anemia- related symptoms on patients with cancer 
(FACT -An) (Yellen 1997 ). The core gener al questionnaire is the same for both instruments;  
as such , at each assessment , the core questionnaire will be administered once along with the 
lung and anemia subscales.   
11.7. Immunologic Markers  
The addition of G1T28 to standard chemotherapy could provide cl inical benefit to patients 
with CDK4/6 -independent cancers through the reduction of myelosuppression- related side 
effects and improved chemotherapy activity.  There are at least 2 potential mechanisms by 
which G1T28 may improve chemotherapy activity: mainta ining dose intensity and 
maintaining immune system function through repeated cycles of chemotherapy. In addition to the common side effects tha t result from myelosuppression, chemotherapy -induced 
immunosuppression may limit response rates and survival due to an inability of the damaged host immune system to effectively mount a response against the cancer. The impact of chemotherapy on the host immune system has been shown to be a double -edged sword, 
where the specific chemotherapeutic agent and dosing regimen (low dose versus standard 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 84 of 105  
G1 Therapeutics CONFIDENTIAL  dosing) dictate the impact on the immune system. Chemotherapeutic agent s may elicit part of 
their antitumor efficacy by modulating the immune system to enhance antigen presentation, 
uptake , and processing; prime the immune resp onse through immunodepletion; inhibit 
regulatory cells; and stimulate immune effector cells ( Zitvogel 2008; McDonnell 2011 ; 
Bracci 2014 ). Conversely, immunosuppression from direct cytotoxicity to the bone marrow 
and immune system over repeated cycles of chemotherapy may counterbalance the positive immunostimulatory effects of chemotherapy. Preclinical mouse models have shown that chemotherapeutic response is more robust in tumors transplanted into immunocompetent mice compared to immunodeficient mice, suggesting that the loss of immune system function is detrimental to the overall efficacy of the chemotherapy ( Apetoh 2007 ; Casares 2005 ). In 
support of these data, severe lymphopenia (<  1000 cells /µL) in patients with breast cancer, 
advanced soft tissue sarcom a, and non -Hodgkin lymphoma has been shown t o negatively 
affect progression -free and overall survival  (Ray-Coquard 2009 ). Since immune 
reprogramming is now believed to be an important mechanism of chemotherapy response, therapeutic approaches to maintain b one marrow health and immune system function should 
enhance this activity. Therefore, t o evaluate the impact of G1T28 administration on 
chemotherapy -induced changes of the  immune system, peripheral blood immune subsets  will 
be characterized in patients enr olled into Part 2 of the study. Immunophenotypic changes will 
be compared between patients receiving E/P therapy  plus placebo or  G1T28. To assess  these 
changes , peripheral blood will be collected  at predose on  Day 1 of C ycles 1, 3, and 5 ; at the 
Post-T reatment V isit, and at 60 days after the Post -Treatment  Visit. 
 
Immun ophenotyping  
Whole blood samples ( 15 mL) for immun ophenotyping will be obtained from patients 
enrolled in Part 2.  Comprehensive information on the blood sample acquisition, the specific 
type of collection tube s with anticoagulant, and handling and storage are to be found in the 
laboratory manual.   
11.8. Appropriateness of Measurements  
The measures of efficacy, PK, and safety evaluated in this study are based on the mechanism 
and activity of G1T28, standard types of assessments typically performed in patients with 
SCLC, and prior clinical observations derived from patient s receiving E/P therapy for SCLC. 
The measurement  of tumor respons e based on the RECIST, Version 1.1 ( Eisenhauer 2009 ) is 
standard. The PK and safety measures included in this study are also standard.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 85 of 105  
G1 Therapeutics CONFIDENTIAL  12. STUDY TERMINATION OR STUDY DRUG 
DISCONTINUATION 
12.1. Study Termination 
The entire study may be terminated in the event of any of the following:  
• Occurrence of AEs unknown to date with respect of their nature, severity, and duration, 
or the unexpected incidence of known AEs  
• Medical or ethical reasons affecting the continued performance of the study  
• Difficulties in the recruitment of patients  
• Cancellation of the d rug development program  
• Sponsor decision for other reasons   
12.2. Site Termination  
A study site will be closed if there is evidence of fraud, other unethical conduct , or 
significant regulatory non compliance to the protocol or to Good Clinical Practice ( GCP ), or 
if insufficient patients have been enrolled to meet the site objectives.  
12.3. Discontinuation of Study Drug  
Study drug will be discontinued if any of the following events occur during the study:  
• A patient suffers an AE  that, in the judgment of the investigator , sponsor , or medical 
monitor, presents an unacceptable risk to the patient  
• General or specific changes in the patient’s condition (eg, a significant intercurrent illness 
or complication)  that,  in the judgment of the investigator , are unacceptable for further 
administration of study drug  
• Occurrence of pregnancy  
• Significant noncompliance with protocol requirements  
• The s ponsor or legal representative of the s ponsor requests  the patient to withdraw  
• Patient has radiologically documented disease  progression 
In the event of study drug discontinuation, patients should be strongly encouraged to 
complete all scheduled assessments through the end of their current 21- day treatment cycle, 
including the PRO scales; CBC assessment on Day 22; the Post -Treatment Visit; and the 
Survival Follow -up Phase of the study . A patient who discontinues study treatment for 
reasons other than PD will  have a CT or MRI scan at the Post- Treatment  Visit , if they have 
not had a scan within the prior 4 weeks.  
The i nvestigator will document th e reason for study drug discontinuation on the applicable 
eCRF page.   
When discontinuation i s due to a SAE  or a G rade 3 or 4 toxicity considered to be related to 
study medication, the investigator should follow the event until resolution, return to baseli ne, 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 86 of 105  
G1 Therapeutics CONFIDENTIAL  or it is deemed that further recovery is unlikely . Data on these events should be collected on 
the AE  CRF.  
In the event a patient discontinues due to an AE  or pregnancy, the investigator should notify 
the medical monitor by telephone within 48 hours  of study drug discontinuation. 
12.4. Withdrawal of Patients from the Study  
Patients may withdraw from the study at their own discretion (or at the discretion of the 
investigator) for any reason at any time. The following list of reasons for withdrawing patients from the study may include but are not limited to:  
• Withdrawal of informed consent  
• Lost to follow -up (must have at least 2 documented attempts to contact the patient; 
1 attempt must be written to the patient and sent via certified letter)  
• If central pathology  review does not confirm SCLC diagnosis, the patient may be 
withdrawn from the study a fter consultation between the principal investigator , medical 
monitor, and sponsor  
All data collected prior to the date of withdr awal of consent  will remain in the clinic al 
database.  
 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 87 of 105  
G1 Therapeutics CONFIDENTIAL  13. STATISTICS  
Full details on the statistical analyses to be performed will be provided in a separate 
statistical analysis plan ( SAP). 
13.1. Sample Size and Power  
The sample size for this study is determined by clinical rather th an statistical consid erations. 
Up to  40 patients ( open -label, dose-finding cohort [s] and an open-label, expansion cohort) 
will be enrolled in Part 1 of the study  and 70 patients will be enrolled in Part 2 of the study 
(randomized).  With 35 patients, the precision for point est imates in each arm  is as follows : 
the 95% confidence interval ( CI) width for binary endpoints based on Wilson score intervals 
are at most the observed  proportion ± 0.157. The 95% CI width for continuous endpoints 
using the t -distrib ution are the observed mean ± 0.344*standard deviation of the endpoint . 
13.2. General Considerations  
13.2.1.  Analysis Populations/Sets 
The full analysis set (FAS) includes all patients who received at least 1 dose of study drug. Analyses using the FAS will be conducted on the basis of the assi gned treatment. All efficacy 
analyses will be assessed using the FAS and the FAS is the primary population for analysis.  
The safety population includes all enrolled patients who received at least 1  dose of study 
drug. The safety population will be conducte d on the basis of the actual treatment received. 
All safety analyses will be assessed using the safety population.  
A per -protocol (PP) subset may also be used to analyze select endpoints and will be based on 
study drug exposure (compliance and/or time on study drug) and major protocol deviations. The criteria for inclusion in the PP subset will be finalized and documented prior to unblinding patients in Part 2 of the study. 
The PK set will include all dosed patients i n Part 1 with evaluable PK data.  
13.2.2.  Timing of Analyses 
13.2.2.1.  Interim Safety Reviews  
A DMC will monitor accumulating safety data according to a charter that defines its roles 
and responsibilities. The DMC will perform reviews approximately every 4 months during  
the Treatment Phase of  Part 2, depending upo n the enrollment rate. Additional reviews may 
occur based on DMC requests. The committee will consist of individuals with extensive multicenter clinical study experience drawn from the fields of clinical oncology (specifically, SCLC) and biostatistics.  These individuals will be entirely independent of the conduct of the 
study.  
Additional details regarding the committee procedures and policies, including table displays and strategy for maintaining study blind, are described in the DMC charter. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 88 of 105  
G1 Therapeutics CONFIDENTIAL  No interim ana lyses of efficacy are planned . 
13.2.2.2.  Final Analysis  
The final analysis will occur when the la st patient completes the Post- Treatment Visit. All 
study data collected up through the time of the final analysis data cut, including Follow -Up 
Survival Phase results, w ill be included in the final analysis. Unblinding will occur at the 
time of the final analysis.  
13.2.2.3.  End of Study Analysis  
If the Follow -up Survival Phase of the study continues after the final analysis, a 
supplementary analysis will be done at  the time of study completion. Reported results will be 
cumulative in nature, including all data collected during the entire study.  
13.2.3.  General Considerations for Data Analysis 
All statistical analyses will be performed using SAS® version 9 or higher.   
Data will be summarized separately by study part (Part 1 and Part 2). Data from Part 1 will 
be summarized descriptively by dose level if applicable and overall.  Data from Part 2 will be 
summarized descriptively by treatment group and overall.  Treatment differences between 
treatment groups for Part 2 will be calculated as  G1T28 + E/P therapy minus placebo + E/P 
therapy . Select safety summaries will include combined data from both Part 1 and Part 2 of 
the study. The descriptive summary for the categorical variables will include coun ts and 
percentages. The descriptive summary for the continuous variables will include means, medians, standard deviations , and minimum and maximum values. The descriptive 
summaries of time to event data will include median, twenty -fifth and seventy -fifth 
percentiles and standard error. All data will be listed for all patients.  Unless specified 
otherwise, safety summaries will include all collected data, and summaries of efficacy will include data collected through the Treatment Phase.  
This study is descript ive in nature, and no formal hypothesis testing  will be per formed across 
treatment groups.  All CIs  will be 95%, unless stated otherwise.  
The effects of covariates and withdrawal from study treatment due to reasons other than death, disease progression , and  toxicity will be assessed to determine the impact on the 
general applicability of results from this study. Further details of the analysis, including the handling of missing data, impact of variable chemotherapy dose exposure including dose reductions, tr ansformations and other data handling procedures will be provided in a separate 
SAP. Exploratory analyses of the data will be conducted as deemed appropriate.   
Summaries that are based on within -cycle, including changes, events , or findings, will 
require a clear definition of “end of cycle” that accounts for variable durations in the cycle due to within -cycle dosing delays, delays in subsequent cycle initiation, and incomplete 
cycles. This will be discussed in the SAP for each applicable endpoint.  
Protocol violations will be fully defined and documented before unblinding. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 89 of 105  
G1 Therapeutics CONFIDENTIAL  13.3. Baseline and Demographic Characteristics  
Demographics and baseline characteristics will be summarized descriptively .  
13.4. Efficacy Analysis 
13.4.1.  Efficacy Endpoints 
Unless otherwise stated, the termi nology ‘hematologic parameters’ refers to ANC , 
lymphocyte, hemoglobin , and platelet counts;  the terminology ‘hematologic toxicities’ refers 
to neutropenia, lymphopenia, anemia, and thrombocytopenia. Each parameter and toxicity 
will be evaluated individuall y, but are described as such to avoid repetition. Hematologic 
toxicities are assigned based  on CTCAE, Version 4.03.  
• Hematologic kinetic endpoints: 
• Change and percent change in hematologic parameter values from baseline to the 
Post- Treatment Visit  
• Change a nd percent change in hematologic parameter values from predose for a 
particular cycle to the end of that cycle  
• Change and percent change in hematologic parameter values from predose for a 
particular cycle to nadir for that cycle  
• Rate of change in hematologic parameter values from predose for a particular cycle to 
nadir for that cycle  
• Change and percent change in hematologic parameter values from nadir for a particular cycle to the end of that cycle  
• Rate of change in hematologic parameter values from nadir f or a particular cycle to 
the end of that cycle  
• Area under the curve in hematologic parameter values from predose for a particular 
cycle to the end of that cycle  
• Area under the curve in hematologic parameters from predose for a particular cycle to 
nadir for  that cycle  
• Area under the curve in hematologic parameter values from nadir for a particular cycle to the end of that cycle  
• By cycle and overall study hematologic parameter nadir values  
• Time to hematologic parameter value nadir by cycle  
• Time to return to predose hematologic parameter values by cycle  
• Proportion of patients with a return to predose hematologic parameter values by cycle  
 
• Hematologic t oxicity e ndpoints:  
• Incidence of Grade 3  and 4 hematologic toxicities  
• Total number of Grade 3  and 4 hematologic toxicities  
• Proportion of patients with a hematologic toxicity recovery by cycle  
• Time to hematologic toxicity recovery by cycle  
 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 90 of 105  
G1 Therapeutics CONFIDENTIAL  • Chemotherapy exposure and c ompliance endpoints: 
• Duration on treatment  
• Number of cycles received  
• Dose intensity and cumulative do se 
• Incidence of dose interruptions, delays, and reductions  
• Incidence of dose delays due to hematologic toxicity  
• Incidence of study treatment termination due to hematologic toxicity  
 
• Other efficacy endpoints : 
• Incidence of infections overall and by severity  
• Incidence of RBC and platelet transfusions  
• Incidence of hematopoietic growth factors use  
• Incidence and duration of systemic antibiotic use 
 
• Explor atory efficacy endpoints : 
• Incidence of Grade 2  or greater nephrotoxicity  
• Incidence of alopecia and mucositis  
• Functional Assessment of Cancer Therapy QOL instrument ( FACT ) total scale score 
(general)  
• FACT domain  scores (physical, social/family, emotional, and functional well- being)  
• FACT -L total s cale s core 
• FACT -L lung cancer subscale s core 
• FACT -L trial outcome in dex s core 
• FACT -An total scale s core 
• FACT -An anemia subscale s core 
• FACT -An trial outcome index s core 
• Composite hematologic score (this will be specified a priori  in a SAP ) 
• Composite efficacy score (this will be specified a priori  in a SAP ) 
 
13.4.2.  Methods of Analysis for Efficacy Endpoints 
Summaries of efficacy will be performed using the FAS. Select summaries will also be 
repeated in the PP analysis set. Unless noted otherwise, hematologic endpoints will be summarized separately by each parameter type (ie, ANC , lymphocytes, etc.). The SAP will 
describe in detail the minimum sampling and dosing requirements for inclusion in the analysis of each endpoint for a given cycle or overall, particularly for those that involve AUC, nadir, and end of cycle results. Sensitivit y analyses may be performed to assess the 
impact of incomplete dosing within a cycle or missing sampling times.   
13.4.2.1.  Analysis of Hematologic Parameter Kinetic Endpoints  
Hematologic parameter values will be tabulated with descriptive statistics using absolute counts, change, and percent change values. By -visit tabulations will incl ude values at study 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 91 of 105  
G1 Therapeutics CONFIDENTIAL  baseline (ie, prior to first dose of study treatment) and each post baseline visit through all 
cycles and the  Post- Treatment Visit. Changes and percent changes will be calculated at each 
postbaseline value.  Additional tabulations for each cycle of treatment will include predose, 
nadir, maximum post nadir, and end of cycle values. The change and percent changes from 
predose to nadir, predose to end of cycle, nadir to maximum post nadir, and nadir to end of 
cycle values will also be tabulated  for each cycle of treatment. Analysis of covariance 
(ANCOVA) models will be performed for summaries on Part 2, separately at each visit and 
for each of the following parameters as dependent variables: change from baseline and  
percent change from baseline. Analysis of covariance models will be performed separately at 
each cycle and for each of the following parameters as dependent variables:  predose (for 
cycles 2 and onward), nadir, the  Post- Treatment Visit counts, change from predose to nadir, 
predose to end of cycle, nadir to maximum post nadir, and nadir to end of cycle; and percent 
change from predose to nadir, predose to end of cycle, nadir to maximum post nadir, and 
nadir to end of c ycle. The models will include terms for treatment, ECOG at entry (0 and 1 or 
2), and baseli ne hematologic parameter value.  The least square (LS) mean for each treatment 
group and LS mean difference between treatment groups will be reported. The treatment b y 
ECOG interaction and treatment by baseline hem atologic value will be tested. If a significant 
treatment by ECOG interaction exists, the LS means and LS mean differences will be reported a t each level of ECOG at entry.  If a treatment by baseline hematologic parameter 
interaction exists, the LS means and LS mean differences will also be reported at various levels of the covariate (10%, 25%, 50%, 75 %, 90%). Two -sided 95% CIs  will be constructed 
around the LS mean differences in treatment groups . 
The most ext reme Treatment Phase nadir value and the cycle at which the most extreme 
nadir occurred wil l be summarized descriptively. Time to nadir will be summarized 
descriptively for each cycle and is calculated for each cycle and defined as date of nadir minus predose date + 1.  
The AUC  in hematologic parameters will be tabulated for each cycle, separately for the 
following windows within a cycle: predose  to end of cycle (AUC
EOC), predose  to nadir 
(AUC Nadir), and nadir to end of cycle (AUC NEOC). Analysis of covariance models similar to 
those described above will be performed separately at each cycle using each of the AUC parameters as dependent variables. Additionall y, a repeated -measures model of AUC 
parameters over all cycles will be performed for each AUC measure s eparately, with fixed 
effects for treatment, treatment cycle, treatment by cycle  interaction, baseline hematologic 
value , and ECOG at entry.  The unstructured covariance model will be used to tabulate the LS 
means for each treatment group and the LS mean difference between treatment groups at each cycle. T wo-sided 95% CI s will be constructed around the LS mean differences in AUC 
between treatment groups. An analysis accounting for cumulative dose exposure at each cycle will be performed to support the evalua tion of AUC over cycles.  
The proportion of subjects that return to predose values will be summarized by cycle f or each 
hematologic parameter.  Percentages for by -cycle summaries will be based on the number of  
patients treated in the cycle.  For tabulations p erformed based on data collected in Part 2, the 
difference in rates between treatment groups will be calculated. Two -sided 95% CI s will be 
constructed around the difference in treatment groups. If there are substantial dose reductions, an incidence rate, adjusting for cumulative exposure, may be reported to account for differing amount of exposure by cycle.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 92 of 105  
G1 Therapeutics CONFIDENTIAL  Time to return to predose levels will be estimated for each cycle using the Kaplan -Meier 
method. Time to return to predose levels is defined for all pat ients as the number of da ys 
from nadir to the first post nadir date of levels greater or equal to predose levels prior to end 
of cycle. A clinically meaningful +/- predose level window will be defined for each 
hematologic parameter and specified in the SAP.  Time to return to post nadir predose levels is 
also calculated from the start of the cycle (first dose in the cycle). Patients who do not return to predose levels within the window will be censored at the last date with non missing results. 
The same analysi s will be repeated on the subset of patients that had a Grade 3  or higher 
toxicity.   
13.4.2.2.  Analysis of Hematologic Toxicity Endpoints  
The number and percentage of patients with Grade 3  and 4 hematologic toxicities at each 
cycle and overall during the Treatment P hase will be tabulated for each type of hematologic 
toxicity and across all type of h ematologic toxicities. Percentages for by -cycle summaries 
will be based on the number of patients treated in the cycle. For tabulations performed based on data collected in Part 2, the difference in rates between treatment groups will be calculated. T wo-sided 95% CI s will be constructed around the difference in treatment groups . 
If there are substantial dose reductions, an incidence rate, adjusting for cumulative exposure, may be reported to account for differing amount of exposure by cycle. 
The total number of Grade 3  and 4 hematologic toxicities will be summed over the entire 
Treatment Phase per patient, separately for each type of hematologic toxicity and across all 
types  of hematologic toxicities. To account for differing amount of exposure, a toxicity rate 
will be calculated for each patient, and defined relative to cumulative exposure (total number 
of toxicities divided by cumulative exposure). A recurrent events model may be performed to 
estimate the incidence of  Grade 3  or higher hematologic toxicities and test for the diffe rence 
between treatment groups.   
For each hematologic parameter and cycle, the following shif t summaries will be performed: 
from predose toxicity to maximum ontreatment toxicity; from predose toxicity to end of 
cycle toxicity; from maximum post dose tox icity to end of cycle toxicity.   
Hematologic recov ery will be defined in the SAP.  The number and percentage of patients 
with hematologic recovery wi ll be calculated at each cycle.  Time  to post dose recovery within 
a cycle will be estimated using the Kaplan -Meier method. A Cox proportional hazard model 
adjusted for baseline hematologic toxicity and ECOG will also be performed.  
13.4.2.3.  Analysis of Chemotherapy Exposure and Compliance 
The following parameters will be summarized by treatment group and overall: total duration of treatment, total number of cycles received, cumulative dose of E/P therapy received, and number and percentage of patients experiencing one or  more dose delay, interruption, and 
reduction. The following parameters will be summarized for each cycle by treatment group and overall: number and percentage of patients receiving dose at the cycle, experiencing one or more dose delay, interruption, and reduction, and cumulative dose of E/P therapy received.  
The number and percentage of patients experiencing a treatment cycle delay due to a hematologic toxicity will be su mmarized by cycle and overall. The number and percentage of 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 93 of 105  
G1 Therapeutics CONFIDENTIAL  patients discontinuing st udy treatment due to a hematologic toxicity and cycle of 
discontinuation will also be summarized . 
13.4.2.4.  Other Efficacy Endpoints  
Infections, RBC and platelet transfusions, systemic antibiotic use , and hematopoietic growth 
factor use will be summarized with the  number and percentage of patients experiencing the 
event any time during the Treatment Phase of the study. For tabulations performed based on 
data collected in Part 2, the difference between treatment groups will be calculated and 
reported as described for the incidence of hematologic endpoints . 
The number and percent of  infections will also be summarized by maximum severity. The 
infection rate will be calculated as the number of infections occurring during the Treatment 
Phase divided by cumulative exposure.   
13.4.2.5.  Analysis of Exploratory Efficacy Endpoints  
Grade 2 or higher nephrotoxicity, alopecia , and mucositis will be summarized with the  
number and percentage of patients experiencing the event any time during the Treatment Phase . For tabulations performed based on data collected in Part 2, the difference between 
treatment groups will be calculated and reported as described for the incidence of hematologic toxicity . 
The FACT  scores will be calculated  per the FAC IT version 4 scoring instructions and 
summarized by visit. The change from baseline in each score will be calculated and 
presented at each post baseline visit. A dditionally the change from pre dose to Day 10 and 
change from pre dose to end of cycle values will be calculated and presented at each cycle.  
Analysi s of covariance models may be performed for summaries on Part 2, similarly to those 
described in Section 13.4.2.1 . The extreme (best and worst) on study values and minimum 
and maximum change will also be analyzed . The number and percent of patients that have 
clinically relevant  improvements or deteriorations will be summarized.  
A single composite endpoint taking into account multiple types of hematologic parameters and other clinically relevant measures is of interest to capture the efficacy of G1T28 + E/P  
therapy . A composite endpoint will be defined a priori  in a SAP.  Factors such as infection 
rate, toxicity rates, chemotherapy dose reductions and/or interruptions, incidence of transfusions, incidence of growth f actor use, AUC, etc. may be incl uded. The association 
between composite endpoints and best overall response, overall sur vival, and PFS may be 
explored.   
Similarly, identifying a composite hematologic score that represents ANC , lymphocytes, 
platelets , and h emoglobin in a meaningful way will be defined a priori  in the SAP.  
13.5. Safety Analysis 
13.5.1.  Safety Endpoints  
• Incidence of treatment -emergent AEs, SAEs, related AEs, related S AEs, and AEs leading 
to study drug discontinuation  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 94 of 105  
G1 Therapeutics CONFIDENTIAL  • Infusion -related reactions  
• Vital signs  
• Physical examination  
• ECG readings  
• Clinical hematology, chemistry , and urinalysis results  
• Concomitant medications  
• Tumor response and best overall response based on RECIST , Version 1.1 
• Progression -free survival  
• Overall s urvival  
13.5.2.  Methods of Analysis for Safety Endpoints  
The safety analysis will be performed in all patients who have received at least 1 dose of 
study drug . Adverse event  data will be coded to system organ class and preferred term using 
MedDRA ( Version  17.1, or later). Treatment emergence is defined  as any AE occurring on 
or after the day o f first dose through the Post- Treatment Visit. The number and percentage of 
patients experiencing any treatment -emergent AE  overall and by system organ class and 
preferred term will be tabulated. The incidence rates by cycle and adjusted by exposure time will also be presented.  Each AE will be counted only once for a given patient at each level of 
summarization. In analyses of grade and causality, if the same AE occurs on multiple occasions, the highest grade and st rongest relationship to study drug will be assumed. 
Infusion -related reactions will be tabulated separately from the AEs.  
Absolute values and changes from baseline in vital signs, ECG readings, and hematology and 
clinical chemistry parameters will be tabulated at each visit  during the Treatment Phase . 
Toxicities for clinical labs will be characterized accord ing to the CTCAE, V ersion 4.03. 
Shifts in toxicity grades from baseline to each visit will be summarized.  
Overall disease responses as determined by RE CIST , Version 1.1  will be summarized by 
response level at each vi sit and best overall response. The number of patients with a 
confirmed objective disease response, defined as patients with a best overall response of 
confirmed CR or PR  obtained during the T reatment Phase, will be summarized.   
Progression -free survival  is measured from date of first dose date until date of documented 
disease progression or death and will be estimated  using the Kaplan -Meier method.  Patients 
who have not died or had documented disease progression at the time of analysis  will b e 
censored on the last on study date with no nmissing tumor response data.  
Overall survival is measured from date of enrollment  until death and will be estimated using 
the Kaplan -Meier method . Patients  alive  at the time of analysis will b e censored on the last 
date the patient was known to be alive.  
Censoring techniques that account for missing tumor assessments and potential differences in the duration of time patient has on study tumor assessments may be ap plied for PFS data. The 
methods will be described in the SAP.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 95 of 105  
G1 Therapeutics CONFIDENTIAL  13.6. Exploratory Analyses 
Exploratory analyses examining the relationship between hematologic toxicity rates and 
hematologic changes with study drug exposure will be performed based on rate of chemot herapy interruptions and rat e of chemotherapy reductions.  
Exploratory analyses will be performed to assess the impact of hematologic kinetics on overall survival, PFS , and best overall response rate.  Similarly, exploratory analyses will be 
performed to as sess the impact of cumulative chemotherapy exposure on overall survival, 
PFS, a nd best overall response rate. Exploratory analyses will be described in the SAP.  
The relationship between G1T28 plasma concentration and hematologic parameter values will be as sessed with the Pearson product -moment correlation  statistics.   
13.7. Pharmacokinetic Analysis 
Pharmacokinetic analyses will be based on  the PK set, and all analysis and reporting of 
plasma concentration and PK parameter data will be performed separately for each analyte.  
During Part 1 of the study, serial blood samples will be collected on Days 1 and 3 of Cycle 1 to determine G1T28, etoposide, and carboplatin plasma concentrations. Plasma concentration 
data will be tabulated descriptively and graphed at each vi sit and time point. Pharmacokinetic 
parameters will be calculated with noncompartmental methods  (WinNonlin Version 6.3 or 
higher)  based on the plasma concentration- time data. The following PK parameters will be 
calculated (when data permit their calculatio n): C
max, Tmax, AUC 0-t, AUC 0-∞, t1/2, CL, and V z. 
Pharmacokinetic parameters will be summarized descriptively by visit and analyte. If 
applicable, G1T28 plasma concentration and PK parameters will also be summarized by dose level.  
Exploratory PK modeling and simulations  may also be performed.  
13.8. Immunologic Markers  
To evaluate the impact of G1T28 administration on chemotherapy -induced changes of the 
immune system, peripheral blood immune subsets will be characterized in patients enrolled 
into Part 2 of the st udy. The immunophenotypic change from baseline will be listed and 
summarized by treatment arm, if data warrant . 
  Additional exploratory analyses on the relationship between the immunophenotypic changes and safety and efficacy findings may be performed.   
 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 96 of 105  
G1 Therapeutics CONFIDENTIAL  14. QUALITY CONTROL AND QUALITY ASSURANCE  
An eCRF must be completed for each patient  enrolled . Each completed eCRF , as well as 
records for those patient s who discontinue the study, will require a signature by the principal 
investigator at the study site. If a patient  withdraws from the study, the reason must be noted 
on the eCRF , and if a patient  is withdrawn from the study because of a treatment -limiting 
AE, thorough efforts should be made to clearly document the outcome. The investigator 
should ensure the accuracy, completeness, legibility, and timeliness of the data reporte d to 
the sponsor in the eCRFs and in all required reports.  
Accurate and reliable data collection will be assured by verification and cross -check of the 
eCRFs against the investigator’s reco rds by the study monitor (source document 
verification), and the maintenance of a drug -dispensing log by the investigator.   
A comprehensive validation check program will verify the data and discrepancy reports will be generated accordingly for resolution b y the  investigator. As patients complete the study 
(or withdraw) and their signed eCRFs become available for review, a comparison check will be run to identify and resolve any discrepancies in the data base.   
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 97 of 105  
G1 Therapeutics CONFIDENTIAL  15. ETHICS AND PROTECTION OF HUMAN PATIENTS 
15.1. Ethical  Conduct  Statement 
The investigator will ensure that this study is conducted in full conforma nce with the 
principles of the Declaration of Helsinki  (as amended in Tokyo, Venice, Hong Kong , and 
South Africa) or with the laws and regulations of the country i n which the research is 
conducted, whichever affords the greater  protection to the individual. The investigator will 
ensure adherence to the basic prin ciples of GCP  as outlined in the current version of 2 1 CFR, 
subchapter D, Part 312, Responsibilitie s of S ponsors and Investigators, part 50, Pro tection of 
Human Subjects, and P art 56, Institutional Review Boards, a nd ICH E6 GCP . The 
investigator will follow all national, state, and local laws of the pertinent regulatory 
authorities.  
15.2. Institutional Review Board /Independent Ethics Committee  
The protocol and all associated amendments and consent/assent materials will be reviewed and approved by the investigative site’s local IRB or a central IRB . It is the investigator’s 
responsibility to obtain approval of the study protocol and informed consent, and any other study related materials such as advertising or i nformation leaflets , from their  IRB  prior to 
initiating the study. Approval must be obtained in writing via a lette r identifying the protocol, 
the date of the IRB  meeting , and the date of approval. Any modifications made to the 
protocol after receipt of the IRB  approval must also be submitted by the investigator to the 
IRB in accordance with local procedures and regulatory requirements. Any updates to the 
protoc ol should receive IRB  approval or favorable opinion, which should be documented in a 
letter to the investigator, prior to implementation.  
15.3. Informed Consent  
It is the responsibility of the investigator to obtain written informed consent from each patient participating in this study, after adequate explanation of the goals , methods, potential 
benefits , and hazards of the study. The investigator or designee must also explain that the 
patient s are allowed  to withdraw from  the study at any time and for any reason . All patient s 
should be given a copy of the informed consent and any updates.  Original signed consent 
form s will be maintained at the site and be made available for inspection, as appropriate.  
15.4. Patient  Confidentiality  
The investigator must assure that pati ents’ anonymity will be maintained and that their 
identities are prote cted from unauthorized parties. Patient names will not be supplied to the 
sponsor and only the patient  number will be recorded in the eCRF and study findings stored 
on a computer will be  stored in accordance w ith local data protection laws. The patient s will 
be inform ed that repre sentatives of the sponsor, IRB , or regulatory authorities may inspect 
their medical records to verify the information collected, and that all personal informatio n 
made available for inspection will be handled in strictest confidence and in accordance with local data protection laws.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 98 of 105  
G1 Therapeutics CONFIDENTIAL  15.5. Adherence to the Protocol  
The study shall be conducted as described in this protocol, except for an emergency situation 
in which proper care of the patient requires immediate alternative intervention. The s ponsor 
will prov ide this protocol to the IRB  and appropriate local regulatory authorities for approval. 
Any protocol amendments will be done in accordance with the provisions agreed u pon in 
Section 15.6. Any deviation from the design of the study as set forth in this document will be 
recorded as a protocol deviation and will be explained in detail as it occurs and/or is detected.  
15.6. Protocol Am endments  
Protocol modifications must be prepared by a representative of the sponsor and initially reviewed and approved by the sponsor. 
All protocol modifications must be s ubmitted to the appropriate IRB  or independent ethics 
committee for information in a ccordance with local requirements. Approval must be awaited 
befor e changes can be implemented (ie, if the risk benefit ratio is affected and/or the 
modification represents a change in basic trial definitions such as objectives, design, sample 
size, and out come measures), except for those changes which would decrease risk to the 
patient or administrative changes.   All substantial protocol amendments must have approval 
from the relevant competent regulatory authority before changes can be implemented.   
15.7. Patie nt Compliance  
Patients must be available f or all scheduled study visits. Any reason for patient 
noncompliance will be documented.  
15.8. Study Discontinuation  
Both the s ponsor and the investigator reserve the right to terminate the study at any time, 
according to  the terms s pecified in the study contract. The inv estigator should notify the IRB  
in writing of the study’s c ompletion or early termination. In terminating the study, the 
sponsor and the investigator will assure that adequate consideration is given to the  protec tion 
of the patient ’s interests.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 99 of 105  
G1 Therapeutics CONFIDENTIAL  16. DATA HANDLING AND RECORD KEEPING  
16.1. Data Collection and Retrieval 
This study will use a 21 CFR Part 11 compliant e lectronic data capture system. An eCRF will 
be used for data recording. All data requested on the eCRF must be entered and all missing 
data must be accounted for.  
Accurate and reliable data collection will be assured by verification and cross -check of the 
eCRF against the i nvestigator’s records by the study monitor (source document verification), 
and the main tenance of a study drug -dispensing log by the i nvestigator.  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a s ponsor 
representative will review the protocol and eCRFs with the i nvestigators and their staff. 
During the study, a monitor will visit the site regularly to check the completeness of patient 
records, the accuracy of entries on the eCRFs , the adherence to the protocol and to GCP, a nd 
the progress of enrollment. The monitor will ensure during on- site visits  that study 
medication is being stored, dispensed, and accounted for according to specifications. Key 
study  personnel must be available to assist the monitors during these visits.  
The investigator must give the monitor access to relevant hospital or clinical rec ords to 
confirm their cons istency with the eCRF entries. No information in these records about the 
identity of the patient s will leave the study center. Monitoring standards require full 
verification for the presence of informed consent, adherence to the i nclusion/exclusion 
criteria, documentation of SAEs , and the recording of primary efficacy and safety variables. 
Additional checks of the consistency of the  source data with the eCRFs are to be performed 
according to the study -specific monitoring plan.  
16.2. Data  Monitoring Committee  
An external DMC  will be used to evaluate safety of Part 2 of the study in an ongoing manner  
(see Section  13.2.2  for further details ). 
16.3. Investigator Reporting Requirements  
Local regulations may require the investigator to provide periodic safety updates on the conduct of the study and to notif y the IRB  of study closure. Such updates and notifications 
are the resp onsibility of the investigator.  
16.4. Records Retention  
After closure  of the study, the investigator will maintain copies of all study records  (ie, 
investigator files and patient  files)  in a secure location. The investigator’s study file will 
contain the protocol, protocol amendments, e CRF and query forms, IRB  and governmen tal 
approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and correspondence.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 100 of 105  
G1 Therapeutics CONFIDENTIAL  Patient clinical source documents may include (but not limited to) patient hospital recor ds, 
physician's and nurse's notes, original laboratory reports, ECG, electroencephalogram ( EEG ), 
X-ray, signed informed consent forms, c onsultant letters, and patient s creening and 
enrollment logs.   
These documen ts must be kept on file by the i nvestigator for a period of 2 years following 
the date the marketing application is approved for the drug indication for which it is being 
investigated. If no application is to be filed or if the application is not approved for such indication, all records pertaining to the conduct of the clinical study must be adequately maintained until 2 years after the investigation is discontinued and the regulatory a uthorities 
are notified. After that period of time , the documents may be destroyed, subject to local 
regulations. 
The investigator must not destroy any records associated with the study witho ut receiving 
approval from the s ponsor. Th e investigator must notify the s ponsor in the event of 
accidental loss or destruction of any study records and should notify the sponsor of an y 
reassignment of study records to another part y or move to another location.  
16.5. Study Monitoring  
Qualified representatives of the sponsor or sponsor designees (study monitors ) will monitor 
the study according to a predetermined monitoring plan. The inve stigator must permit the 
study m onitors to periodically review all eCRFs and source documents supporting the 
participation of each patient  in the study. The eCRFs and other documentation supporting the 
study must be kept up to date by the investigator an d the staff at the study site. These study 
materials must be available for  review by the study m onitor, and/or other qualified 
representatives of the sponsor,  at each monitoring visit and must be provided in a way such 
that the patient’s confidentiality is maintained in accordance with local institution, state, 
country, and federal requirements.  
16.6. Audits and Inspections  
At some point during the study or after the study, appropriately qualified personnel from the 
sponsor’s Quality Assurance group, or their authorized representative, or a representative 
from a regulatory authority may visit the investigator to conduct an inspect ion of the study 
and the site. During this audit, the investigator agrees to give the auditor direct access to all 
relevant documents supporting the eCRFs and other study -related documents and to discuss 
any findings with the auditor. In the event of an inspection by a regulatory agency, the investigator agrees to give the inspector direct access to all relevant documents and to discuss any findings with the inspector.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 101 of 105  
G1 Therapeutics CONFIDENTIAL  17. PUBLICATION POLICY 
By signing the study protocol, the investigator and his or her institution agree that the results 
of the study may be used by G1 Therapeutics  for the purposes of national and international 
registration, publ ication, and information for medical and pharmaceutical professionals. If 
necessary, the authorities will be notified of the investigator’s name, address, qualifications, and extent of involvement.  
Initial publication of the results of this study will be o f a cooperative nature that may include 
authors representing the sponsor, i nvestigator(s), and co llaborating scientists.  Independent 
publications by involved individuals may follow. Investigators and their institutions agree not to publish or publicly pres ent any interim results of studies without the prior written consent 
of G1 Therapeutics.  
At least 60 days prior to expected submission to the intended publi sher or meeting 
committee, the investigator will submit a copy of the desired presentation (oral or written) or publicat ion manuscript to the sponsor. This review period may be shortened upon mutual 
consent where circumstances require expeditious review. The s ponsor reserves the right to 
request modification of any publicati on, presentation or use by the  investigator if such 
activity may jeopardize a patent application, an existing patent, or oth er proprietary rights. 
The s ponsor shall determine order of authorship of any publication combining all clinical 
results of this trial.  
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 102 of 105  
G1 Therapeutics CONFIDENTIAL  18. REFERENCES  
Apetoh L, Ghiri nghelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 
dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev . 
2007 Dec;220:47-59. 
Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with 
small- cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview 
Collaborative Group. N Engl J Med . 1999 Aug 12;341(7):476- 484. 
Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune -based mechanisms of cytotoxic 
chemotherapy: i mplications for the design of novel and rationale -based combined treatments 
against cancer. Cell Death Differ . 2014 Jan;21(1):15 -25. 
Cagle PT, el -Naggar AK, Xu HJ, Hu SX, Benedict WF. Differential retinoblastoma protein 
expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J 
Pathol. 1997;150:393- 400. 
Casares N, Pequignot MO, Tesniere A, et al. Caspase- dependent immunogenicity of 
doxorubicin- induced tumor cell death. J Exp Med . 2005 Dec 19;202(12):1691-1701. 
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy -Lung (FACT -L) quality of life instrument. 
Lung Cancer . 1995 Jun;12(3):199- 220. 
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. 
D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 
mutations in small- cell lung cancer cell lines and tumors. Oncogene . 1992;7:339-346. 
Eckardt JR, von Pawel J, Papai Z, et al.  Open -label, multicenter, randomized, phase III study 
comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy naive patients with extensive- disease small -cell lung cancer. J Clin Oncol. 
2006;24:2044-2051. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: revised RECIST guideline (version 1.1). Eur J Cancer . 2009;45:228-247. 
Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin -dependent kinase 4/6 by 
PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther . 
2004 Nov;3(11):1427-1438. 
Gouyer V, Gazzeri S, Brambilla E, et al. Loss of heterozygosity at the RB locus correlates 
with loss of RB protein in primary malignant neuro- endocrine lung carcinomas. Int J Cancer . 
1994;58:818-824. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 103 of 105  
G1 Therapeutics CONFIDENTIAL  Hanna N, Bunn PA, Jr., Langer C, et al. Randomized phase III trial comparing 
irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive stage disease small -cell lung cancer. J Clin Oncol.  2006;24:2038-2043. 
Heighway J, Betticher DC. Lung: small cell cancer. Atlas of Genetics and Cytogenetics in Oncology and Haematology . June 2004 URL : 
http://atlasgeneticsoncology.org/Tumors/LungSmallCellID5142.html. 
Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide 
plus carboplatin in extensive small -cell lung cancer: a randomized phase III trial. J Clin 
Oncol. 2008;26:4261-4267. 
McDonnell AM, Nowak AK, Lake RA. Contribution of the immune system to the 
chemotherapeutic response. Semin Immunopathol . 2011 Jul;33(4):353 -367. 
Noda K, NishiwakiY, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell -lung cancer. N Engl J Med . 2002;346:85-91. 
Peifer M, Fernandez -Cuesta L, Sos ML, et al. Integrative genome analyses identify key 
somatic driver mutations of small- cell lung cancer. Nat Genet . 2012;44:1104-1110. 
Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for 
overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res . 
2009 Jul 1;69(13):5383-5391. 
Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small -cell lung cancer. Nat Genet .2012;44:1111-1116. 
Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small -cell lung cancer. Ann Oncol. 2006;17:663-667. 
Schmittel A, Sebastian M, Fischer von Weikersthal L, et al. A German multicenter, randomized phase III trial comparing irinotecan -carboplatin with etoposide- carboplatin as 
first-line therapy for extensive- disease small -cell lung cancer. Ann Oncol. 
2011;22: 1798-1804. 
Slotman B, Faivre -Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive 
small- cell lung cancer. N Engl J Med . 2007 Aug 16;357(7):664- 672. 
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence based clinical practice guideline. J Clin Oncol . 2006 Jul 1;24(19):3187 -3205. 
Socinski M, Smit E, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in c hemotherap y-naive patients with 
extensive -stage small -cell lung cancer. J Clin Oncol. 2009;27(28):4787-4792. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 104 of 105  
G1 Therapeutics CONFIDENTIAL  Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other 
anemia- related symptoms with the Functional Assessment of Cancer Therapy (FACT) 
measurement system. J Pain Symptom Manage . 1997 Feb;13(2):63- 74. 
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1 -3 
and multidrug and toxin extrusion family). J Pharmacol Exp Ther . 2006 
Nov;319(2):879-886. 
Yong WP, Desai AA, Innocenti F, et al. Pharmacokinetic modulation of oral etoposide by 
ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol . 2007 
Nov;60(6):811-819.  
Yuan J, Knorr J, Altmannsberger M, et al. Expression of p16 and lack of pRB in primary 
small cell lung cancer. J Pathol . 1999;189:358-362. 
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy . Nat Rev Immunol . 2008 Jan;8(1):59 -73. 
G1 Therapeutics  
Clinical Study Protocol G1T28 -02 G1T28  
 
Version: 8.0, dated 15 September  2016   Page 105 of 105  
G1 Therapeutics CONFIDENTIAL  19. APPENDICES  
APPENDIX 1: Common Terminology Criteria  for Adverse Events (CTCAE) – Version  4.03 
The NCI CTCAE V ersion 4.0 3 (CTCAE 4.03 14  June 2010) can be accessed from the 
following National Cancer Institute (NCI) webs ite: 
http://evs.nci.nih.gov/ftp1/CTCAE/About.html  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_5x7.pdf  
APPENDIX 2: Package I nsert s for Chemotherapy Agents  
Etopophos® (etoposide phosphate) package insert link: 
http://packageinserts .bms.com/pi/pi_etopophos.pdf   
Paraplatin® (carboplatin) package insert link: 
http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005 -
4180b_03_05_Carboplatin%20label%201-9- 04%20FDA.pdf  
APPENDIX 3: Package Insert s for Colony Stimulating Factors  
Neupogen® (filg rastim) package insert link: 
http://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf 
Neulasta® (pegfilgrastim) package insert link:  
http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf  
APPENDIX 4: Package Inserts for Erythr opoiesis Stimulating Agents  
Aranesp® (darbepoetin alfa) package insert link:  
http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf  
Epogen® (epoetin alfa) package insert link:  
http://pi.amgen.com/united_states/epogen/epogen_pi_hcp_englis h.pdf  
 